

ROYAL CARIBBEAN CRUISES LTD
Form 10-K
February 25, 2013

Table of Contents

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

FORM 10-K

(Mark One)

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2012

or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to _____
Commission file number: 1-11884

ROYAL CARIBBEAN CRUISES LTD.

(Exact name of registrant as specified in its charter)

Republic of Liberia
(State or other jurisdiction of
incorporation or organization)

98-0081645
(I.R.S. Employer Identification No.)

1050 Caribbean Way, Miami, Florida 33132
(Address of principal executive offices) (zip code)

(305) 539-6000
(Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Name of each exchange on which registered
Common Stock, par value \$.01 per share	New York Stock Exchange
Securities registered pursuant to Section 12(g) of the Act: None	

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes No

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes No

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Edgar Filing: ROYAL CARIBBEAN CRUISES LTD - Form 10-K

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes No

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company (See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act).

Large accelerated filer Accelerated filer Non-accelerated filer Smaller reporting company

(Do not check if a
smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes No

The aggregate market value of the registrant's common stock at June 29, 2012 (based upon the closing sale price of the common stock on the New York Stock Exchange on June 29, 2012) held by those persons deemed by the registrant to be non-affiliates was approximately \$4.5 billion. Shares of the registrant's common stock held by each executive officer and director and by each entity or person that, to the registrant's knowledge, owned 10% or more of the registrant's outstanding common stock as of June 29, 2012 have been excluded from this number in that these persons may be deemed affiliates of the registrant. This determination of possible affiliate status is not necessarily a conclusive determination for other purposes.

There were 219,168,946 shares of common stock outstanding as of February 13, 2013.

DOCUMENTS INCORPORATED BY REFERENCE

Portions of the registrant's Definitive Proxy Statement relating to its 2013 Annual Meeting of Shareholders are incorporated by reference in Part III, Items 10-14 of this Annual Report on Form 10-K as indicated herein.

Table of Contents

**ROYAL CARIBBEAN CRUISES LTD.
TABLE OF CONTENTS**

		Page
<u>PART I</u>		
<u>Item 1.</u>	<u>Business</u>	<u>1</u>
<u>Item 1A.</u>	<u>Risk Factors</u>	<u>26</u>
<u>Item 1B.</u>	<u>Unresolved Staff Comments</u>	<u>34</u>
<u>Item 2.</u>	<u>Properties</u>	<u>34</u>
<u>Item 3.</u>	<u>Legal Proceedings</u>	<u>35</u>
<u>Item 4.</u>	<u>Mine Safety Disclosures</u>	<u>36</u>
<u>PART II</u>		
<u>Item 5.</u>	<u>Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</u>	<u>37</u>
<u>Item 6.</u>	<u>Selected Financial Data</u>	<u>39</u>
<u>Item 7.</u>	<u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	<u>40</u>
<u>Item 7A.</u>	<u>Quantitative and Qualitative Disclosures About Market Risk</u>	<u>65</u>
<u>Item 8.</u>	<u>Financial Statements and Supplementary Data</u>	<u>68</u>
<u>Item 9.</u>	<u>Changes In and Disagreements With Accountants on Accounting and Financial Disclosure</u>	<u>68</u>
<u>Item 9A.</u>	<u>Controls and Procedures</u>	<u>68</u>
<u>Item 9B.</u>	<u>Other Information</u>	<u>69</u>
<u>PART III</u>		
<u>Item 10.</u>	<u>Directors, Executive Officers and Corporate Governance</u>	<u>70</u>
<u>Item 11.</u>	<u>Executive Compensation</u>	<u>70</u>
<u>Item 12.</u>	<u>Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</u>	<u>70</u>
<u>Item 13.</u>	<u>Certain Relationships and Related Transactions, and Director Independence</u>	<u>70</u>
<u>Item 14.</u>	<u>Principal Accounting Fees and Services</u>	<u>70</u>
<u>PART IV</u>		
<u>Item 15.</u>	<u>Exhibits, Financial Statement Schedules</u>	<u>71</u>
<u>Signatures</u>		<u>72</u>

Table of Contents

PART I

As used in this Annual Report on Form 10-K, the terms "Royal Caribbean," the "Company," "we," "our" and "us" refer to Royal Caribbean Cruises Ltd. and, depending on the context, Royal Caribbean Cruises Ltd.'s consolidated subsidiaries and/or affiliates. The terms "Royal Caribbean International," "Celebrity Cruises," "Pullmantur," "Azamara Club Cruises," "CDF Croisières de France," and "TUI Cruises" refer to our cruise brands. However, our operating results and other disclosures herein do not include TUI Cruises unless otherwise specified. In accordance with cruise vacation industry practice, the term "berths" is determined based on double occupancy per cabin even though many cabins can accommodate three or more passengers.

This Annual Report on Form 10-K also includes trademarks, trade names and service marks of other companies. Use or display by us of other parties' trademarks, trade names or service marks is not intended to and does not imply a relationship with, or endorsement or sponsorship of us by, these other parties other than as described herein.

Item 1. Business

General

Royal Caribbean was founded in 1968 as a partnership. Its corporate structure evolved over the years and the current parent corporation, Royal Caribbean Cruises Ltd., was incorporated on July 23, 1985 in the Republic of Liberia under the Business Corporation Act of Liberia.

We are the world's second largest cruise company. We own Royal Caribbean International, Celebrity Cruises, Pullmantur, Azamara Club Cruises and CDF Croisières de France, as well as TUI Cruises through a 50% joint venture. Together, these six brands operate a combined 41 ships in the cruise vacation industry with an aggregate capacity of approximately 98,650 berths as of December 31, 2012.

Our ships operate on a selection of worldwide itineraries that call on approximately 455 destinations on all seven continents. In addition to our headquarters in Miami, Florida, we have offices and a network of international representatives around the world which focus on our global guest sourcing.

We compete principally on the basis of exceptional service provided by our crew; innovation and quality of ships; variety of itineraries; choice of destinations; and price. We believe that our commitment to build state-of-the-art ships and to invest in the maintenance and revitalization of our fleet to, among other things, incorporate our latest signature innovations, allows us to continue to attract new and loyal repeat guests.

We believe cruising continues to be a widely accepted vacation choice due to its inherent value, extensive itineraries and variety of shipboard and shoreside activities. In addition, we believe that our products appeal to a large consumer base and are not dependent on a single market or demographic.

Our Brands

Our global brands include Royal Caribbean International, Celebrity Cruises, and Azamara Club Cruises. These brands are complemented by our Pullmantur brand, which has been tailored to serve the cruise markets in Spain, Portugal and Latin America; our CDF Croisières de France brand, which provides us with a tailored product targeted at the French market; and our 50% joint venture TUI Cruises which is specifically tailored for the German market. The operating results of all of our brands are included in our consolidated results of operations, except for TUI Cruises, which is accounted for under the equity method of accounting. See Note 1. *General* and Note 6. *Other Assets* to

Table of Contents

our consolidated financial statements under Item 8. *Financial Statements and Supplementary Data* for further details.

We believe our global brands possess the versatility to enter multiple cruise market segments within the cruise vacation industry. Although each of our brands has its own marketing style as well as ships and crews of various sizes, the nature of the products sold and services delivered by our brands share a common base (i.e. the sale and provision of cruise vacations). Our brands also have similar itineraries as well as similar cost and revenue components. In addition, our brands source passengers from similar markets around the world and operate in similar economic environments with a significant degree of commercial overlap. As a result, we strategically manage our brands as a single business with the ultimate objective of maximizing long-term shareholder value.

Royal Caribbean International

We currently operate 22 ships with an aggregate capacity of approximately 62,000 berths under our Royal Caribbean International brand, offering cruise itineraries that range from two to 18 nights. As previously announced, we will redeploy *Monarch of the Seas* from Royal Caribbean International to Pullmantur in April 2013. In addition, we currently have three ships on order for our Royal Caribbean International brand with an aggregate capacity of approximately 13,600 berths which are expected to enter service in the fourth quarter of 2014, the second quarter of 2015 and the second quarter of 2016, respectively. This includes our recently ordered third Oasis-class ship. Royal Caribbean International offers a variety of itineraries to destinations worldwide, including Alaska, Asia, Australia, Bahamas, Bermuda, Canada, the Caribbean, Europe, the Middle East, the Panama Canal, South America, South Pacific and New Zealand.

Royal Caribbean International is positioned at the upper end of the contemporary segment of the cruise vacation industry, generally characterized by cruises that are seven nights or shorter and feature a casual ambiance as well as a variety of activities and entertainment venues. We believe that the quality of the Royal Caribbean International brand also enables it to attract guests from the premium segment, which is generally characterized by cruises that are seven to 14 nights and appeal to the more experienced guest who is usually more affluent. This allows Royal Caribbean International to achieve market coverage that is among the broadest of any of the major cruise brands in the cruise vacation industry.

Royal Caribbean International's strategy is to attract an array of vacationing guests by providing a wide variety of itineraries and cruise lengths with multiple innovative options for onboard dining, entertainment and other onboard activities. During 2011 Royal Caribbean International initiated a vessel revitalization program in order to incorporate some of the most popular features of our newer ships across the fleet. Nine ships were revitalized under this program during 2011 and 2012 and an additional three ships are scheduled for revitalization during 2013.

Royal Caribbean International offers a variety of shore excursions at each port of call. We believe that the variety and quality of Royal Caribbean International's product offerings represent excellent value to consumers, especially to couples and families traveling with children. Because of the brand's extensive and innovative product offerings, we believe Royal Caribbean International is well positioned to attract new consumers to the cruise vacation industry and to continue to bring loyal repeat guests back for their next vacation.

Celebrity Cruises

We currently operate 11 ships with an aggregate capacity of approximately 24,800 berths under our Celebrity Cruises brand, offering cruise itineraries that range from two to 18 nights. Celebrity Cruises offers a global cruise experience by providing a variety of cruise lengths and itineraries to marquee destinations throughout the world, including Alaska, Asia, Australia, Bermuda, Canada, the Caribbean,

Edgar Filing: ROYAL CARIBBEAN CRUISES LTD - Form 10-K

Table of Contents

Europe, Hawaii, New England, New Zealand, the Panama Canal, the US Pacific Coast and South America. Celebrity Cruises was the first major cruise line to operate a ship in the Galapagos Islands, *Celebrity Xpedition*, operating in this location since 2004. *Celebrity Xpedition* has 96 berths and provides this unique experience on seven day cruises that include pre-cruise tours in Ecuador.

Celebrity Cruises is positioned within the premium segment of the cruise vacation industry. Celebrity Cruises delivers a modern luxury cruise vacation experience that appeals to experienced cruisers, resulting in a strong base of loyal repeat guests. The brand also appeals to vacationers who have not yet cruised who seek to explore destinations throughout the world and would enjoy the high quality, service-focused and modern luxury experience the brand offers.

Celebrity Cruises' strategy is to deliver an intimate experience onboard upscale ships that offer luxurious accommodations, a high staff-to-guest ratio, fine dining, personalized service, extensive spa facilities, and unique onboard activities and entertainment. The brand began a revitalization program for all four Millennium-class ships in 2010 in order to incorporate well received concepts from the Solstice-class ships. The revitalization program is expected to be completed in 2013 when *Celebrity Constellation*, the final Millennium-class vessel to be revitalized, will undergo a second revitalization to incorporate additional amenities and staterooms.

Azamara Club Cruises

We currently operate two ships with an aggregate capacity of approximately 1,400 berths under our Azamara Club Cruises brand, offering cruise itineraries that range from four to 18 nights. Azamara Club Cruises is designed to serve the up-market segment of the North American, United Kingdom and Australian markets. The up-market segment incorporates elements of the premium segment and the luxury segment which is generally characterized by smaller ships, high standards of accommodation and service, higher prices and exotic itineraries to ports which are inaccessible to larger ships.

Azamara Club Cruises' strategy is to deliver distinctive destination experiences, featuring unique itineraries with more overnights and longer stays as well as thorough tours allowing guests to truly experience the destination. Azamara Club Cruises' focus is to attract experienced travelers who are looking for more in-depth destination experiences, and who seek a more intimate onboard experience and a high level of service. Azamara Club Cruises sails in Asia, Northern and Western Europe, the Mediterranean, South and Central America, the less-traveled islands of the Caribbean and North America.

Azamara Club Cruises offers a variety of onboard services, amenities and activities, including gaming facilities, fine dining, spa and wellness, butler service for suites, as well as entertainment venues. Azamara Club Cruises also includes as part of the base price of the cruise certain complimentary onboard services, amenities and activities which are not normally included in the base price of other cruise lines.

Pullmantur

We currently operate three ships with an aggregate capacity of approximately 5,300 berths under our Pullmantur brand, offering cruise itineraries that range from four to 12 nights. As previously announced, *Monarch of the Seas* will be redeployed from Royal Caribbean International to Pullmantur in April 2013.

Pullmantur serves the contemporary segment of the Spanish, Portuguese and Latin American cruise markets. Pullmantur also has land-based tour operations and owns a 49% interest in an air business that operates four Boeing 747 aircraft in support of its cruise and tour operations.

Pullmantur's strategy is to attract cruise guests by providing a variety of cruising options and land-based travel packages. Pullmantur offers a range of cruise itineraries to Brazil, the Caribbean and

Table of Contents

Europe. Pullmantur offers a wide array of onboard activities and services to guests, including exercise facilities, swimming pools, beauty salons, gaming facilities, shopping, dining, certain complimentary beverages, and entertainment venues. Pullmantur's tour operations sell land-based travel packages primarily to Spanish guests, including hotels and flights mainly to Caribbean resorts, and land-based tour packages to Europe primarily aimed at Latin American guests. In addition, Pullmantur owns a travel agency network that offers a wide array of travel related products to guests in Spain.

CDF Croisières de France

CDF Croisières de France currently operates the 1,350-berth *Horizon*. CDF Croisières de France is designed to serve the contemporary segment of the French cruise market by providing a brand tailored for French cruise guests. CDF Croisières de France offers seasonal itineraries to the Mediterranean and a variety of onboard services, amenities and activities, including entertainment venues, exercise and spa facilities, fine dining, and gaming facilities.

TUI Cruises

TUI Cruises is designed to serve the contemporary and premium segments of the German cruise market by offering tailored product for German guests. All onboard activities, services, shore excursions and menu offerings are designed to suit the preferences of this target market. TUI Cruises operates two ships, *Mein Schiff I* and *Mein Schiff II*, with an aggregate capacity of approximately 3,800 berths. In addition, TUI Cruises has two ships on order, each with a capacity of 2,500 berths, scheduled for delivery in the second quarter of 2014 and second quarter of 2015, respectively. TUI Cruises is a joint venture owned 50% by us and 50% by TUI AG, a German tourism and shipping company that also owns 51% of TUI Travel, a British tourism company.

Industry

Cruising is considered a well established vacation sector in the North American market, a growing sector over the long-term in the European market and a developing but promising sector in several other emerging markets. Industry data indicates that a significant portion of cruise guests carried are first-time cruisers. We believe this presents an opportunity for long-term growth and a potential for increased profitability.

We estimate that the global cruise industry carried 20.8 million cruise guests in 2012 compared to 20.2 million cruise guests carried in 2011 and 18.8 million cruise guests carried in 2010. We estimate that the global cruise fleet was served by approximately 432,000 berths on approximately 282 ships at the end of 2012. There are approximately 19 ships with an estimated 65,000 berths that are expected to be placed in service in the global cruise market between 2013 and 2017, although it is also possible that ships could be taken out of service during these periods. The majority of cruise guests have historically been sourced from North America and Europe.

North America

The North American cruise market has historically experienced significant growth. The compound annual growth rate in cruise guests for this market was approximately 4.5% from 2008 to 2012. We estimate that North America was served by 144 ships with approximately 212,000 berths at the beginning of 2008 and by 146 ships with approximately 258,000 berths at the end of 2012. There are approximately 10 ships with an estimated 40,000 berths that are expected to be placed in service in the North American cruise market between 2013 and 2017.

Edgar Filing: ROYAL CARIBBEAN CRUISES LTD - Form 10-K

Table of Contents

Europe

As compared to North America, the European cruise market represents a smaller but even faster growing sector of the vacation industry. It has experienced a compound annual growth rate in cruise guests of approximately 7.6% from 2008 to 2012. This market has recently experienced a number of challenges as a result of the effects of the Costa Concordia incident and the continued instability in the European economic landscape. However, we continue to believe in the long term growth potential of this market. We estimate that Europe was served by 102 ships with approximately 108,000 berths at the beginning of 2008 and by 117 ships with approximately 156,000 berths at the end of 2012. There are approximately 9 ships with an estimated 25,000 berths that are expected to be placed in service in the European cruise market between 2013 and 2017.

The following table details the growth in the global, North American and European cruise markets in terms of cruise guests and estimated weighted-average berths over the past five years:

Year	Global Cruise Guests ⁽¹⁾	Weighted-Average	North American Cruise Guests ⁽²⁾	Weighted-Average	European Cruise Guests	Weighted-Average
		Supply of Berths Marketed Globally ⁽¹⁾		Supply of Berths Marketed in North America ⁽¹⁾		Supply of Berths Marketed in Europe ⁽¹⁾
2008	17,184,000	347,000	10,093,000	219,000	4,500,000	120,000
2009	17,340,000	363,000	10,198,000	222,000	5,000,000	131,000
2010	18,800,000	391,000	10,781,000	232,000	5,540,000	143,000
2011	20,227,000	412,000	11,625,000	245,000	5,894,000	149,000
2012	20,823,000	425,000	12,044,000	254,000	6,040,000	152,000

(1) Source: Our estimates of the number of global cruise guests, and the weighted-average supply of berths marketed globally, in North America and Europe are based on a combination of data that we obtain from various publicly available cruise industry trade information sources including Seatrade Insider and Cruise Line International Association ("CLIA"). In addition, our estimates incorporate our own statistical analysis utilizing the same publicly available cruise industry data as a base.

(2) Source: Cruise Line International Association based on cruise guests carried for at least two consecutive nights for years 2008 through 2011. Year 2012 amounts represent our estimates (see number (1) above).

(3) Source: CLIA Europe, formerly European Cruise Council, for years 2008 through 2011. Year 2012 amounts represent our estimates (see number (1) above).

Other Markets

In addition to expected industry growth in North America and Europe as discussed above, we expect the Asia/Pacific region to demonstrate an even higher growth rate in the near term, although it will continue to represent a relatively small sector compared to North America and Europe.

Competition

We compete with a number of cruise lines. Our principal competitors are Carnival Corporation & plc, which owns, among others, Aida Cruises, Carnival Cruise Lines, Costa Cruises, Cunard Line, Holland America Line, Iberocrueros, P&O Cruises and Princess Cruises; Disney Cruise Line; MSC Cruises; Norwegian Cruise Line and Oceania Cruises. Cruise lines compete with other vacation alternatives such as land-based resort hotels and sightseeing destinations for consumers' leisure time. Demand for such activities is influenced by political and general economic conditions. Companies within the vacation market are dependent on consumer discretionary spending.

Table of Contents

Operating Strategies

Our principal operating strategies are to:

protect the health, safety and security of our guests and employees and protect the environment in which our vessels and organization operate,

strengthen and support our human capital in order to better serve our global guest base and grow our business,

further strengthen our consumer engagement in order to enhance our revenues,

increase the awareness and market penetration of our brands globally,

focus on cost efficiency, manage our operating expenditures and ensure adequate cash and liquidity, with the overall goal of maximizing our return on invested capital and long-term shareholder value,

strategically invest in our fleet through the revitalization of existing ships and the transfer of key innovations across each brand, while prudently expanding our fleet with the new state-of-the-art cruise ships recently delivered and on order,

capitalize on the portability and flexibility of our ships by deploying them into those markets and itineraries that provide opportunities to optimize returns, while continuing our focus on existing key markets,

further enhance our technological capabilities to service customer preferences and expectations in an innovative manner, while supporting our strategic focus on profitability, and

maintain strong relationships with travel agencies, which continue to be the principal industry distribution channel, while enhancing our consumer outreach programs.

Safety, Environment and Health policies

We are committed to protecting the safety, environment and health of our guests, employees and others working on our behalf. We are also committed to protecting the marine environment in which our ships sail and the communities in which we operate by reducing/mitigating adverse environmental consequences and using resources efficiently. As part of this commitment, we have established a Safety, Environment and Health Department to oversee our maritime safety, global security, environmental stewardship and medical/public health activities. We also have a Maritime Advisory Board of experts as well as the Safety, Environment and Health (SEH) Committee of our Board of Directors which oversees these important areas. In addition, we publish an annual Stewardship Report on our performance in these important areas, which can be accessed on our brand websites.

Following the Costa Concordia incident in early 2012, we and other cruise lines performed reviews of safety and emergency response procedures to identify lessons learned and best practices to further protect the safety of our guests and crew. During this process, we held regular meetings with other cruise companies to propose new industry-wide policies that we believe will further drive our Company's and the industry's safety performance. A number of these policies have already been implemented and/or publicly announced by the Cruise Lines International Association as well as shared with international regulators.

Strengthen and support our human capital

Edgar Filing: ROYAL CARIBBEAN CRUISES LTD - Form 10-K

We believe that our employees, both shipboard and shoreside, are a critical success factor for our business. We strive to identify, hire, develop, motivate, and retain the best employees, with backgrounds

Table of Contents

and perspectives as diverse as our guest base. Attracting, engaging, and retaining key employees has been and will remain critical to our success.

We continue our focus on providing our employees with a competitive compensation structure, development and other personal and professional growth opportunities in order to strengthen and support our human capital. We also seek to select, develop and retain leaders to advance the enterprise now and in the future. To that end, we pay special attention to identifying high performing potential leaders and develop deep bench strength so these leaders can assume leadership roles throughout the organization. We strive to maintain a work environment that reinforces collaboration, motivation and innovation, and believe that maintaining our vibrant and distinctive culture is critical to the growth of our business.

Strengthen our consumer engagement

We place a strong focus on identifying the needs of our guests and creating product features that our customers value. We are focused on targeting high value guests by better understanding consumer data and insights and creating communication strategies that best resonate with our target audiences.

We interact with customers across all touch points and seek to identify underlying needs for which guests are willing to pay a premium. We rely on various programs prior to, during and after a cruise vacation aimed at increasing our ticket prices, onboard revenues and occupancy. In 2013, we will continue to strategically invest in a number of potential revenue enhancing projects, including the implementation of new onboard revenue initiatives. We believe these initiatives will provide opportunities for increased ticket and onboard revenues.

Global awareness and market penetration

We increase brand awareness and market penetration of our cruise brands in various ways, including by using communication strategies and marketing campaigns designed to emphasize the unique qualities of each brand and to broaden the awareness of the brand, especially among the brand target customer groups. Our marketing strategies include the use of traditional media, social media, brand websites and travel agencies. Our brands engage past and potential guests by collaborating with travel partners and through call centers, international offices and international representatives. In addition, Royal Caribbean International, Celebrity Cruises and Azamara Club Cruises retain repeat guests with exclusive benefits offered through their respective loyalty programs.

We also increase brand awareness across all of our brands through travel agencies who generate the majority of our bookings. We are committed to further developing and strengthening this very important distribution channel by continuing to focus the travel agents on the unique qualities of each of our brands.

We sell and market our global brands, Royal Caribbean International, Celebrity Cruises and Azamara Club Cruises, to guests outside of North America through our offices in the United Kingdom, France, Germany, Norway, Italy, Spain, Singapore, China, Brazil, Australia and Mexico. We believe that having a local presence in these markets provides us with the ability to react more quickly to local market conditions and better understand our consumer base in each market. We further extend our geographic reach with a network of 36 independent international representatives located throughout the world covering 111 countries. Historically, our focus has been to primarily source guests for our global brands from North America. Over the last several years, we have continued to expand our focus on selling and marketing our cruise brands to guests in countries outside of North America through fleet innovation and by responding to the itinerary preferences and cultural characteristics of our international guests. In 2013, we will continue to focus on the development of key markets in Asia and we will focus on sourcing guests and adding capacity to the markets where we expect significant growth and profitability, such as China and Australia.

Table of Contents

We are also focused on expanding our Pullmantur brand into Latin America, with particular emphasis in Brazil. We also look for opportunities to acquire or develop brands tailored to specific markets. TUI Cruises, our joint venture with TUI AG, is a cruise brand targeted at the cruise market in Germany. TUI Cruises complements our other tailored brands including Pullmantur and CDF Croisières de France.

Passenger ticket revenues generated by sales originating in countries outside of the United States were approximately 49% of total passenger ticket revenues in 2012 and 2011, and 45% in 2010. International guests have grown from approximately 1.3 million in 2008 to approximately 2.2 million in 2012.

Focus on cost efficiency, manage our operating expenditures and ensure adequate cash and liquidity

We are committed to our efforts to identify and implement cost containment initiatives, including a number of initiatives to reduce energy consumption and, by extension, fuel costs. These include the design of more fuel efficient ships as well as the implementation of more efficient hardware, including propulsion and cooling systems incorporating energy efficiencies. In addition, we are focused on maintaining a strong liquidity position, reducing our debt and improving our credit metrics. We are also continuing to pursue our long-term objective of returning our credit ratings to investment grade. We believe these strategies enhance our ability to achieve our overall goal of maximizing our return on invested capital and long-term shareholder value.

Fleet revitalization, maintenance and expansion

We place a strong focus on product innovation, which we seek to achieve by introducing new concepts on our new ships and continuously making improvements to our fleet. Several of these innovations have become signature elements of our brands, such as the "Royal Promenade" (a boulevard with shopping, dining and entertainment venues), ice skating rinks, rock climbing walls, miniature golf and full court basketball for the Royal Caribbean International brand, and the design of the ships, contemporary quality dining, spacious staterooms and suites with verandas, spa facilities and variety of bars and lounges for the Celebrity Cruises brand. In 2009 and 2010, Royal Caribbean International took delivery of sister ships, *Oasis of the Seas* and *Allure of the Seas*, which are the largest and most innovative cruise ships in the cruise industry. With the same focus on product innovation, Celebrity Cruises ordered a total of five Solstice-class ships, the last of which, *Celebrity Reflection*, was delivered in 2012. The Solstice-class ships incorporate many new and improved design features.

Our revitalization and maintenance programs enable us to incorporate our latest signature innovations and allow us to benefit from economies of scale by leveraging our suppliers. Ensuring consistency across our fleet provides us with the flexibility to redeploy our ships among our brand portfolio. As part of these efforts:

Royal Caribbean International initiated a vessel revitalization program in 2011 in order to introduce some of the most popular features of the Oasis-class ships on certain Freedom-class, Radiance-class and Vision-class ships. *Liberty of the Seas*, *Freedom of the Seas*, *Radiance of the Seas* and *Splendour of the Seas* were revitalized in 2011 and *Rhapsody of the Seas*, *Mariner of the Seas*, *Grandeur of the Seas*, *Serenade of the Seas* and *Enchantment of the Seas* were revitalized in 2012 as part of this revitalization program. An additional three ships are scheduled for revitalization in 2013.

Table of Contents

Celebrity Cruises began investing in the revitalization of the Millennium-class ships in 2010 as *Celebrity Constellation* underwent a revitalization of its onboard amenities and public areas to incorporate certain Solstice-class features. In 2011 and the early part of 2012, *Celebrity Infinity*, *Celebrity Summit* and *Celebrity Millennium* added onboard amenities, public areas and new staterooms. In 2013, *Celebrity Constellation* will undergo a second revitalization to incorporate additional amenities and staterooms.

We are also committed to building state-of-the-art ships, and currently our brands, including our 50% joint venture TUI Cruises, have signed agreements for the construction of five new ships. These consist of our recently ordered third Oasis-class ship which is scheduled to enter service in the second quarter of 2016, two ships of a new generation of Royal Caribbean International cruise ships to be known as the Quantum-class which are scheduled to enter service in the fourth quarter of 2014 and second quarter of 2015, respectively, and two ships of a new generation for TUI Cruises, which are scheduled to enter service in the second quarter of 2014 and second quarter of 2015, respectively. These additions are expected to increase our passenger capacity by approximately 18,600 berths by December 31, 2016, or approximately 18.9%, as compared to our capacity as of December 31, 2012. We continuously evaluate opportunities to order new ships, purchase existing ships or sell ships in our current fleet.

In support of our maintenance programs, we own a 40% interest in a ship repair and maintenance facility, Grand Bahama Shipyard Ltd., which is the largest cruise ship dry-dock repair facility in the world and is located in Freeport, Grand Bahama. We utilize this facility, among other ship repair facilities, for our regularly scheduled drydocks and certain emergency repairs as may be required. In addition, the facility serves unaffiliated cruise and cargo ships, oil and gas tankers, and offshore units.

Markets and itineraries

In an effort to penetrate untapped markets, diversify our consumer base and respond to changing economic and geopolitical market conditions, we continue to seek opportunities to optimally deploy ships to new and stronger markets and itineraries throughout the world. The portability of our ships and our investment in infrastructure allows us to expand into new markets and helps us reduce our dependency on any one market by allowing us to create "home ports" around the world. In addition, it allows us to readily deploy our ships to meet demand within our existing cruise markets.

Our ships offer a wide selection of itineraries that call on approximately 455 ports in 95 countries, spanning all seven continents. We are focused on obtaining the best possible long-term shareholder returns by operating in established markets while growing our presence in developing markets. New capacity allows us to expand into new markets and itineraries. Our brands have expanded their mix of itineraries while strengthening our ability to penetrate the Asian, Caribbean, European, and Latin American markets further. In addition, in order to capitalize on the summer season in the Southern Hemisphere and mitigate the impact of the winter weather in the Northern Hemisphere, our brands have increased deployment to Australia and Latin America.

We continue to focus on the acceleration of Royal Caribbean International's, Celebrity Cruises' and Azamara Club Cruises' strategic positioning as global cruise brands. In 2012, Royal Caribbean International continued its global expansion by seasonally adding a second ship in Asia and a third ship in Australia, adding new departure ports in Southern Europe in order to target guests in key source markets in the region and increasing capacity in Northern Europe. The brand also modified certain of its itineraries for 2012 due to continuing geopolitical unrest in Northern Africa and Greece. In 2013, *Monarch of the Seas* will be redeployed to the Pullmantur fleet and Royal Caribbean International will decrease its European capacity by approximately 23% in order to mitigate its exposure to the uncertain outlook in the European market. Royal Caribbean International will continue to offer short Bahamas

Edgar Filing: ROYAL CARIBBEAN CRUISES LTD - Form 10-K

Table of Contents

sailings, return to year-round southern Caribbean sailings and increase capacity in Asia and China with the repositioning of *Mariner of the Seas*.

In October 2012, Celebrity Cruises introduced *Celebrity Reflection*, the fifth and final Solstice-class ship, which offers sailings in Europe and the Caribbean. The addition of *Celebrity Reflection* allows Celebrity Cruises to introduce a Solstice-class ship in Alaska and Australia/New Zealand, offer a British Isles/Northern European program, and an Asia program for 2013. The added product offerings in Europe result in a 12% capacity increase for 2013. Celebrity Cruises is expanding its focus on destination by emphasizing exotic ports and calling on new destinations in Australia and New Zealand, Hawaii, the Panama Canal and Asia, with longer cruises in Southeast Asia, Indonesia, China and Japan.

In 2013, Azamara Club Cruises' voyages will be sailing to 184 ports in 60 countries around the globe with more than 50% of its ports-of-call featuring late night stays or overnights, allowing guests to experience the destination by day and by night. The Azamara Club Cruises 2013 deployment features South America, including Carnival in Rio de Janeiro, Antarctica, the West Indies, British Isles and Western Europe, Scandinavia and the Baltics, Eastern & Western Mediterranean, as well as the Indian Ocean and Asia. Also, Pullmantur and CDF Croisières de France will continue to offer itineraries in the Caribbean, Europe and South America with particular emphasis in Brazil.

In an effort to secure desirable berthing facilities for our ships, and to provide new or enhanced cruise destinations for our guests, we actively assist or invest in the development or enhancement of certain port facilities and infrastructure, including mixed-use commercial properties, located in strategic ports of call. Generally, we collaborate with local, private or governmental entities by providing management and/or financial assistance and often enter into long-term port usage arrangements. Our participation in these efforts is generally accomplished via investments with the relevant government authority and/or various other strategic partners established to develop and/or operate the port facilities, by providing direct development and management expertise or in certain limited circumstances, by providing direct or indirect financial support. In exchange for our involvement, we generally secure preferential berthing rights for our ships.

Enhance our technological capabilities

The need to develop and use innovative technology is increasingly important. To this end, technology is a pervasive part of virtually every business process we use in order to support our strategic focus and provide a quality experience to our customers before, during and after their cruise. Moreover, as the use of our various websites and social media platforms continue to increase along with the increasing use of technology onboard our ships by both our guests and crew, we continually need to upgrade our systems, infrastructure and technologies to facilitate this growth. To further our customer-centricity, during 2013, we intend to continue to improve our customer experiences online through the launch of a new digital platform which will include among other improvements, revamped websites, new vacation packaging capabilities, support of mobile applications and increased bandwidth onboard our ships helping our guests remain well-connected while at sea. Active engagement in social media channels is also an integral part of our marketing strategy and a part of our broader consumer engagement strategy and relationship management platform.

To support our strategic focus on improving revenue yields, during 2012, we began to implement new capabilities to improve our revenue management systems and decision support processes in advance of our WAVE season (traditionally the first two months of the year where cruise lines experience disproportionately higher volume cruise sales). In 2013, we will continue to build on this new platform and introduce new price optimization tools and promotion management capabilities in our reservations system.

Table of Contents

As part of the Royal Caribbean International and Celebrity Cruises revitalization programs, we have incorporated many of the technological innovations from the Oasis-class ships and Solstice-class ships, respectively, across our fleet. In addition, to position ourselves for the future, we have embarked on several multi-year information technology strategic initiatives to ensure that we can continue to innovate and respond to the ever increasing expectations of our guests in a scalable and cost effective manner.

Travel agency support and direct business

Travel agencies continue to be the primary source of ticket sales for our ships. We believe in the value of this distribution channel and invest heavily in maintaining strong relationships with our travel partners. To accomplish this goal, we seek to ensure that our commission rates and incentive structures remain competitive with the marketplace. We also provide brand dedicated sales representatives who assist our travel partners through a number of platforms, including trained customer service representatives, call centers and online training tools.

To support our direct sales initiatives, we have established a Consumer Outreach department which allows consumers 24 hour access to our certified vacation planners, group vacation planners and customer service agents in our call centers throughout the world. In addition, we maintain and invest in our websites, including mobile applications and mobile websites, which allow guests to directly plan, book and customize their cruise, as well as encourage guests to book their next cruise vacations onboard our ships.

Guest Services

We offer to handle virtually all travel aspects related to guest reservations and transportation, including arranging guest pre- and post-hotel stay arrangements and air transportation.

Royal Caribbean International, Celebrity Cruises and Azamara Club Cruises offer rewards to their guests through their loyalty programs, Crown & Anchor Society, Captain's Club and Le Club Voyage, respectively, to encourage repeat business. Crown & Anchor Society has over 7.2 million members worldwide. Captain's Club and Le Club Voyage have 2.0 million members combined worldwide. Members are typically eligible to enroll in these complimentary programs after one sailing and earn increasing membership status by accumulating cruise points or credits, depending on the brand, which may be redeemed on future sailings. Members are awarded points or credits in proportion to the number of cruise days and stateroom category. The loyalty programs provide certain tiers of membership benefits which can be redeemed by guests after accumulating the number of cruise points or credits specified for each tier. In addition, upon achieving a certain level of cruise points or credits, members benefit from reciprocal membership benefits across all of our loyalty programs. Examples of the rewards available under our loyalty programs include, but are not limited to, priority ship embarkation, priority waitlist for shore excursions, complimentary laundry service, complimentary internet, booklets with onboard discount offers, upgraded bathroom amenities, private seating on the pool deck, ship tours and, in the case of our most loyal guests who have achieved the highest levels of cruise points or credits, complimentary cruises. We regularly work to enhance each of our loyalty programs by adding new features and amenities in order to reward our repeat guests.

Operations

Cruise Ships and Itineraries

As of December 31, 2012, our brands, including our 50% joint venture TUI Cruises, operate 41 ships with a selection of worldwide itineraries ranging from two to 18 nights that call on approximately 455 destinations.

Table of Contents

The following table presents summary information concerning the ships we will operate in 2013 under our six cruise brands, including our 50% joint venture TUI Cruises, and their geographic areas of operation based on 2013 itineraries (subject to change).

**Approximate
Berths**

ve not requested, and do not intend to request, a ruling from the IRS that the Operating Partnership will be classified as a partnership and not a corporation for federal income tax purposes. If for any reason the Operating Partnership were taxable as a corporation, rather than as a partnership for federal income tax purposes, we likely would not be able to qualify as a REIT unless we qualified for certain relief provisions. See the discussion under “Satisfy Income Tests,” “Asset Tests” and “Failure to Qualify” set forth above. In addition, any change in a Partnership’s status for tax purposes would constitute a taxable event, in which case we might incur tax liability without any related cash distribution. See “*Annual Distribution Requirements*” above. Items of income and deduction of such Partnership would not pass through to its partners, and its partners would be treated as stockholders of a corporation. Consequently, such Partnership would be required to pay income tax at corporate rates on its net income, and distributions to its partners would constitute dividends that would not be deductible in computing such Partnership’s taxable income.

, Not the Partnerships, Subject to Tax. A partnership is not a taxable entity for federal income tax purposes. Rather, we are required to allocate our allocable share of each Partnership's income, gains, losses, deductions, and credits for any taxable year of such Partnership ending with our taxable year, without regard to whether we have received or will receive any distribution from such Partnership.

Partnership Allocations. Although a partnership agreement generally will determine the allocation of income and losses among partners, such allocations are not regarded for tax purposes if they do not comply with the provisions of the Code and Treasury Regulations governing partnership allocations. If an allocation is not recognized for federal income tax purposes, the item subject to the allocation will be reallocated in accordance with the partners' interests in the partnership, which will be determined by taking into account all of the facts and circumstances relating to the economic arrangement of the partnership with respect to such item.

Allocations With Respect to Partnership Properties. Income, gain, loss, and deduction attributable to property that has appreciated or depreciated and contributed to a partnership in exchange for an interest in the partnership must be allocated in a manner such that the contributing partner is charged with its share of, respectively, the unrealized gain or unrealized loss associated with the property at the time of the contribution (the "704(c) Allocation"). The amount of such unrealized gain or unrealized loss, referred to as "built-in gain" or "built-in loss", generally is equal to the difference between the fair market value of the contributed property at the time of contribution and the adjusted tax basis of such property at the time of contribution (a "book-tax difference"). The rules with respect to book-tax differences are solely for federal income tax purposes and do not affect the book capital accounts or other economic allocations among the partners. A book-tax difference attributable to depreciable property generally is decreased on an annual basis as a result of depreciation deductions to the contributing partner for book purposes but not for tax purposes. The Treasury Regulations require entities to use a "reasonable method" for allocating items with respect to which there is a book-tax difference and outline several reasonable methods.

Any gain or loss recognized by a Partnership on the disposition of contributed properties will be allocated first to the partners of the Partnership who contributed such properties to the extent of their built-in gain or loss on those properties for federal income tax purposes. The partners' built-in gain or loss on contributed properties will equal the difference between the partners' proportionate share of the book value of those properties and the partner's tax basis allocable to those properties at the time of the contribution as reduced for any decrease in the book-tax difference. Any remaining gain or loss recognized by the Partnership on the disposition of the contributed properties, and any gain or loss recognized by the Partnership on the disposition of other properties, generally will be allocated among the partners in accordance with the partnership agreement, unless such allocations and agreements conflict with the requirements of applicable Treasury Regulations, in which case the allocation will be made in accordance with the partners' interests in the partnership.

On April 1, 2015, we acquired substantially all of the assets of Aviv REIT, Inc., through a merger of Aviv REIT, Inc., with and into our wholly owned subsidiary, which merger included a combination which resulted in the acquisition by the Operating Partnership of substantially all of our assets from the assets of Aviv Healthcare Properties Limited Partnership. We treated such transfer of the properties to the Operating Partnership as a contribution to the Operating Partnership. The Operating Partnership received a "carryover" tax basis in the contributed properties. As a result, such properties had significant built-in gain or loss subject to Section 704(c) of the Code. As general partner of the Operating Partnership, we may account for the book-tax difference with respect to the properties contributed to the Operating Partnership under any method approved by Section 704(c) of the Code and the Treasury Regulations, except that for those properties acquired by the Operating Partnership that were contributed by Aviv REIT, Inc., with respect to which the Operating Partnership has elected to use the "remedial method" of allocation pursuant to Treasury Regulations Section 1.704-1(b)(5)(D).

Partnership's Property. Generally, any gain realized by a Partnership on the sale of property held by the Partnership for more than one year is long-term capital gain, except for any portion of such gain that is treated as depreciation or cost recovery recapture. Our share of any gain realized on the sale of any property held by the Partnership as inventory or other property held primarily for sale to customers in the ordinary course of our or such Partnership's trade or business will be treated as income from a prohibited transaction that is subject to a 100% penalty tax. Such prohibited transactions may have an adverse effect upon our ability to satisfy the income tests for REIT status. See "*Income Tests*" above. We do not presently intend to acquire or hold or to allow any Partnership to acquire or hold any property that represents inventory or other property held primarily for sale to customers in the ordinary course of our or such Partnership's trade or business.

Government Regulation and Reimbursement

Healthcare industry is heavily regulated. Our operators are subject to extensive and complex federal, state and local healthcare laws and regulations. These laws and regulations are subject to frequent and substantial changes resulting from the adoption of new legislation, rules and regulations, administrative and judicial interpretations of existing law. The ultimate timing or effect of these changes, which may be applied retroactively, is uncertain. Changes in laws and regulations impacting our operators, in addition to regulatory non-compliance by our operators, can have a significant impact on the operations and financial condition of our operators, which in turn may adversely impact us. The following is a discussion of certain regulations generally applicable to our operators, and in certain cases

Healthcare Reform. A substantial amount of rules and regulations have been issued under the Patient Protection and Affordable Care Act, as amended by the Health Care and Education and Reconciliation Act of 2010 (collectively referred to as the “Healthcare Reform Law”). We expect additional rules and interpretations under the Healthcare Reform Law to be issued that may materially affect our operators’ financial condition and operations.

Under the Healthcare Reform Law, a Federal Commission on Long-Term Care was established which issued its report in September 2013. One of the recommendations was the convening of the White House Conference on Aging which met in July, 2015. At that meeting, it was announced that the Centers for Medicare and Medicaid Services (“CMS”) was issuing a proposed rule on July 16, 2015 that included a significant number of revisions to the conditions of participation for SNFs to receive Medicare and Medicaid payments. These proposed regulations will substantially impact the operations of our operators and reflect the advances made over the past 24 years in the theory and practices of service delivery and safety, including the impact of other regulations emphasizing service quality, value over volume of services, and consistency in reporting. A final rule has not yet been published.

Due to the complexity of the Healthcare Reform Law and the substantial requirements for regulation thereunder, the impact of the Healthcare Reform Law on our operators or their ability to meet their obligations to us cannot be predicted. The Healthcare Reform Law could result in decreases in payments from Medicare and Medicaid that otherwise adversely affect the financial condition of our operators, thereby negatively impacting our financial condition. Our operators may be successful in modifying their operations to lessen the impact of any increased costs or other adverse effects resulting from changes in government regulations, private insurance and/or employee welfare benefit plans. The impact of the Healthcare Reform Law on each of our operators will vary due to the mix, resident conditions and a variety of other factors. In addition to the provisions relating to reimbursement, other provisions of the Healthcare Reform Law may impact our operators as employers (e.g., requirements related to providing health insurance for employees).

Reimbursement Generally. A significant portion of our operators’ revenue is derived from governmentally-funded reimbursement programs, including Medicare and Medicaid. As federal and state governments focus on healthcare reform initiatives, and as the federal government and many states face significant current and future budget deficits, efforts to reduce costs by government payors will likely continue, which may result in reduced reimbursement at both the federal and state levels. These cost-cutting measures could result in a significant reduction of reimbursement rates for our operators under both the Medicare and Medicaid programs. Additionally, new and evolving payor and provider programs, including but not limited to Medicare Advantage, dual eligible, accountable care organizations, and bundled payments could adversely impact our tenants’ and operators’ financial condition or results of operations.

y believe that our operator coverage ratios are adequate and that our operators can absorb moderate reimbursement rate reductions and obligations to us. However, significant limits on the scopes of services reimbursed and/or reductions of reimbursement rates could have a effect on our operators' results of operations and financial condition, which could adversely affect our operators' ability to meet their ob

caid. State budgetary concerns, coupled with the implementation of rules under the Healthcare Reform Law, may result in significant cuts in spending at the state level. Many states are currently focusing on the reduction of expenditures under their state Medicaid programs, which could result in a reduction in reimbursement rates for our operators. The need to control Medicaid expenditures may be exacerbated by the potential for increased enrollment in Medicaid due to unemployment and declines in family incomes. Since our operators' profit margins on Medicaid patients are relatively low, more than modest reductions in Medicaid reimbursement or an increase in the number of Medicaid patients could adversely impact our operators' results of operations and financial condition, which in turn could negatively

Healthcare Reform Law provided for Medicaid coverage to be expanded to all individuals under age 65 with incomes up to 133% of the federal poverty line beginning January 1, 2014. The federal government committed to paying the entire cost for Medicaid coverage for newly eligible beneficiaries from 2014 through 2016. In 2017, the federal share will decline to 95%; in 2018, to 94%; in 2019, to 93%; and in 2020 and subsequent years

On June 28, 2012, however, the Supreme Court ruled that states could not be required to expand Medicaid or risk losing federal funding of their Medicaid programs. As of December 31, 2015, thirty-one states including the District of Columbia have expanded or are expanding Medicaid coverage in accordance with the requirements contemplated by the Healthcare Reform Law, with many of the remaining states involved in a variety of legislative proposals or discussions

On April 1, 2014, President Obama signed the "Protecting Access to Medicare Act of 2014" which calls for the United States Department of Health and Human Services ("HHS") to develop a value based purchasing program for SNFs aimed at lowering readmission rates beginning on October

On July 30, 2015, the Centers for Medicare & Medicaid Services ("CMS") issued a final rule outlining the FY 2016 Medicare payment rates for SNFs. SNF per diem payments are projected to increase by \$430 million, or 1.2%, from payments in FY 2015. This estimated increase is attributable to a market basket increase, reduced by a 0.6% forecast error adjustment and further reduced by 0.5% in accordance with the multifactor productivity adjustment required by law. The final rule also includes policies that advance setting measurable goals and timelines for paying SNFs based on quality of care rather than the quantity of care to

The "Medicare Access and CHIP Reauthorization Act of 2015" extended the Medicare therapy cap exceptions process through December 31, 2016. The Medicare Part B outpatient cap for occupational therapy is \$1,960 for 2016, and the combined cap for physical therapy and speech therapy is \$2,000 for 2016. These caps do not apply to therapy services covered under Medicare Part A for SNFs, although the caps apply in most other settings involving patients in SNFs or long-term care facilities who receive therapy services covered under Medicare Part B. The exception process allows for medically necessary therapy services beyond the cap limits. Expiration of the therapy cap exceptions process in the future could have a material adverse effect on our operators' financial condition and operations, which could adversely impact their ability to meet their obligations

The "Bipartisan Budget Act of 2015" ("BBA") was signed by President Obama on November 2, 2015. While the BBA provides \$80 billion in deficit reduction and sequestration relief over two years, it also extended Medicare sequestration, which generally cuts Medicare provider and plan payments by 2% per year, for an additional year, through 2025. The BBA also provides a uniform 2% reduction for 2024 instead of applying different rates for the first and second halves of the fiscal year. However, the fiscal year 2025 sequestration will be "front loaded," such that, a 4% reduction will be imposed during the first six months of the fiscal year and no reduction will be imposed during the second half of the fiscal year.

of Care Initiatives. CMS has implemented a number of initiatives focused on the quality of care provided by nursing homes that could, for instance, in December 2008, CMS released quality ratings for all of the nursing homes that participate in Medicare or Medicaid under the “Quality Rating System.” Facility rankings, ranging from five stars (“much above average”) to one star (“much below average”) are updated annually. SNFs are required to provide information for the CMS Nursing Home Compare website regarding staffing and quality measures. Based on the results of state health inspections, SNFs are then rated based on the five-star rating system. In 2015, CMS made changes to the rating system including: (1) revising scoring methodology by which quality measure ratings are calculated for SNFs; (2) increasing the number and type of quality measures that are not solely based on self-reported data and (3) adding critical measures to staffing such as turnover and retention. It is possible that any other ranking system could lead to future reimbursement policies that reward or penalize facilities on the basis of the reported quality of care. pa

has incorporated hospital readmissions review into the Quality Indicators Survey. Under Medicare's Inpatient Prospective Payment System, existing payments to hospitals for excessive readmissions of patients for heart attacks, heart failure and pneumonia during fiscal years beginning on or after October 1, 2012. Long term care facilities are under increased scrutiny to prevent residents from being readmitted to hospitals for these conditions. In particular, and have an opportunity to demonstrate their quality of care by reducing their hospital readmission rates. It is anticipated that hospital readmissions will be a consideration in the future in the CMS five-star rating system.

Inspector General Activities. The Office of Inspector General's (the "OIG") Work Plan for government fiscal year 2016, which describes the OIG plans to address during the fiscal year, includes two projects related specifically to nursing homes. (1) compliance with various aspects of the SNF prospective payment system; and (2) background checks for employees.

Fraud and Abuse. There are various federal and state civil and criminal laws and regulations governing a wide array of healthcare provider practices and arrangements, including laws and regulations prohibiting fraud by healthcare providers. Many of these complex laws raise issues that have not been clearly interpreted by the relevant governmental authorities and

issues include: (i) federal and state false claims acts, which, among other things, prohibit providers from filing false claims or making false statements to receive payment from Medicare, Medicaid or other federal or state healthcare programs; (ii) federal and state anti-kickback and fee-splitting laws, including the Medicare and Medicaid anti-kickback statute, which prohibit the payment or receipt of remuneration to induce referrals or recommendations for items or services, such as services provided in a SNF; (iii) federal and state physician self-referral laws (commonly referred to as the Stark Law), which generally prohibit referrals by physicians to entities for designated health services (some of which are provided in SNFs) with which the physician or a family member has a financial relationship; (iv) the federal Civil Monetary Penalties Law, which prohibits, among other things, the submission of a false or fraudulent claim for certain healthcare services and (v) federal and state privacy laws, including the privacy and security provisions of the Health Insurance Portability and Accountability Act of 1996, which provide for the privacy and security of personal health information.

Violations of healthcare fraud and abuse laws carry civil, criminal and administrative sanctions, including punitive sanctions, monetary penalties, imprisonment, denial of Medicare and Medicaid reimbursement and potential exclusion from Medicare, Medicaid or other federal or state healthcare programs. Additionally, there are criminal provisions that prohibit filing false claims or making false statements to receive payment or certification from Medicare and Medicaid, as well as failing to refund overpayments or improper payments. Violation of the anti-kickback statute or Stark Law may constitute a federal False Claims Act violation. These laws are enforced by a variety of federal, state and local agencies and can also be enforced by private litigants. In addition, though, among other things, federal and state false claims acts, which allow private litigants to bring qui tam or whistleblower actions, which have become more frequent in recent years.

Privacy. Our operators are subject to various federal, state and local laws and regulations designed to protect the confidentiality and security of personal information, including the federal Health Insurance Portability and Accountability Act of 1996, as amended, the Health Information Technology for Economic and Clinical Health Act, and the corresponding regulations promulgated thereunder (collectively referred to herein as "HIPAA"). HHS conducts audits of covered entities to evaluate compliance with HIPAA, and it will continue its audit program in 2016 which will also include audits of business associates and a focus on security risk assessments.

ates have similar laws and regulations that govern the maintenance and safeguarding of patient records, charts and other information generated with the provision of professional medical services. These laws and regulations require our operators to expend the requisite resources to protect health information, including the funding of costs associated with technology upgrades. Operators found in violation of HIPAA or other regulation may face large penalties. In addition, compliance with an operator's notification requirements in the event of a breach of protected health information could cause reputational harm to an operator's

Licensing and Certification. Our operators and facilities are subject to various federal, state and local licensing and certification laws and regulations, including laws and regulations under Medicare and Medicaid requiring operators of SNFs and ALFs to comply with extensive standards and conditions. Governmental agencies administering these laws and regulations regularly inspect our operators' facilities and investigate compliance and their managers receive notices of observed violations and deficiencies from time to time, and sanctions have been imposed from time to time on operators operated by them. In addition, many states require certain healthcare providers to obtain a certificate of need, which requires prior approval for the construction, expansion or closure of certain healthcare facilities, which has the potential to impact some of our operators' abilities to expand their business.

Americans with Disabilities Act (the "ADA"). Our properties must comply with the ADA and any similar state or local laws to the extent they require public accommodations as defined in those statutes. The ADA may require removal of barriers to access by persons with disabilities in certain areas of our properties where such removal is readily achievable. Should barriers to access by persons with disabilities be discovered at any time, we may be directly or indirectly responsible for additional costs that may be required to make facilities ADA-compliant. Noncompliance with the ADA could result in the imposition of fines or an award of damages to private litigants. Our commitment to make readily achievable accommodations pursuant to the ADA is ongoing, and we continue to assess our properties and make modifications as appropriate in the future.

Consumer Protection and Regulations. Additional federal, state and local laws and regulations affect how our operators conduct their operations, including laws protecting consumers against deceptive practices and otherwise generally affecting our operators' management of their property and operations. These laws include laws governing the conduct of their operations (including laws and regulations involving fire, health and safety; quality of services, including care and food services; and residents' rights, including abuse and neglect laws; and the health standards set by the federal Occupational Safety and Health Administration).

Arbitration and Professional Liability. Although arbitration agreements have been effective in limiting general and professional liabilities for SNF providers, there have been numerous lawsuits challenging the validity of arbitration agreements in long term care settings. On July 16, 2015, the Department of Health and Human Services proposed a rule on, Reform of Requirements for Long-Term Care Facilities, which would require SNFs to explain binding arbitration agreements to residents and their families before they sign them. The rule would also prohibit requiring arbitration agreements as a condition of admission. While the rule has not been promulgated, if this rule is finalized as proposed, there would likely be an increase in liabilities for SNF and long term care providers.

Executive Officers of Our Company

As of February 1, 2016, the executive officers of our company were as follows:

Taylor Pickett (54) is our Chief Executive Officer and has served in this capacity since June 2001. Mr. Pickett has also served as Director of our company since May 30, 2002. Mr. Pickett's term as a Director expires in 2017. Mr. Pickett has also been a member of the board of trustees of the American Properties Trust, an office REIT focusing on U.S. government agencies and defense contractors, since November 2013. Mr. Pickett is also a director of iStockphoto, a technology company. From January 1993 to June 2001, Mr. Pickett served as a member of the senior management team of Integrated Health Services, Inc., most recently as Executive Vice President and Chief Financial Officer. Prior to joining Integrated Health Services, Inc. Mr. Pickett held various positions at PHH Corporation and KPMG Peat Marwick Main & Smith.

John Booth (52) is our Chief Operating Officer and has served in this capacity since October 2001. From 1993 to October 2001, Mr. Booth served as a member of the management team of Integrated Health Services, Inc., most recently serving as Senior Vice President, Finance. Prior to joining Integrated Health Services, Inc., Mr. Booth served as a Vice President in the Healthcare Lending Division of Maryland National Bank (now Bank of America).

J. Insoft (51) is our Chief Corporate Development Officer and has served in this capacity since April 1, 2015. Mr. Insoft served as President and Managing Officer of Aviv REIT, Inc. since 2012, while previously serving as Chief Financial Officer and Treasurer. Prior to joining Aviv REIT, Inc. in 2012, Mr. Insoft spent eight years as a Vice President and Senior Investment Officer of Nationwide Health Properties, Inc., a publicly-traded real estate company, where that, he was President and Chief Financial Officer of CMI Senior Housing & Healthcare, Inc., a privately-held nursing home and assisted living facility operations and development company, for seven years. Mr. Insoft received an M.B.A. from Columbia University and a B.S.E. in Mechanical Engineering from the University of Pennsylvania.

Stephen Stephenson (52) is our Chief Financial Officer and has served in this capacity since August 2001. From 1996 to July 2001, Mr. Stephenson served as Senior Vice President and Treasurer of Integrated Health Services, Inc. Prior to joining Integrated Health Services, Inc., Mr. Stephenson held senior financial positions at CSX Intermodal, Inc., Martin Marietta Corporation and Electronic Data Systems Corporation.

el D. Ritz (47) is our Chief Accounting Officer and has served in this capacity since February 2007. From April 2005 to February 2007, I served as the Vice President, Accounting & Assistant Corporate Controller of Newell Rubbermaid Inc., and from August 2002 to April 2005, I served as the Director, Financial Reporting of Newell Rubbermaid Inc. From July 2001 through August 2002, Mr. Ritz served as the Director of Accounting and Controller of Nov

As of December 31, 2015, we had 58 full-time employees, including the five executive officers listed below.

Item 1A - Risk Factors

There are some of the risks and uncertainties that could cause the Company's financial condition, results of operations, business and prospects to differ materially from those contemplated by the forward-looking statements contained in this report or the Company's other filings with the SEC. These risks should be read in conjunction with the other risks described in this report including but not limited to those described in "Taxation" and "Insurance and Reimbursement" under "Item 1" above. The risks described below are not the only risks facing the Company and there may be additional risks of which the Company is not presently aware or that the Company currently considers unlikely to significantly impact the Company. Our business, results of operations or liquidity could be materially adversely affected by any of these risks, and, as a result, the trading price of our common stock could decline.

Risks Related to the Operators of Our Vessels

Our financial position could be weakened and our ability to make distributions and fulfill our obligations with respect to our indebtedness could be impaired if our major operators become unable to meet their obligations to us or fail to renew or extend their relationship with us as their lease terms expire, mortgages mature, or if we become unable to lease or re-lease our facilities or make mortgage loans on economically favorable terms. We do not have control over our operators. Adverse developments concerning our operators could arise due to a number of factors, including those listed below.

The bankruptcy or insolvency of our operators could limit or delay our ability to recover on our investments.

We are also exposed to the risk that a distressed operator may not be able to meet its lease, mortgage or other obligations to us or other third parties. This risk is heightened during a period of economic or political instability. Although each of our lease and loan agreements typically provide us with the right to evict an operator, foreclose on our collateral, demand immediate payment and exercise other remedies upon the bankruptcy or insolvency of an operator, Title 11 of the United States Code, as amended and supplemented (the "Bankruptcy Code"), would limit or, at a minimum, delay our ability to recover on our investments. We may be required to pay unpaid pre-bankruptcy rents and mortgage payments and to pursue other remedies against a bankrupt operator.

bankruptcy filing by one of our lessee operators would typically prevent us from collecting unpaid pre-bankruptcy rents or evicting the lessee without the approval of the bankruptcy court. The Bankruptcy Code provides a lessee with the option to assume or reject an unexpired lease with certain limitations and periods of time. Generally, a lessee is required to pay all rent that becomes payable between the date of its bankruptcy filing and the date of its assumption or rejection of the lease (although such payments will likely be delayed as a result of the bankruptcy filing). If one of our lessee operators assumes its lease with us, the operator must cure all monetary defaults existing under the lease (including payment of unpaid pre-bankruptcy rents) and provide adequate assurance of its ability to perform its future obligations under the lease. If one of our lessee operators opts to reject its lease, we would have a claim against such operator for unpaid and future rents payable under the lease, but such claim would be subject to a statutory cap and generally result in a recovery substantially less than the face value of such claim. Although the operator's rejection of the lease would prevent us from recovering possession of the leased facility, we would likely face losses, costs and delays associated with re-leasing the facility to a new lessee.

Other factors could impact our rights under leases with bankrupt operators. First, the operator could seek to assign its lease with us to a third party. The bankruptcy Code generally disregards anti-assignment provisions in leases to permit the assignment of unexpired leases to third parties (provided that the operator defaults under the lease are cured and the third party can demonstrate its ability to perform its obligations under the lease). Second, in instances where we have entered into a master lease agreement with an operator that operates more than one facility, the bankruptcy court could determine whether the lease was comprised of separate, divisible leases (each of which could be separately assumed or rejected), rather than a single, integrated lease (which would have to be assumed or rejected in its entirety). Finally, the bankruptcy court could re-characterize our lease agreement as a disguised sale or other arrangement, which could require us to receive bankruptcy court approval to foreclose or pursue other remedies with respect to the lease.

Third, a bankruptcy filing by an operator to whom we have made a mortgage loan would typically prevent us from collecting unpaid pre-bankruptcy payments and foreclosing on our collateral, absent approval of the bankruptcy court. As an initial matter, we could ask the bankruptcy court to require the operator to make periodic payments or provide other financial assurances to us during the bankruptcy case (known as “adequate protection”). The decision regarding “adequate protection” (including the timing and amount) rests with the bankruptcy court. In addition, we would need the court’s approval before commencing or continuing any foreclosure action against the operator’s facility. The bankruptcy court could withhold such approval if the operator can demonstrate that the facility is necessary for an effective reorganization and that we have a sufficient “equity cushion” in the facility. If the bankruptcy court does not either grant us “adequate protection” or permit us to foreclose on our collateral, we may not receive any payments until after the bankruptcy court confirms a plan of reorganization for the operator. Even if the bankruptcy court permits us to foreclose on the facility, we would still be subject to the losses, costs and other risks associated with a foreclosure sale, including possible successor liability, environmental programs, indemnification obligations and suspension or delay of third-party payments. Should such events occur, our income and cash flow from operations would be adversely affected.

Our operators to comply with various local, state and federal government regulations may adversely impact their ability to make debt payments.

Our operators are subject to numerous federal, state and local laws and regulations, including those described below, that are subject to frequent and substantial changes (sometimes applied retroactively) resulting from new legislation, adoption of rules and regulations, and administrative and judicial interpretations of existing law. The ultimate timing or effect of these changes cannot be predicted. These changes may have a dramatic effect on the costs of doing business and on the amount of reimbursement by both government and other third-party payors. The failure of any of our operators to comply with these laws, requirements and regulations could adversely affect their ability to meet their obligations to us.

Medicare and Medicaid. A significant portion of our operators’ revenue is derived from governmentally-funded reimbursement programs such as Medicare and Medicaid. See “Item 1. Business – Government Regulation and Reimbursement – Healthcare Reform,” “– Reimbursement from Governmental and Other Third-Party Payors,” and the risk factor entitled “Our operators depend on reimbursement from governmental and other third-party payors, and reimbursement from these payors may be reduced” for a further discussion on governmental and third-party payor reimbursement and the associated risks presented. Failure to maintain certification in these programs would result in a loss of funding from such programs and could negatively impact an operator’s ability to meet its obligations to us.

Quality of Care Initiatives. The CMS has implemented a number of initiatives focused on the quality of care provided by nursing homes, which could affect our operators, including a quality rating system for nursing homes. See “Item 1. Business – Government Regulation and Reimbursement – Quality of Care Initiatives.” Any unsatisfactory rating of our operators under any rating system promulgated by the CMS could result in a loss of funding from such programs and could negatively impact an operator’s ability to meet its obligations to us.

result in the loss of our operators' residents or lower reimbursement rates, which could adversely impact their revenues and our business.

Licensing and Certification. Our operators and facilities are subject to various federal, state and local licensing and certification laws and regulations, including laws and regulations under Medicare and Medicaid requiring operators of SNFs and ALFs to comply with extensive standards governing operations. See “*Item 1. Business – Government Regulation and Reimbursement – Licensing and Certification.*” Government agencies administering these laws and regulations regularly inspect our operators' facilities and investigate complaints. Our operators and managers receive notices of observed violations and deficiencies from time to time, and sanctions have been imposed from time to time on facilities operated by them. Failure to obtain any required licensure or certification, the loss or suspension of any required licensure or certification, or any violations or deficiencies with respect to relevant operating standards may require a facility to cease operations or render it ineligible for reimbursement until the necessary licenses or certifications are obtained or reinstated, or any such violations or deficiencies are cured. In such event, our revenues from these facilities could be reduced or eliminated for an extended period of time or permanently. Furthermore, many states require certain healthcare providers to obtain a certificate of need, which requires prior approval for the construction, expansion or closure of certain healthcare facilities, which has the potential to impact some of our operators' abilities to expand or change their business.

Fraud and Abuse Laws and Regulations. There are various federal and state civil and criminal laws and regulations governing a wide array of healthcare provider referrals, relationships and arrangements, including laws and regulations prohibiting fraud by healthcare providers. These complex laws raise issues that have not been clearly interpreted by the relevant governmental authorities and courts. In addition, federal and state governments are devoting increasing attention and resources to anti-fraud initiatives against healthcare providers. See “*Item 1. Business – Government Regulation and Reimbursement – Fraud and Abuse.*” The violation by an operator of any of these laws or regulations, including the anti-kickback statute and the Stark Law, may result in the imposition of fines or other penalties, including exclusion from Medicare, Medicaid and all other federal and state healthcare programs. Such fines or penalties could jeopardize an operator’s ability to make lease or mortgage payments to us or to continue operating its facility. Additionally, many states have adopted or are considering legislative proposals similar to federal anti-fraud and abuse laws, some of which extend beyond the Medicare and Medicaid programs to third-party payors, to prohibit payment or receipt of remuneration for the referral of patients and physician self-referrals, regardless of whether the service was reimbursed by Medicare or Medicaid.

Privacy Laws. Our operators are subject to federal, state and local laws and regulations designed to protect the privacy and security of protected health information, including HIPAA, among others. See “*Item 1. Business – Government Regulation and Reimbursement – Privacy.*” These laws and regulations require our operators to expend the requisite resources to protect and secure patient health information, including the full costs associated with technology upgrades. Operators found in violation of HIPAA or any other privacy or security law may face significant penalties. In addition, a breach of unsecured protected health information could cause reputational harm to an operator’s business.

Other Laws. Other federal, state and local laws and regulations affect how our operators conduct their operations. See “*Item 1. Business – Government Regulation and Reimbursement – Other Laws and Regulations.*” We cannot predict the effect that the costs of complying with these laws may have on the revenues of our operators, and thus their ability to meet their obligations to us.

Legislative and Regulatory Developments. Each year, legislative and regulatory proposals are introduced at the federal, state and local level that, if adopted, would result in major changes to the healthcare system. See “*Item 1. Business – Government Regulation and Reimbursement – Legislative and Regulatory Developments.*” In addition to the other risk factors set forth below, we cannot accurately predict whether any proposals will be adopted, and if adopted, what (if any) these proposals would have on our operators or our business.

Provisions of the Protecting Access to Medicare Act of 2014 require certain changes to reimbursement and studies of reimbursement policies that adversely affect payments

Provisions of the Protecting Access to Medicare Act of 2014 and other legislation will affect Medicare payments to SNFs, including, but not limited to, provisions changing the payment methodology, implementing value-based purchasing and payment bundling and studying the appropriate adjustments on payments for health care acquired conditions. These provisions are in various stages of implementation. See “*Item 1. Business – Government Regulation and Reimbursement – Healthcare Reform,*” “*– Reimbursement,*” “*– Medicaid,*” and “*– Medicare.*” Although we cannot accurately predict when such provisions may be implemented, or the effect any such implementation would have on our operators or our business, these provisions could result in decreases in payments to our operators, increase our operators’ costs or otherwise adversely affect the financial condition of our operators, which could negatively impact their ability to meet their obligations to us.

The Healthcare Reform Law imposes additional requirements on SNFs regarding compliance and

Healthcare Reform Law required SNFs to implement, by March 2013, a compliance and ethics program that is effective in preventing and promoting quality of care. However to date, HHS has failed to issue the proposed regulations to implement this law. While the timing for implementation and specific requirements may be in question, there is a clear statutory mandate for Medicare and CHIP providers or suppliers and nursing facilities to have effective compliance and ethics programs. Accordingly, it remains unclear when the provision of the law will be enforced until the regulations are issued. See “*Item 1. Business – Government Regulation and Reimbursement – Compliance*.” If our operators fall short in their compliance and ethics programs and quality assurance and performance improvement programs, if required, their reputations and ability to attract residents could be adversely

Our operators depend on reimbursement from governmental and other third-party payors, and reimbursement rates from such payors may be

impacted by a change in the reimbursement rate or methods of payment from third-party payors, including the Medicare and Medicaid programs, or the implementation of measures to reduce reimbursements for services provided by our operators has in the past, and could in the future, result in a substantial reduction in our operators’ revenues and operating margins. See “*Item 1. Business – Government Regulation and Reimbursement – Reimbursement, – Medicare and Medicaid*.” We currently believe that our operator coverage ratios are adequate and that our operators can absorb moderate reimbursement rate reductions and still meet their obligations to us. However, significant limits on the scopes of services reimbursed and on reimbursement rates could have a material adverse effect on our operators’ results of operations and financial condition, which could cause the revenues of our operators to decline and impact their ability to meet their obligations

Additionally, net revenue realizable under third-party payor agreements can change after examination and retroactive adjustment by payors during payment processes or as a result of post-payment audits. Payors may disallow requests for reimbursement based on determinations that certain services are not reimbursable or reasonable, additional documentation is necessary or certain services were not covered or were not medically necessary. Legislative and regulatory proposals could impose further limitations on government and private payments to healthcare providers. In some cases, states are considering enacting measures designed to reduce Medicaid expenditures and to make changes to private healthcare insurance. We cannot make assurances that adequate third-party payor reimbursement levels will continue to be available for the services provided by our operators.

Government budget deficits could lead to a reduction in Medicare and Medicaid reimbursement

President Obama and members of the U.S. Congress have approved or proposed various spending cuts and tax reform initiatives that have resulted in changes (including substantial reductions in funding) to Medicare, Medicaid or Medicare Advantage Plans. Any such existing or future legislation relating to deficit reduction that reduces reimbursement payments to healthcare providers could have a material adverse effect on certain operators’ liquidity, financial condition or results of operations, which could adversely affect their ability to satisfy their obligations to us and could have a material adverse effect on us. Additionally, many states are focusing on the reduction of expenditures under their Medicaid programs, which may result in a reduction in reimbursement rates for our operators. See “*Item 1. Business – Government Regulation and Reimbursement – Reimbursement, – Medicare and Medicaid*.” These potential reductions could be compounded by the potential for federal cost-cutting efforts that could lead to reductions in reimbursements.

ers under both the Medicare and Medicaid programs. Potential reductions in Medicare and Medicaid reimbursement to our operators could reduce the cash flow of our operators and their ability to make rent or mortgage payments to us. The need to control Medicaid expenditures may be exacerbated by the need to pay for increased enrollment in Medicaid due to unemployment and declines in family incomes. Medicaid enrollment may continue to increase as the Healthcare Reform Law allowed states to increase the number of people who are eligible for Medicaid in 2014. Since our operators' margins on Medicaid patients are generally relatively low, more than modest reductions in Medicaid reimbursement and an increase in the number of Medicaid patients could place some operators in financial distress, which in turn could adversely affect us. If funding for Medicare and/or Medicaid is reduced, it could have a material adverse effect on our operators' results of operations and financial condition, which could adversely affect our ability to meet their obligations.

We may be unable to find a replacement operator for one or more of our leased properties.

From time to time, we may need to find a replacement operator for one or more of our leased properties for a variety of reasons, including expiration of the lease term or the occurrence of an operator default. During any period in which we are attempting to locate one or more replacement operators, there could be a decrease or cessation of rental payments on the applicable property or properties. We cannot assure you that any of our operators will elect to renew their respective leases with us upon expiration of the terms thereof. Similarly, we cannot assure you that we will be able to find a suitable replacement operator or, if we are successful in locating a replacement operator, that the rental payments from the new operator will be significantly less than the existing rental payments. Our ability to locate a suitable replacement operator may be significantly delayed or limited by state licensing, receivership, certificate of need or other laws, as well as by Medicare and Medicaid change-of-ownership rules. We also may incur significant additional expenses in connection with any such licensing, receivership or change-of-ownership proceedings. Any such delays, limitations or expenses could materially delay or impact our ability to collect rent, obtain possession of leased properties or otherwise exercise remedies for operator default.

An economic slowdown could adversely impact our operating income and earnings, as well as the results of operations of our operators, which could impair their ability to meet their obligations.

Because the risks associated with our investments will be more acute during periods of economic slowdown or recession (such as the recent recession), we may experience an adverse impact caused by various factors including inflation, deflation, increased unemployment, volatile energy costs, geopolitical instability, and cost of credit, the U.S. mortgage market, a distressed real estate market, market volatility and weakened business and consumer confidence. An economic operating environment caused by an economic slowdown or recession could have an adverse impact on the ability of our operators to collect rent, occupancy rates, which could harm their financial condition. Any sustained period of increased payment delinquencies, foreclosures or loss of operators under our leases and loans could adversely affect our income from investments in our properties.

Certain third parties may not be able to satisfy their obligations to us or our operators due to uncertainty in the capital markets.

Interest rate fluctuations, financial market volatility or credit market disruptions could limit the ability of our operators to obtain credit to finance their operations on acceptable terms, which could adversely affect their ability to satisfy their obligations to us. Similarly, if any of our other counterparties, such as lender of credit issuers, insurance carriers, banking institutions, title companies and escrow agents, experience difficulty in accessing capital markets or sources of funds or fail to remain a viable entity, it could have an adverse effect on our operations.

Our operators may be subject to significant legal actions that could result in their increased operating costs and substantial uninsured liabilities, which may affect their ability to meet their obligations.

As a result of our involvement in the long-term healthcare industry, our operators are often subject to claims for damages relating to the services that they provide. We provide no assurance that the insurance coverage maintained by our operators will cover all claims made against them or continue to be available.

able cost, if at all. In some states, insurance coverage for the risk of punitive damages arising from professional and general liability claims may not, in certain cases, be available to operators due to state law prohibitions or limitations of availability. As a result, our operators operating in these states may be liable for punitive damage awards that are either not covered or are in excess of their insurance policies.

We believe that there has been, and will continue to be, an increase in governmental investigations of long-term care providers, particularly in connection with Medicare/Medicaid false claims, as well as an increase in enforcement actions resulting from these investigations. Insurance is not available to cover such losses. Any adverse determination in a legal proceeding or governmental investigation, whether currently asserted or arising in the future, could have a material adverse effect on an operator's financial condition. If an operator is unable to obtain or maintain insurance coverage, or if recoveries are obtained in excess of the insurance coverage, if an operator is required to pay uninsured punitive damages, or if an operator is subject to a material government enforcement action, the operator could be exposed to substantial additional liabilities. Such liabilities could adversely affect an operator's ability to meet its obligations.

on, we may in some circumstances be named as a defendant in litigation involving the services provided by our operators. Although we are not directly involved in the services provided by our operators, and our standard lease agreements and loan agreements generally require our operators to indemnify us and carry insurance to cover us in certain cases, a significant judgment against us in such litigation could exceed our and our operators' insurance coverage, which would require us to make payments to cover the judgment.

Increased competition as well as increased operating costs result in lower revenues for some of our operators and may affect the ability of our operators to meet their obligations to us.

The senior care and healthcare industry is highly competitive and we expect that it may become more competitive in the future. Our operators are competing with other companies providing similar healthcare services or alternatives such as home health agencies, life care at home, community-based retirement communities and convalescent centers. Our operators compete on a number of different levels including the quality of care provided, the physical appearance of a facility, price, the range of services offered, family preference, alternatives for healthcare delivery, the availability of long-term care properties, physicians, staff, referral sources, location and the size and demographics of the population in the surrounding areas. We do not guarantee that the operators of all of our facilities will be able to achieve occupancy and rate levels that will enable them to meet all of their obligations to us. Our operators may encounter increased competition in the future that could limit their ability to attract residents or expand their businesses and, in some cases, affect their ability to pay their lease or mortgage payments.

In addition, the market for qualified nurses, healthcare professionals and other key personnel is highly competitive and our operators may experience difficulties in attracting and retaining qualified personnel. Increases in labor costs due to higher wages and greater benefits required to attract and retain healthcare personnel incurred by our operators could affect their ability to meet their obligations to us. This situation could be particularly acute in certain states that have enacted legislation establishing minimum staffing requirements.

We may be unable to successfully foreclose on the collateral securing our mortgage loans, and even if we are successful in our foreclosure efforts, we may be unable to successfully find a replacement operator, or operate or occupy the underlying real estate, which may adversely affect our ability to recover our investment.

If an operator defaults under one of our mortgage loans, we may foreclose on the loan or otherwise protect our interest by acquiring title to the property. In some scenarios, we may be required to make substantial improvements or repairs to maximize the facility's investment potential. Operators may, in the event of foreclosure or other remedies, seek bankruptcy protection against our exercise of enforcement or other remedies and/or bring claims for injunctive relief in response to actions to enforce mortgage obligations. Even if we are able to successfully foreclose on the collateral securing our mortgage loans, we may be unable to expeditiously find a replacement operator, if at all, or otherwise successfully operate or occupy the property, which could adversely affect our ability to recover our investment.

Uninsured losses or losses in excess of our operators' insurance coverage could adversely affect our financial position and our cash flow.

terms of our leases, our operators are required to maintain comprehensive general liability, fire, flood, earthquake, boiler and machinery, automobile or long-term care professional liability and extended coverage insurance with respect to our properties with policy specifications, limits and deductibles set forth in the leases or other written agreements between us and the operator. However, our properties may be adversely affected by events which exceed insurance coverages and reserves. Should an uninsured loss occur, we could lose both our investment in, and anticipated cash flows from, the property. Even if it were practicable to restore the property to its condition prior to the damage caused by a major casualty, operations of the affected property would likely be suspended for a considerable period of time. In the event of any substantial loss affecting a property, there could be disputes over insurance claims covering the loss.

Risks Related to Us and Our Operating Partnership

Our primary assets are the units of partnership interest in Omega OP and, as a result, we will depend on distributions from the Partnership, including dividends and distributions.

The Company is a holding company and has no material assets other than units of partnership interest in its operating partnership, Omega OP. We rely on the Partnership to make distributions to partners, including the Company, in an amount sufficient to allow us to qualify as a REIT for U.S. tax purposes and to pay all of our expenses. To the extent we need funds and Omega OP is restricted from making distributions under applicable law, or if Omega OP is otherwise unable to provide such funds, the failure to make such distributions could materially adversely affect our operations and financial condition.

external sources of capital to fund future capital needs, and if we encounter difficulty in obtaining such capital, we may not be able to fund future investments necessary to grow our business or meet maturing commitments.

To qualify as a REIT under the Code, we are required to, among other things, distribute at least 90% of our REIT taxable income each year to our investors. Because of this distribution requirement, we may not be able to fund, from cash retained from operations, all future capital needs, including investments and to satisfy or refinance maturing commitments. As a result, we rely on external sources of capital, including equity financing. If we are unable to obtain needed capital at all or only on unfavorable terms from these sources, we might not be able to fund investments needed to grow our business, or to meet our obligations and commitments as they mature, which could negatively affect the ratings of our debt. In extreme circumstances, affect our ability to continue operations. Our access to capital depends upon a number of factors over which we have little or no control, including the performance of the national and global economies generally; competition in the healthcare industry; issues in the healthcare industry, including regulations and government reimbursement policies; our operators' operating costs; the ratings of our debt securities; the market's perception of our growth potential; the market value of our properties; our current and potential future earnings and cash distributions; and the price of the shares of our capital stock. Difficult capital market conditions in our industry during the past several years, and our need to raise capital, have limited and may continue to limit our access to capital. While we currently have sufficient cash flow from operations to fund our obligations and commitments, we may not be in a position to take advantage of future investment opportunities in the event that we are unable to access the capital markets on a timely basis or we are only able to obtain financing on unfavorable

economic conditions and turbulence in the credit markets may create challenges in securing third-party borrowings or refinancing our existing debt.

Under current economic conditions, the availability and cost of credit, turmoil in the mortgage market and depressed real estate markets have contributed to increased volatility and diminished expectations for real estate markets and the economy as a whole. Significant economic disruption and volatility could impact our ability to secure third-party borrowings or refinance our existing debt in the future.

Our ability to raise capital through equity sales is dependent, in part, on the market price of our common stock, and our failure to meet market expectations with respect to our business could negatively impact the market price of our common stock and availability of equity capital.

As a publicly-traded company, the availability of equity capital will depend, in part, on the market price of our common stock which, in turn, will depend upon various market conditions and other factors that may change from time to time including:

- the extent of investor interest;
- the reputation of REITs and the attractiveness of their equity securities in comparison to other equity securities, including securities issued by non-REIT based companies;

- the financial performance of us and our operators;
- analyst reports on us and the REIT industry in general;
- stock and bond market conditions, including changes in interest rates on fixed income securities, which may lead prospective purchasers of our common stock to demand a higher annual yield from future distributions;

to maintain or increase our dividend, which is dependent, to a large part, on the increase in funds from operations, which in turn depend on revenues from additional investments and rental increases; and

- other factors such as governmental regulatory action and changes in REIT tax laws.

The market value of the equity securities of a REIT is generally based upon the market's perception of the REIT's growth potential and its expected future earnings and cash distributions. Our failure to meet the market's expectation with regard to future earnings and cash distributions likely adversely affect the market price of our common stock and, as a result, the availability of equity capital.

subject to risks associated with debt financing, which could negatively impact our business and limit our ability to make distributions to stockholders and to repay matur

ing required to make future investments and satisfy maturing commitments may be provided by borrowings under our credit facilities, issuings of debt or equity, the assumption of secured indebtedness, mortgage financing on a portion of our owned portfolio or through joint ventures. If we must obtain debt financing from external sources to fund our capital requirements, we cannot guarantee such financing will be available on favorable terms, if at all. In addition, if we are unable to refinance or extend principal payments due at maturity or pay them with proceeds from other sources, our cash flow may not be sufficient to make distributions to our stockholders and repay our maturing debt. Furthermore, if prevailing market conditions or changes in our debt ratings or other factors at the time of refinancing result in higher interest rates upon refinancing, the interest expense related to our secured indebtedness would increase, which could reduce our profitability and the amount of dividends we are able to pay. Moreover, additional debt financing increases the amount of our leverage. The degree of leverage could have important consequences to stockholders, including affecting our investment grade ratings and our ability to obtain additional financing in the future, and making us more vulnerable to a downturn in our operations or the economy generally.

Unforeseen costs associated with the acquisition of new properties could reduce our pro

cess strategy contemplates future acquisitions that may not prove to be successful. For example, we might encounter unanticipated difficulties relating to our acquired properties, including contingent liabilities, or our newly acquired properties might require significant maintenance that would otherwise be devoted to our ongoing business. As a further example, if we agree to provide funding to enable healthcare operators to build and renovate facilities on our properties and the project is not completed, we could be forced to become involved in the development and completion or we could lose the property. Such costs may negatively affect our results of operations.

We may not be able to adapt our management and operational systems to integrate and manage our growth without additional

resources. We cannot assure you that we will be able to adapt our management, administrative, accounting and operational systems to integrate and manage our long-term care facilities we have acquired in the past and those that we may acquire under our existing cost structure in a timely manner. Our inability to integrate and manage recent and future acquisitions or developments could have a material adverse effect on our results of operations and financial condition.

We may be subject to additional risks in connection with our recent and future acquisitions of long-term care facilities.

We may be subject to additional risks in connection with our recent and future acquisitions of long-term care facilities, including but not limited to the following:

our limited prior business experience with certain of the operators of the facilities we have recently acquired or may acquire in the future; the facilities may underperform due to various factors, including unfavorable terms and conditions of the lease agreements that we assume; interruptions caused by the management of the operators of the facilities or changes in economic conditions impacting the facilities and/or operators;

- diversion of our management's attention away from other business concerns;
- exposure to any undisclosed or unknown potential liabilities relating to the facilities; and
- potential underinsured losses on the facilities.

cannot assure you that we will be able to manage our recently acquired or future new facilities without encountering difficulties or that difficulties will not have a material adverse effect on our business.

Our assets may be subject to impairment

Periodically, but not less than annually, evaluate our real estate investments and other assets for impairment indicators. The judgment regarding impairment indicators is based on factors such as market conditions, operator performance and legal structure. If we determine that a significant impairment has occurred, we are required to make an adjustment to the net carrying value of the asset, which could have a material adverse effect on our results of operations and funds from operations in the period in which the write-off occurs.

We may not be able to sell certain closed facilities for their book value

From time to time, we close facilities and actively market such facilities for sale. To the extent we are unable to sell these properties for our book value, we may be required to take a non-cash impairment charge or loss on the sale, either of which would reduce our net income.

Our indebtedness could adversely affect our financial condition

As a result of a material amount of indebtedness and we may increase our indebtedness in the future. Debt financing could have important consequences for our stockholders. For example:

- increase our vulnerability to adverse changes in general economic, industry and competitive conditions;
- limit our ability to borrow additional funds for working capital, capital expenditures, acquisitions, debt service requirements, execution of our business plan or other general corporate purposes on satisfactory terms or at all;
- require us to dedicate a substantial portion of our cash flow from operations to make payments on our indebtedness and leases, thereby reducing the amount of our cash flow to fund working capital, capital expenditures and other general corporate purposes;
- limit our ability to make material acquisitions or take advantage of business opportunities that may arise;
- expose us to fluctuations in interest rates, to the extent our borrowings bear variable rates of interests;
- limit our flexibility in planning for, or reacting to, changes in our business and the industry in which we operate; and
- place us at a competitive disadvantage compared to our competitors that have less debt.

Covenants in our debt documents limit our operational flexibility, and a covenant breach could materially adversely affect our operations

The terms of our credit agreements and note indentures require us to comply with a number of customary financial and other covenants which may, at the lender's discretion by restricting our ability to, among other things, incur additional debt, redeem our capital stock, enter into certain transactions, pay dividends and make other distributions, make investments and other restricted payments, and create liens. Any additional financing agreements we enter into could contain similar or more restrictive covenants. Our continued ability to incur indebtedness and conduct our operations is subject to our compliance with these covenants.

financial and other covenants. Breaches of these covenants could result in defaults under the instruments governing the applicable indebtedness, which could result in a default under the instruments governing the applicable indebtedness on to any other indebtedness cross-defaulted against such instruments. Any such breach could materially adversely affect our business, operations and financial condition.

We have now, and may have in the future, exposure to contingent rent expense.

We derive revenue primarily by leasing our assets under leases that are long-term triple-net leases in which the rental rate is generally fixed with certain escalators, subject to certain limitations. Certain leases contain escalators contingent on changes in the Consumer Price Index. If the Consumer Price Index does not increase, our revenues may not increase.

We are subject to particular risks associated with real estate ownership, which could result in unanticipated losses or

Business is subject to many risks that are associated with the ownership of real estate. For example, if our operators do not renew their leases or re-lease the facilities at favorable rental rates, if at all. Other risks that are associated with real estate acquisition and ownership include, but are not limited to, the following:

- general liability, property and casualty losses, some of which may be uninsured;
- the inability to purchase or sell our assets rapidly to respond to changing economic conditions, due to the illiquid nature of real estate and the real estate market;
- the expiration of leases that are not renewed or are renewed at lower rental amounts at expiration;
- the exercise of purchase options by operators resulting in a reduction of our rental revenue;
- the need for capital expenditures for maintenance and repair of our facilities and the need to make expenditures due to changes in governmental regulations, including those relating to the Americans with Disabilities Act;
- environmental hazards created by prior owners or occupants, existing tenants, mortgagors or other persons for which we may be liable;
- acts of God affecting our properties; and
- acts of terrorism affecting our properties.

Our real estate investments are relatively

illiquid and generally cannot be sold quickly. In addition, some of our properties serve as collateral for our debt obligations and cannot be readily sold. Additional factors that are specific to our industry also tend to limit our ability to vary our portfolio properties in response to changes in economic or other conditions. For example, all of our properties are “special purpose” properties that cannot be readily converted to residential, retail or office use. In addition, transfers of operations of nursing homes and other healthcare-related facilities are subject to requirements not required for transfers of other types of commercial operations and other types of real estate. Thus, if the operation of any of our properties becomes unprofitable due to competition, age of improvements or other factors such that an operator becomes unable to meet its obligations to us, the market value of the property may be substantially less, particularly relative to the amount owing on any related mortgage loan, than would be the case if the property were readily adaptable to other uses. Furthermore, the receipt of liquidation proceeds or the replacement of an operator that has defaulted on a mortgage loan could be delayed by the approval process of any federal, state or local agency necessary for the transfer of the property or the replacement of the operator with a new operator licensed to manage the facility. In addition, certain significant expenditures associated with real estate investments, such as taxes and maintenance costs, are generally not reduced when circumstances cause a reduction in income from the investment. Should such circumstances occur, our income and cash flows from operations would be adversely

As an owner or lender with respect to real property, we may be exposed to possible environmental

risks. Under various federal, state and local environmental laws, ordinances and regulations, a current or previous owner of real property or a secured lender may be liable in certain circumstances for the costs of investigation, removal or remediation of, or related releases of, certain hazardous substances at, under or disposed of in connection with such property, as well as certain other potential costs relating to hazardous or toxic substances.

government fines and damages for injuries to persons and adjacent property. Such laws often impose liability based on the owner's knowledge or negligence for, the presence or disposal of such substances. As a result, liability may be imposed on the owner in connection with the activities conducted on the property. The cost of any required investigation, remediation, removal, fines or personal or property damages and the owner's liability for such costs could exceed the value of the property and/or the assets of the owner. In addition, the presence of such substances, or the failure to investigate or remediate such substances, may adversely affect an operators' ability to attract additional residents and our ability to sell or rent such property or to borrow using such property as collateral which, in turn, could negatively impact our

Although our leases and mortgage loans require the lessee and the mortgagor to indemnify us for certain environmental liabilities, the scope of such indemnification may be limited. For instance, most of our leases do not require the lessee to indemnify us for environmental liabilities arising before the commencement of possession of the premises. Further, we cannot assure you that any such mortgagor or lessee would be able to fulfill its indemnification obligations.

Industry in which we operate is highly competitive. Increasing investor interest in our sector and consolidation at the operator level or REIT level could increase competition and reduce our profitability.

Our industry is highly competitive and we expect that it may become more competitive in the future. We compete for healthcare facility investment with other REITs and healthcare investors, including other REITs, some of which have greater resources and lower costs of capital than we do. Increased competition is challenging for us to identify and successfully capitalize on opportunities that meet our business goals. If we cannot capitalize on our development pipeline, identify and purchase a sufficient quantity of healthcare facilities at favorable prices, or if we are unable to finance such acquisitions on financially favorable terms, our business, results of operations and financial condition may be materially adversely affected. In addition, if our cost of capital could increase relative to the cost of capital of our competitors, the spread that we realize on our investments may decline if competitive financing is not available to limit or prevent us from charging higher lease or mortgage rates.

We may be named as defendants in litigation arising out of professional liability and general liability claims relating to our previously owned and operated facilities that if decided against us, could adversely affect our financial condition.

Several of our wholly-owned subsidiaries were named as defendants in professional liability and general liability claims related to our operations at facilities prior to 2005. Other third-party managers responsible for the day-to-day operations of these facilities were also named as defendants in these claims. In these suits, patients of certain previously owned and operated facilities have alleged significant damages, including punitive damages, against the defendants. Although all of these prior suits have been settled, we or our affiliates could be named as defendants in similar suits to the extent we operate facilities in the future. There can be no assurance that we would be successful in our defense of such potential matters or in our ability to recover against various managers of the subject facilities or that the amount of any settlement or judgment would be substantially covered by insurance. We cannot guarantee that any punitive damages will be covered by insurance.

Our charter and bylaws contain significant anti-takeover provisions which could delay, defer or prevent a change in control or other transactions that could provide our stockholders with the opportunity to realize a premium over the then-prevailing market price of our common stock.

Our charter and bylaws contain various procedural and other requirements which could make it difficult for stockholders to effect certain corporate actions. Our Board of Directors has the authority to issue additional shares of preferred stock and to fix the preferences, rights and limitations of the preferred stock without stockholder approval. In addition, our charter contains limitations on the ownership of our capital stock intended to ensure we continue to qualify for treatment as a REIT. These provisions could discourage unsolicited acquisition proposals or make it more difficult for a third party to acquire control of us, which could adversely affect the market price of our securities and/or result in the delay, deferral or prevention of a change in control. We cannot guarantee that any such actions that could provide our stockholders with the opportunity to realize a premium over the then-prevailing market price of our common stock.

The interests of our management and Board of Directors are holders of units of partnership interest in Omega OP, and their interests may differ from the interests of our public stockholders.

Members of our management and Board of Directors are holders of units of partnership interest in Omega OP. Those unitholders may have conflicts of interest with holders of the Company's common stock. For example, such unitholders of OP units may have different tax positions from the holders of the Company's common stock, which could influence their decisions in their capacities as members of management regarding whether to dispose of assets, whether and when to incur new or refinance existing indebtedness and how to structure future transactions.

The Company is exposed to risks associated with entering new geographic markets.

The Company's acquisition and development activities may involve entering geographic markets where the Company has not previously had a presence. Expansion and/or acquisition of properties in new geographic areas involves risks, including the risk that the property will not perform as anticipated and that the Company will incur significant actual costs for site development and improvements identified in the pre-construction or pre-acquisition due diligence process without realizing the expected benefits. There is, and it is expected that there will continue to be, significant competition for investment opportunities that meet management's investment criteria, as well as risks associated with obtaining financing for acquisition activities, if needed.

Ownership of property outside the U.S. may subject us to different or greater risks than those associated with our U.S. investments.

investments in the United Kingdom, and may from time to time may seek to acquire other properties in the United Kingdom or otherwise in the U.S. Although we currently have investments in the United Kingdom, we have limited experience investing in healthcare properties or other non-healthcare-related assets located outside the United States. International development, investment, ownership and operating activities involve risks that are different from those we face with respect to our U.S. properties and operations. These risks include, but are not limited to, any international currency fluctuations; changes with respect to changes in exchange rates may not qualify under the 75.0% gross income test or the 95.0% gross income test that we must meet in order to qualify and maintain our status as a REIT; challenges with respect to the repatriation of foreign earnings and cash; changes in regulatory, and economic conditions, including regionally, nationally, and locally; challenges in managing international operations; challenges with a wide variety of foreign laws and regulations, including those relating to real estate, corporate governance, operations, taxes, employment, and legal proceedings; foreign ownership restrictions with respect to operations in countries; diminished ability to legally enforce our contractual rights in countries; differences in lending practices and the willingness of domestic or foreign lenders to provide financing; regional or country-specific economic cycles and economic instability; and changes in applicable laws and regulations in the U.S. that affect foreign operations. In addition, we have limited investing experience in international markets. If we are unable to successfully manage the risks associated with international expansion, our results of operations and financial condition may be adversely affected.

We may be adversely affected by fluctuations in currency exchange rates.

Ownership of properties in the United Kingdom currently subjects us to fluctuations in the exchange rates between U.S. dollars and the British pound sterling, which may, from time to time, impact our financial condition and results of operations. If we continue to expand our international presence through investments in, or acquisitions or development of healthcare assets outside the United States or the United Kingdom, we may transact business in multiple currencies. Although we may pursue hedging alternatives, including borrowing in local currencies, to protect against foreign currency fluctuations, we cannot assure you that such fluctuations will not have a material adverse effect on our results of operations or financial condition.

Our future results will suffer if we do not effectively manage our expanded operations following the Merger with Aviv.

We have expanded our operations as a result of the Merger with Aviv and intend to continue to expand our operations through additional acquisitions, some of which may involve complex challenges. Our future success will depend, in part, upon our ability to manage the integration of our operations and our expansion opportunities, each of which may pose substantial challenges for us to integrate new operations into our existing business in a timely manner, and upon our ability to successfully monitor our operations, costs, regulatory compliance and service quality, and to implement necessary internal controls. There is no assurance that our expansion or acquisition opportunities will be successful, or that we will realize the operating efficiencies, cost savings, revenue enhancements, synergies or other benefits from any future acquisitions we may acquire.

We may change our investment strategies and policies and capital structure.

ard of Directors, without the approval of our stockholders, may alter our investment strategies and policies if it determines that a change
rs' best interests. The methods of implementing our investment strategies and policies may vary as new investments and financing tech
d

Our success depends in part on our ability to retain key personnel and our ability to attract or retain other qualified p

performance depends to a significant degree upon the continued contributions of our executive management team and other key employ
services of our current executive management team could have an adverse impact on our operations. Although we have entered into em
ts with the members of our executive management team, these agreements may not assure their continued service. In addition, our futur
part, on our ability to attract, hire, train and retain other qualified personnel. Competition for qualified employees is intense, and we cor
ed employees with companies with greater financial resources. Our failure to successfully attract, hire, retain and train the people we ne
significantly impede our ability to implement our business

Failure to properly manage our rapid growth could distract our management or increase our capital requirements

experienced rapid growth and development in a relatively short period of time and expect to continue this rapid growth in the future. This growth has resulted in increased levels of responsibility for our management. Future property acquisitions could place significant additional demands on us to expand, our management, resources and personnel. Our failure to manage any such rapid growth effectively could harm our business, our financial condition, results of operations and cash flows, which could negatively affect our ability to make distributions to stockholders and the trading price of our common stock. Our growth could also increase our capital requirements, which may require us to issue potentially dilutive securities and incur additional

Our dependence on information technology in our operations, and any material failure, inadequacy, interruption or security failure of that technology, could harm our operations

on information technology networks and systems, including the Internet, to process, transmit and store electronic information, and to manage a variety of business processes, including financial transactions and records, personal identifying information, tenant and lease data. We obtain some of our information technology from vendors, on whom our systems depend. We rely on commercially available systems, software, and hardware, and monitoring to provide security for processing, transmission and storage of confidential tenant and other customer information, such as personally identifiable information, including information relating to financial accounts. Although we have taken steps to protect the security of our information systems and the data maintained in those systems, it is possible that our safety and security measures will not be able to prevent the systems' operation from being interrupted or damaged, or the improper access or disclosure of personally identifiable information such as in the event of cyber attacks. Security breaches, including physical or electronic break-ins, computer viruses, attacks by hackers and similar breaches, can create system disruptions, shut down our systems, and result in unauthorized disclosure of confidential information. Any failure to maintain proper function, security and availability of our information systems could interrupt our operations, damage our reputation, subject us to liability claims or regulatory penalties and could have a material adverse effect on our business, financial condition and results of operations.

Our failure to maintain effective internal control over financial reporting could have a material adverse effect on our business, results of operations and financial condition and stock price

Pursuant to the Sarbanes-Oxley Act of 2002, we are required to provide a report by management on internal control over financial reporting, including management's assessment of the effectiveness of such control. Changes to our business will necessitate ongoing changes to our internal control systems. Internal control over financial reporting may not prevent or detect misstatements due to inherent limitations, including the possibility of circumvention or overriding of controls, or fraud. Therefore, even effective internal controls can provide only reasonable assurance with respect to the preparation and fair presentation of financial statements. In addition, projections of any evaluation of effectiveness of internal control over financial reporting for future periods are subject to the risk that the control may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. If we fail to maintain the adequacy of our internal controls, including any failure to implement required internal controls, or if we experience difficulties in their implementation, our business, results of operations and financial condition could be materially adversely harmed, we could fail to meet our reporting obligations and there could be a material adverse effect on our stock price.

If we fail to maintain our REIT status, we will be subject to federal income tax on our taxable income at regular corporate

organized to qualify for taxation as a REIT under Sections 856 through 860 of the Code. See “Item 1. Business – Taxation.” We believe we have operated in such a manner as to qualify for taxation as a REIT under the Code and intend to continue to operate in a manner that will maintain our qualification as a REIT. Qualification as a REIT involves the satisfaction of numerous requirements, some on an annual and some on a quarterly basis, established under highly technical and complex provisions of the Code for which there are only limited judicial and administrative interpretations. The determination of various factual matters and circumstances not entirely within our control. We cannot assure you that we will at all times comply with these rules.

we were to fail to qualify as a REIT in any taxable year, as a result of a determination that we failed to meet the annual distribution requirements, we would be subject to federal income tax, including any applicable alternative minimum tax, on our taxable income at regular corporate rates to each such taxable year for which the statute of limitations remains open. Moreover, unless entitled to relief under certain statutory provisions, we would be disqualified from treatment as a REIT for the four taxable years following the year during which qualification is lost. This treatment could significantly reduce our net earnings and cash flow because of our additional tax liability for the years involved, which could significantly impact our financial condition.

We generally must distribute annually at least 90% of our taxable income to our stockholders to maintain our REIT status. To the extent that we do not distribute all of our net capital gain or do distribute at least 90%, but less than 100% of our “REIT taxable income,” as adjusted, we will be subject to tax thereon at regular ordinary and capital gain corporate rates.

Even if we remain qualified as a REIT, we may face other tax liabilities that reduce our cash available for distribution.

Even if we remain qualified for taxation as a REIT, we may be subject to certain federal, state and local taxes on our income and assets, including taxes on undistributed income, tax on income from some activities conducted as a result of a foreclosure, and state or local income, property and transfer taxes. These taxes would decrease cash available for the payment of our debt obligations. In addition, to meet REIT qualification requirements, we may be required to dispose of our non-healthcare assets through taxable REIT subsidiaries or other subsidiary corporations that will be subject to corporate level income tax at regular rates.

Following the completion of the Merger, Aviv availed itself of the self-determination provisions and the deficiency dividend procedures under Sections 1361 and 1362 of the Code and supporting Treasury Regulations and IRS pronouncements to remedy certain potential technical violations of REIT requirements. If there is an adjustment to Aviv’s REIT taxable income or dividends paid deductions as a result of Aviv taking such actions by the IRS, the Company could be required to further implement the deficiency dividend procedures in order to maintain Aviv’s REIT status. Further steps to remedy any past non-compliance by Aviv. Any such further implementation of the deficiency dividend procedures could require Aviv to make significant distributions to its stockholders and to pay significant penalties and interest to the IRS, which could impair the Company’s ability to expand its business and raise capital, reduce its cash available for distribution to its stockholders and materially adversely affect the value of the Company’s common stock.

Maintaining qualification as a REIT involves highly technical and complex provisions of the Code and complying with REIT requirements may affect our operations.

Maintaining qualification as a REIT involves the application of technical and intricate Code provisions. Even a technical or inadvertent violation could jeopardize our REIT qualification. To qualify as a REIT for federal income tax purposes, we must continually satisfy tests concerning, among other things, the nature and location of our assets, the sources of our income and the amounts we distribute to our stockholders. Thus, we may be required to liquidate certain investments from our portfolio, or be unable to pursue investments that would be otherwise advantageous to us, to satisfy the asset and income tests. We may also be required to make distributions to stockholders at disadvantageous times when we do not have funds readily available for distribution (e.g., if we have assets which generate mismatches between taxable income and available cash).

comply with the distribution requirement could cause us to: (i) sell assets in adverse market conditions; (ii) borrow on unfavorable terms; (iii) distribute amounts that would otherwise be invested in future acquisitions, capital expenditures or repayment of debt. As a result, satisfying the distribution requirements could have an adverse effect on our business results and prospects.

Future changes in the tax laws could impact our ability to qualify as a REIT in the future.

Recent changes in the tax laws, such as the “Protecting Americans from Tax Hikes Act of 2015” (the “PATH Act”) that was enacted on December 18, 2015, which contains several provisions pertaining to REIT qualification and taxation, could impact our ability to qualify as a REIT in the future. For more information on the discussion regarding our taxation as a REIT, see “Item 1. Business – Taxation,” some of the provisions from the PATH Act that could impact us. However, we do not believe that any of these provisions will materially impact our ability to maintain our qualification as a REIT. While many of the recent changes to the tax laws impacting REITs have been “relief” that generally ease the burden of complying with the tax rules, there can be no assurance that future changes in tax laws will not adversely impact our ability to qualify as a REIT in the future.

Risks Related to O

In addition to the risks related to our operators and our operations described above, the following are additional risks associated with o

The market value of our stock could be substantially affected by variou

atility may adversely affect the market price of our common stock. As with other publicly traded securities, the share price of our stock on many factors, which may change from time to time, i

- the market for similar securities issued by REITs;
- changes in estimates by analysts;
- our ability to meet analysts' estimates;
- prevailing interest rates;
- our credit rating;
- general economic and market conditions; and
- our financial condition, performance and prospects.

issuance of additional capital stock, warrants or debt securities, whether or not convertible, may reduce the market price for our own securities, including our common stock, and dilute the ownership interests of existing stock

predict the effect, if any, that future sales of our capital stock, warrants or debt securities, or the availability of our securities for future sales, may have on the market price of our securities, including our common stock. Sales of substantial amounts of our common stock or preferred shares, warrants or debt securities convertible into or exercisable or exchangeable for common stock in the public market, or the perception that such sales might occur, may negatively impact the market price of our stock and the terms upon which we may obtain additional equity financing in the future.

In addition, we may issue additional capital stock in the future to raise capital or as a result of the fo

and exercise of options to purchase our common stock or other equity awards under remuneration plans (we may also issue equity to our directors in lieu of cash bonuses or to our directors in lieu of director's fees);

- the issuance of shares pursuant to our dividend reinvestment and direct stock purchase plan or at-the-market offerings;
- the issuance of debt securities exchangeable for our common stock;
- the exercise of warrants we may issue in the future;
- the issuance of warrants or other rights to acquire shares to current or future lenders in connection with providing financing; and

the sales of securities convertible into our common stock.

There are no assurances of our ability to pay dividends in the

ability to pay dividends may be adversely affected upon the occurrence of any of the risks described herein. Our payment of dividends is subject to compliance with restrictions contained in our credit agreements, the indentures governing our senior notes and any preferred stock that our Board of Directors may from time to time designate and authorize for issuance. All dividends will be paid at the discretion of our Board of Directors and will be dependent upon our earnings, our financial condition, maintenance of our REIT status and such other factors as our Board of Directors may deem relevant from time to time. There are no assurances of our ability to pay dividends in the future. In addition, our dividends in the past have included, and may in the future include, a return of

ed stock that we may issue from time to time may have liquidation and other rights that are senior to the rights of the holders of our

of Directors has the authority to designate and issue preferred stock that may have dividend, liquidation and other rights that are senior to
our comm

Legislative or regulatory action could adversely affect purchasers of o

nt legislative, judicial and administrative changes to the federal income tax laws could adversely impact the income tax consequences o
Such changes have occurred in the past and are likely to continue to occur in the future, and we cannot assure you that any of these cha
y affect an investment in our stock or on our stock's market value or resale potential. Stockholders are urged to consult with their own t
respect to the impact that past legislative, regulatory or administrative changes or potential legislation may have on their investment in o

*ade of our credit rating could impair our ability to obtain additional debt financing on favorable terms, if at all, and significantly re
trading price of our comm*

y rating agency downgrades our credit rating, or places our rating under watch or review for possible downgrade, then it may be more d
nsive for us to obtain additional debt financing, and the trading price of our common stock may decline. Factors that may affect our cre
ude, among other things, our financial performance, our success in raising sufficient equity capital, adverse changes in our debt and fix
ratios, our capital structure and level of indebtedness and pending or future changes in the regulatory framework applicable to our oper
our industry. We cannot assure you that these credit agencies will not downgrade our credit rating in ti

Item 1B – Unresolved Staff C

December 31, 2015, our real estate investments included long-term care facilities and rehabilitation hospital investments, in the form of facilities that are leased to operators or their affiliates, (ii) investments in direct financing leases to operators or their affiliates and (iii) mortgages that are operated by the mortgagors or their affiliates. The properties are located in 42 states and the United Kingdom and are operated by operators. We use the term “operator” to refer to our tenants and mortgagees and their affiliates who manage and or operate our properties. In some cases, our tenants and mortgagees contract with a healthcare operator to operate the facilities. The following table summarizes our property investments as of December

Investment Structure/Operator	Number of Operating Beds	Number of Facilities	Gross Real Estate Investment (in thousands)
Operating Lease Facilities⁽¹⁾			
Maplewood Real Estate Holdings, LLC	841	10	\$ 494,247
Daybreak Venture, LLC	4,729	54	363,232
Genesis HealthCare	6,194	58	360,320
Laurel	2,606	27	308,047
Health and Hospital Corporation	4,606	44	304,719
Diversicare Healthcare Services	4,504	36	281,098
CommuniCare Health Services, Inc.	3,310	28	280,105
Saber Health Group	2,458	29	276,850
EmpRes Healthcare Group, Inc.	2,287	27	264,016
Airamid Health Management	4,527	37	246,503
Fundamental Long Term Care Holding, LLC	2,809	26	238,516
Signature Holdings II, LLC	3,180	31	232,914
Capital Funding Group, Inc.	2,231	21	219,455
S&F Management Company, LLC	1,920	15	217,073
Gulf Coast Master Tenant I, LLC	2,514	20	189,095
Sun Mar Healthcare	1,262	11	178,055
Healthcare Homes	1,010	23	169,700
Guardian LTC Management Inc.	1,679	23	125,971
Mission Health	1,438	20	124,473
Preferred Care, Inc.	1,607	16	124,462
Consulate Health Care	2,023	17	117,654
Nexion Health Inc.	2,067	19	92,064
Trillium Healthcare Group	1,326	17	88,156
Affiliates of Persimmon Ventures, LLC & White Pine Holdings, LLC	757	5	83,965
Essex Healthcare Corporation	1,236	13	83,564
Providence Group, Inc.	863	10	82,191

Edgar Filing: ROYAL CARIBBEAN CRUISES LTD - Form 10-K

Bridgemark Healthcare LLC	1,249	11	82,121
TenInOne Acquisition Group, LLC	1,271	9	73,563
Peregrine Health Services, Inc.	624	4	68,191
Trinity HealthCare	954	13	63,585
Swain/Herzog	1,008	9	59,746
Prestige Care, Inc.	542	9	56,672
Ide Management Group, LLC	1,285	14	56,318
CareMeridian	186	16	51,804
Southern Administrative Services, LLC	1,084	11	44,843
StoneGate Senior Care LP	726	7	38,833
Sava Senior Care, LLC	469	3	36,970
New Ark Investments, Inc.	345	3	34,600
Reliance Health Care Management, Inc.	340	3	34,496
Haven Health Management	476	6	33,426
Hi-Care Management	278	3	30,883
Pinon Management, LLC	527	6	30,390
Cardinal Care Management, Inc.	185	2	28,629
Sovran Management Company, LLC	300	1	28,500
Physicians Hospital Group	67	3	23,394
Lion Health Centers	162	1	20,457
Safe Haven Healthcare	135	2	17,057
Hope Healthcare	371	4	16,460
Lakeland Holding Company	274	1	15,795
Transitions Healthcare, LLC	135	1	15,300

Investment Structure/Operator	Number of Operating Beds	Number of Facilities	Gross Real
			Estate Investment (in thousands)
Rest Haven Nursing Center Inc.	176	1	14,400
Health Systems of Oklahoma LLC	407	3	12,470
Orion Operating Services	93	1	12,420
JK&L	104	2	12,312
Washington N&R	239	2	12,152
Better Senior Living Consulting LLC	310	3	11,910
UltraCare Healthcare, LLC	134	3	11,281
Phoenix Senior Living	125	2	10,800
Care Initiatives, Inc.	188	1	10,347
Adcare Health Systems	301	2	10,000
Ensign Group, Inc.	271	3	9,656
NuCare	94	1	9,570
Markleysburg Healthcare Investors, LP	207	2	8,993
Health Dimensions	90	1	8,885
Covenant Care	102	1	8,610
Community Eldercare Services, LLC	100	1	7,572
Southwest LTC	150	1	6,839
Longwood Management Corporation	185	2	6,448
Elite Senior Living, Inc.	105	1	5,893
AMFM	150	2	5,786
Sante Operations	52	1	5,739
Brius Management Company	99	1	4,546
LTP Generations	96	2	4,417
HMS Holdings at Texarkana, LLC	114	1	4,281
Hoosier Enterprises Inc.	47	1	3,622
Castle Rock	60	1	3,620
New Beginnings Care	102	1	3,240
Life Generations Healthcare, Inc.	59	1	3,007
Hickory Creek Healthcare Foundation	63	1	2,834
Diamond Care Vida Encantada, LLC	102	1	2,028
Closed Facilities	-	4	1,802
	81,302	829	6,743,958
Assets Held for Sale			
TenInOne Acquisition Group, LLC	180	1	5,999
Preferred Care, Inc.	55	1	350
Signature Holdings II, LLC	-	1	250
	235	3	6,599
Investment in Direct Financing Leases			
New Ark Investment, Inc.	5,440	56	560,308
Reliance Health Care Management, Inc.	120	1	15,509

Sun Mar Healthcare	83	1	11,381
Markleysburg Healthcare Investors, LP	52	1	503
	5,695	59	587,701
Mortgages⁽²⁾			
Ciena Healthcare	3,383	31	422,785
Guardian LTC Management, Inc.	808	9	112,500
CommuniCare Health Services, Inc.	1,043	8	77,399
Affiliates of Persimmon Ventures, LLC & White Pine Holdings, LLC	412	4	26,500
Meridian	240	3	15,780
Saber Health Group	100	1	12,509
Benchmark Healthcare	111	2	6,445
Phoenix Senior Living	-	-	5,877
	6,097	58	679,795
Total	93,329	949	\$ 8,018,053

(1) Certain of our lease agreements contain purchase options that permit the lessees to purchase the underlying properties

(2) In general, many of our mortgages contain prepayment provisions that permit prepayment of the outstanding principal amounts th

The following table presents the concentration of our real estate investments by state as of December

	Number of	Number of	Gross Real	% of
	Facilities	Operating Beds	Estate	Gross
			Investment	Estate
			(in thousands)	Inves
Ohio	86	8,868	\$ 815,405	10.2
Texas	109	10,964	726,326	9.1
Florida	98	11,332	697,239	8.7
Michigan	47	4,898	592,864	7.4
California	60	4,922	521,421	6.5
Pennsylvania ⁽¹⁾	44	4,194	474,542	5.9
Indiana	60	5,711	403,014	5.0
South Carolina	22	2,084	241,889	3.0
Connecticut	6	493	241,034	3.0
Arkansas	32	3,341	230,215	2.9
Mississippi	19	2,017	226,829	2.8
Massachusetts	16	1,423	185,342	2.3
Kentucky	26	2,238	184,367	2.3
Maryland	16	2,080	174,077	2.2
United Kingdom	23	1,010	169,700	2.1
Washington	22	1,586	168,825	2.1
Missouri	23	2,198	153,516	1.9
Tennessee ⁽¹⁾	20	2,517	149,634	1.9
North Carolina	17	1,871	136,757	1.7
Arizona	16	1,528	132,871	1.6
Illinois	17	1,836	118,619	1.5
New York	-	-	116,424	1.4
Virginia	6	924	100,734	1.3
Georgia	10	1,100	84,369	1.0
Idaho	12	1,006	82,977	1.0
Colorado	12	1,307	79,659	1.0
New Mexico ⁽¹⁾	11	1,003	77,898	1.0
West Virginia	11	1,255	75,796	0.9
Iowa	12	917	72,634	0.9
Nevada	6	596	62,981	0.8
Wisconsin	9	913	62,970	0.8
Minnesota	5	548	61,417	0.8
Louisiana	13	1,390	59,735	0.7
Kansas	17	931	57,793	0.7
Oregon	7	410	52,710	0.7
Alabama	9	1,087	48,089	0.6
Oklahoma	9	835	45,178	0.6

Rhode Island	4	558	43,534	0.5
Nebraska	7	650	24,713	0.3
New Hampshire	3	221	23,082	0.3
Utah	4	347	21,027	0.3
Montana	2	105	12,922	0.2
Vermont	1	115	6,925	0.1
Total	949	93,329	\$ 8,018,053	100

(1) These states each include a facility/property that is classified as held-for-sale as of December

Geographically Diverse Property Portfolio. Our portfolio of properties is broadly diversified by geographic location. Our portfolio includes properties located in 42 states and the United Kingdom. In addition, the majority of our 2015 rental, direct financing lease and mortgage income was derived from properties located in facilities in states that require state approval for development and expansion of healthcare facilities. We believe that such state approvals will increase the demand for our facilities, increase competition for our operators and enhance the value of our portfolio.

Large Number of Tenants. Our facilities are operated by 83 different public and private healthcare providers and/or managers. Except for New Ark Health Services, Inc. (“New Ark”) (7%), Maplewood Real Estate Holdings, LLC (6%) and Ciena Healthcare (5%), which together hold approximately 18% of our portfolio (by investment), no other single tenant holds greater than 5% of our portfolio (by investment).

Significant Number of Long-term Leases and Mortgage Loans. At December 31, 2015, approximately 79% of our operating leases, 81% of our mortgage loans and 86% of our direct financing leases have primary terms that expire after 2020. The majority of our leased real estate properties are subject to the provisions of master lease agreements. We also lease facilities under single facility leases. The initial terms of both types of leases typically range from 5 to 15 years, plus renewal options, with the exception of our investment in the direct financing leases with New Ark which expire on various dates.

Our leased properties are leased under long term, triple-net leases. The following table displays the expiration of the annualized straight-line rental revenues under our operating lease agreements as of December 31, 2015 by year without giving effect to any renewal options.

Expiration Year	Annualized Straight-line Rental Revenue Expiring	Number of Leases Expiring
(\$ in thousands)		
2016	\$ 3,090	3
2017	13,526	9
2018	43,947	14
2019	3,422	5
2020	6,988	9
2021	27,664	32
2022	69,544	31
2023	88,139	22
2024	65,483	12
2025	54,701	13
2026	19,202	7
Thereafter	262,902	30
Total	\$ 658,608	187

Item 3 - Legal Proceedings

subject to various legal proceedings, claims and other actions arising out of the normal course of business. While any legal proceeding or event of uncertainty, management believes that the outcome of each lawsuit, claim or legal proceeding that is pending or threatened, or all combined, will not have a material adverse effect on our consolidated financial position or results of operations.

Item 4 - Mine Safety Disclosures

Not applicable.

Item 5 - Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity

of common stock are traded on the New York Stock Exchange under the symbol "OHI." The following table sets forth, for the periods and low prices as reported on the New York Stock Exchange Composite for the periods indicated and cash dividends declared per common

2015			2014				
			Dividends				
Quarter	High	Low	Declared	Quarter	High	Low	De
			Per Share				
First	\$45.46	\$37.76	\$ 0.89	(1) First	\$33.89	\$29.32	\$
Second	42.00	34.18	0.18	(2) Second	38.33	33.22	
Third	37.24	32.01	0.55	Third	39.31	33.69	
Fourth	37.16	31.56	0.56	Fourth	40.74	33.89	
			\$ 2.18				\$

In addition to the regular \$0.53 per share quarterly dividend declared and paid in the first quarter of 2015, on March 5, 2015 the Board of Directors declared a prorated dividend of \$0.36 per share of Omega's common stock in view of the then pending Aviv Merger. This \$0.36 per share dividend amount represented dividends for February and March 2015 at a quarterly dividend rate of \$0.54 per share of common stock. The \$0.36 per share dividend was paid in cash on April 7, 2015 to stockholders of record as of the close of business on March 31, 2015. On April 15, 2015, the Board of Directors declared a prorated dividend of \$0.18 per share of Omega's common stock in view of the recently closed Aviv Merger. The \$0.18 per share dividend amount represented dividends for April 2015 at a quarterly dividend rate of \$0.54 per share of common stock. The \$0.18 per share dividend was paid in cash on May 15, 2015 to stockholders of record as of the close of business on April 30, 2015.

The closing price for our common stock on the New York Stock Exchange on February 19, 2016 was \$30.55 per share. As of February 19, 2016 there were 188,131,753 shares of common stock outstanding with approximately 2,943 registered

The following table provides information about shares available for future issuance under our equity compensation plans as of December

Equity Compensation Plan Information

Category	(a) Number of securities to be issued upon exercise of outstanding options, warrants and rights (1)	(b) Weighted-average exercise price of outstanding options, warrants and rights (2)	(c) Number of securities remaining available for future issuance under equity compensation plans and arrangements excluding securities reflected in column (1)
Equity compensation plans approved by security holders	1,672,430	\$ —	2,139,785
Equity compensation plans not approved by security holders	—	—	—
Total	1,672,430	\$ —	2,139,785

Reflects (i) a maximum of 203,179 shares that could be issued if certain performance conditions are achieved related to the December 2013 award of performance restricted stock units, (ii) a maximum of 271,268 shares that could be issued if certain performance conditions are achieved related to the January 1, 2014 award of performance restricted stock units, (iii) 106,778 restricted stock units that were granted on January 1, 2014, (iv) 62,286 restricted stock units that were granted on December 31, 2013, (v) 109,585 restricted stock units that were granted on March 31, 2015, (vi) 274,498 shares that could be issued if certain performance conditions are achieved related to the March 2015 award of performance restricted stock units, (vii) 64,938 restricted stock units that were granted on April 1, 2015, (viii) 108,300 shares that could be issued if certain performance conditions are achieved related to the April 1, 2015 award of performance restricted stock units, (ix) 55,840 restricted stock units that were granted on July 31, 2015, (x) 14,942 shares that could be issued if certain performance conditions are achieved related to the July 31, 2015 award of performance restricted stock units and, (xi) 400,814 shares in respect of outstanding deferred stock units. Does not include 2,510,809 shares issuable upon the exercise of outstanding options that were assumed in the Merger with Aviv, with a weighted-average exercise price of \$19.38 as of December 31, 2015.

No exercise price is payable with respect to the restricted stock units, performance restricted stock units or deferred stock units.
 (3) Reflects shares of common stock remaining available for future awards under our 2013 Stock Incentive Plan.

Fourth quarter of 2015, we purchased 18,626 outstanding shares of our common stock from employees to pay the withholding taxes related to the vesting of restricted stock.

Issuer Purchases of Common Stock

Period	(a) Total Number of Shares Purchased (1)	(b) Average Price Paid per Share	(c) Purchased as Part of Publicly Announced Plans or Programs	(d) Maximum Number (or Approximate Dollar Value) of Shares that may be Purchased Under these Plans or Programs
October 1, 2015 to October 31, 2015	-	-	-	-
November 1, 2015 to November 30, 2015	-	-	-	-
December 1, 2015 to December 31, 2015	18,626	\$ 34.69	-	-
Total	18,626	\$ 34.69	-	-

The 18,626 shares purchased from employees to pay the withholding taxes related to the vesting of restricted stock. The shares were not part of a stock repurchase plan or program.

Unregistered Sales of Equity Securities

We may from time to time issue shares of common stock pursuant to redemptions by the limited partners of Omega OP of OP units. Pursuant to the Omega OP Agreement, each time OP units are redeemed for shares of Common Stock, the limited partner is deemed to sell to Omega a number of shares of Common Stock equal to the number of shares of Common Stock that were issued in transactions that are not registered under the Securities Act in reliance on the Securities Act due to the fact that the shares of Common Stock were issued only to the limited partner effecting the redemption and the sale does not involve a public offering.

Item 6 - Selected Financial Data

The following table sets forth our selected financial data and operating data for our Company on a historical basis. The following data should be read in conjunction with our audited consolidated financial statements and notes thereto and Management's Discussion and Analysis of Financial Condition and Results of Operations included elsewhere herein. Our historical operating results may not be comparable to our future operating results. The comparison of our historical financial data is significantly affected by our acquisitions and new investments from 2011 to 2015. See "Item 7 – Management's Discussion and Analysis of Financial Condition and Results of Operations – Portfolio and Other Developments"

	Year Ended December 31,				
	2015	2014	2013	2012	2011
	(in thousands, except per share amounts)				
Operating Data					
Revenues	\$743,617	\$504,787	\$418,714	\$350,460	\$287,000
Net income	\$233,315	\$221,349	\$172,521	\$120,698	\$100,000
Net income available to common stockholders	\$224,524	\$221,349	\$172,521	\$120,698	\$100,000
Per share amounts:					
Net income available to common stockholders:					
Basic	\$1.30	\$1.75	\$1.47	\$1.12	\$1.00
Net income :					
Diluted	1.29	1.74	1.46	1.12	1.00
Dividends, Common Stock ⁽¹⁾	\$2.18	\$2.02	\$1.86	\$1.69	\$1.50
Dividends, Series D Preferred ⁽¹⁾	-	-	-	-	-
Weighted-average common shares outstanding, basic	172,242	126,550	117,257	107,591	100,000
Weighted-average common shares outstanding, diluted	180,508	127,294	118,100	108,011	100,000

	As of December 31,				
	2015	2014	2013	2012	2011
	(in thousands)				
Balance Sheet Data					
Gross investments	\$8,107,352	\$4,472,840	\$3,924,917	\$3,325,533	\$2,800,000
Total assets	8,019,009	3,921,645	3,462,216	2,982,005	2,800,000
Revolving line of credit	230,000	85,000	326,000	158,000	270,000
Term loans	750,000	200,000	200,000	100,000	-
Other long-term borrowings	2,589,086	2,093,503	1,498,418	1,566,932	1,430,000
Total equity	4,100,865	1,401,327	1,300,103	1,011,329	800,000

(1)

Dividends per share are those declared and paid during such period.

Item 7 – Management's Discussion and Analysis of Financial Condition and Results of Operations

Forward-looking Statements, Reimbursement Issues and Other Factors Affecting Future Results

Following discussion should be read in conjunction with the financial statements and notes thereto appearing elsewhere in this document, and should not be construed as a guarantee of future performance. This document contains forward-looking statements within the meaning of the securities laws. These statements relate to our expectations, beliefs, intentions, plans, objectives, goals, strategies, future events, performance and other statements other than statements of historical facts. In some cases, you can identify forward-looking statements by the use of forward-looking terminology including, but not limited to, terms such as “may,” “will,” “anticipates,” “expects,” “believes,” “intends,” “should” or “could” and other similar words and phrases. These statements are based on information available on the date of this filing and only speak as to the date hereof and no obligation is assumed that our actual results will conform to the forward-looking statements contained herein as a result of a variety of factors, including, among others, the following:

- (i) those items discussed under “Risk Factors” in Part I, Item 1A of this report;
- (ii) uncertainties relating to the business operations of the operators of our assets, including those relating to reimbursement by third-party payors, regulatory matters and occupancy levels;
- (iii) the ability of any operators in bankruptcy to reject unexpired lease obligations, modify the terms of our mortgages and impede our ability to collect on or interest during the process of a bankruptcy proceeding and retain security deposits for the debtors’ obligations;
- (iv) our ability to sell closed or foreclosed assets on a timely basis and on terms that allow us to realize the carrying value of these assets;
- (v) our ability to negotiate appropriate modifications to the terms of our credit facilities;
- (vi) our ability to manage, re-lease or sell any owned and operated facilities;
- (vii) the availability and cost of capital;
- (viii) changes in our credit ratings and the ratings of our debt securities;
- (ix) competition in the financing of healthcare facilities;
- (x) regulatory and other changes in the healthcare sector;
- (xi) the effect of economic and market conditions generally and, particularly, in the healthcare industry;
- (xii) changes in the financial position of our operators;
- (xiii) changes in interest rates;
- (xiv) the amount and yield of any additional investments;
- (xv) changes in tax laws and regulations affecting real estate investment trusts;
- (xvi) the possibility that we will not realize estimated synergies or growth as a result of our merger with Aviv, or that such benefits may take longer to be realized than expected; and
- (xvii) our ability to maintain our status as a real estate investment trust.

Our core business is to provide financing and other services to the long-term healthcare industry with a particular focus on SNFs located in the United States and the United Kingdom. Our core portfolio consists of long-term leases and mortgage agreements. All of our leases are “triple-net” leases, which require the tenants to pay all property-related expenses.

revenue derives from fixed rate mortgage loans, which are secured by first mortgage liens on the underlying real estate and personal property. The mortgage loans are primarily made to third-party operators of the mortgage pools.

Our portfolio of investments at December 31, 2015, included 949 healthcare facilities, located in 42 states and the United Kingdom that are operated by third-party operators. Our gross real estate investment in these facilities totaled approximately \$8.0 billion at December 31, 2015, with 99% of our investments related to long-term healthcare facilities. The portfolio is made up of (i) 782 SNFs, (ii) 85 ALFs, (iii) 16 specialty facilities, (iv) one long-term care building, (v) fixed rate mortgages on 56 SNFs and two ALFs and (vi) seven SNFs that are currently closed or held-for-sale. At December 31, 2015, we also held other investments of approximately \$89.3 million, consisting primarily of secured loans to third-party operators of our facilities.

Changes in market and economic conditions, including deficits at both the federal and state level could result in additional cost-cutting at both the federal and state levels resulting in additional reductions to reimbursement rates and levels to our operators under both the Medicare and Medicaid programs. Such reductions could be exacerbated by the potential for increased enrollment in Medicaid due to prolonged high unemployment levels and declining state personal incomes, which could cause states to reduce state expenditures under their respective state Medicaid programs by lowering reimbursement rates.

ly believe that our operator coverage ratios are strong and that our operators can absorb moderate reimbursement rate reductions under Medicare and still meet their obligations to us. However, significant limits on the scope of services reimbursed and on reimbursement rates could have a material adverse effect on an operator's results of operations and financial condition, which could adversely affect the operator's ability to meet its obligations.

consolidated financial statements include the accounts of (i) Omega, (ii) Omega OP and (iii) all direct and indirect wholly-owned subsidiaries. All inter-company accounts and transactions have been eliminated in consolidation, and our net earnings are reduced by the portion of net earnings attributable to noncontrolling interests.

2015 and Recent History

Acquisition and Other Investments

In 2015, we completed the following transactions totaling approximately \$4.4 billion in new investments:

In 2015, Omega completed the Aviv Merger, which was structured as a stock-for-stock merger. As a result of the Aviv Merger, Omega acquired 100% of Aviv, two facilities subject to direct financing leases, one medical office building, two mortgages and other investments. The facilities are located in the United Kingdom and are operated by 38 third-party operators.

In 2015, we closed a purchase/leaseback transaction (the "Care Homes Transaction") of approximately \$193.8 million for 23 care homes located in the United Kingdom.

In addition to the aforementioned acquisitions, we also completed approximately \$228.7 million of acquisitions throughout the United States. Specifically, we acquired 1 SNFs and 4 ALFs with 1,542 operating beds.

\$101.0 million of investments in our capital expenditure programs.

See "*Portfolio and Other Developments*" below for a description of 2015 acquisitions and other investments.

Financing

During 2015, we paid approximately \$188.5 million to retire 24 mortgage loans guaranteed by U.S. Department of Housing and Urban Development. The payoffs resulted in a \$4.2 million gain on the extinguishment of the debt due to the write-off of approximately \$13.3 million of unamortized value adjustments recorded at the time of acquisition offset by prepayment fees of approximately \$9.0 million.

Senior

During 2015, we redeemed all of our outstanding \$575 million 6.75% Senior Notes due 2022 (the "2022 Notes") and our \$200 million 7.5% Senior Notes due 2023. As a result of the redemptions, we recorded approximately \$33.0 million in redemption related costs and write-offs, including \$26.9 million in early redemption or call premiums and \$6.1 million in net write-offs associated with unamortized deferred financing costs and original issue discounts. Total premiums/costs were approximately \$6.1 million.

On September 23, 2015, we sold \$600 million aggregate principal amount of our 5.250% Senior Notes due 2026 (the "2026 Notes"). The 2026 Notes were sold at an issue price of 99.717% of their face value before the initial purchasers' discount. Our total net proceeds from the offering, after deducting initial purchasers' discounts and other offering expenses, were approximately \$594.4 million. On March 18, 2015, we sold \$700 million aggregate principal amount of our 4.50% Senior Notes due 2027 (the "2027 Notes"). The 2027 Notes were sold at an issue price of 98.546% of their face value before the initial purchasers' discount. Our total net proceeds from the offering, after deducting initial purchasers' discounts and other offering expenses, were approximately \$688.0 million.

During 2015, we paid approximately \$1.2 billion to retire debt assumed in the Aviva

\$250 Million Term Loan

September 16, 2015, we entered into a \$250 million senior unsecured term loan facility (the “2015 Term Loan Facility”). The 2015 Term Loan Facility bears interest at LIBOR plus an applicable percentage (beginning at 180 basis points, with a range of 140 to 235 basis points) based on our ratings from Standard & Poor’s, Moody’s and/or Fitch

Unsecured Credit

On September 27, 2014, we entered into a credit agreement (as amended, the “2014 Credit Agreement”) providing us with \$1.2 billion unsecured credit facilities consisting of a \$1 billion senior unsecured revolving credit facility (the “Revolving Credit Facility”) and a \$200 million senior unsecured term loan facility (the “Tranche A-1 Term Loan Facility,” and, collectively, the “2014 Credit Facilities”). The 2014 Credit Facilities replaced our previous \$700 million senior unsecured credit facility (the “2012 Credit

Agreement”). On January 1, 2015, we entered into a First Amendment to Credit Agreement (the “First Amendment to Omega Credit Agreement”) which amended the 2014 Credit Facilities. Under the First Amendment to Omega Credit Agreement, the Company (i) increased the aggregate revolving commitment amount under the Revolving Credit Facility from \$1 billion to \$1.25 billion and (ii) obtained a \$200 million senior unsecured incremental term loan facility (the “Acquisition Term Loan Facility” or “Tranche A-2 Term Loan

Omega OP Term Loan

Facility”). In 2015, Omega OP entered into a credit agreement (the “Omega OP Credit Agreement”) providing it with a \$100 million senior unsecured term loan facility (the “Omega OP Term Loan Facility”). The Omega OP Term Loan Facility bears interest at LIBOR plus an applicable percentage (beginning at 180 basis points, with a range of 100 to 195 basis points) based on our ratings from Standard & Poor’s, Moody’s and/or Fitch

Issuance of 10.925 Million Shares of Common

Stock. On January 9, 2015, we completed an underwritten public offering of 10.925 million shares of our common stock at \$42.00 per share before underwriting offering expenses. The Company’s total net proceeds from the offering were approximately \$440 million, after deducting underwriting

and commissions and other estimated offering

See “*Financing Activities and Borrowing Arrangements*” below for a description of the 2015 financing activities and borrowing arr

Portfolio and Other Development

ing tables summarize the significant transactions that occurred from 2013 to 2015. The 2015 table excludes the acquisition of Care Homes in the United Kingdom and the Aviv Merger in the second quarter of 2015, which are discussed separately.

2015 Acquisitions and

Period	Number of Facilities			Number of Operating Beds	Total Investment	Land	Building & Site Improvements	Furniture & Fixtures	
	SNF	ALF	State						
Q1	1	-	TX	93	\$ 6.8	\$0.1	\$ 6.1	\$ 0.6	
Q3	6	-	NE	530	15.0	1.4	12.1	1.5	
Q3	1	2	WA	136	18.0	2.2	14.9	0.9	
Q3	-	2	GA	125	10.8	1.2	9.0	0.6	
Q3	1	-	VA	300	28.5	(1)	1.9	24.2	2.4
Q3	2	-	FL	260	32.0	(4)	1.4	29.0	1.6
Q3	-	-	NY	-	111.7	(2)(3)	111.7	-	-
Q4	1	-	AZ	6	0.6	(3)	0.3	0.3	-
Q4	1	-	TX	92	5.3		1.8	3.0	0.5
Total	13	4		1,542	\$ 228.7		\$22.0	\$ 98.6	\$ 8.1

(1) In July 2015, we leased the facility to a new operator with an initial lease term of 10 years.

(2) In December 2014, 2015, we purchased five buildings located in New York City, New York for approximately \$111.7 million. We and our operator plan to develop a 201,000 square-foot assisted living and memory care facility. The properties were added to the operator's existing master lease. The land is held for a 5% annual cash yield on the land during the construction phase. Upon issuance of a certification of occupancy, the annual cash yield will increase to 7% in year one and 8% in year two with annual 2.5% annual escalators thereafter.

(3) Accounted for as an asset acquisition.

The company estimated the fair values of the assets acquired on the acquisition date based on certain valuation analyses that have yet to be finalized. Accordingly, the assets acquired, as detailed, are subject to adjustment once the analyses are completed.

As of the ended December 31, 2015, we recognized revenue attributable to the aforementioned acquisitions of approximately \$4.9 million and net income attributable to the acquisitions of approximately \$2.3 million. Acquisition costs related to the above were expensed as period costs. For the year ended December 31, 2015, we expensed \$2.2 million of acquisition related costs. No goodwill was recorded in connection with these acquisitions.

Acquisition of Care Homes in the United Kingdom

2015, we closed on a purchase/leaseback Care Homes Transaction for 23 care homes located in the United Kingdom and operated by Healthcare Homes. As part of the transaction, we acquired title to the 23 care homes with 1,018 registered beds and leased them to Healthcare Homes pursuant to a master lease agreement with an initial annual cash yield of 7%, and annual escalators of 2.5%. The care homes, comparable to ALFs in the United Kingdom, are located throughout the East Anglia region (north of London) of the United Kingdom. Healthcare Homes is headquartered in Colchester, Essex, England. We recorded approximately \$193.8 million of assets consisting of land (\$20.7 million), building and site improvements (\$152.1 million), furniture and fixtures (\$5.3 million) and goodwill (\$15.7 million).

We incurred approximately \$3.2 million in acquisition related costs associated with the Care Homes Transaction. For the year ended December 31, 2015, we recognized approximately \$9.5 million of rental revenue in connection with the Care Homes Transaction.

Aviv

On April 1, 2015, Omega completed the Aviv Merger, which was structured as a stock-for-stock merger. Under the terms of the Merger Agreement, one share of Aviv common stock was converted into 0.90 of a share of Omega common stock. In connection with the Aviv Merger, Omega issued approximately 43.7 million shares of common stock to former Aviv stockholders. As a result of the Aviv Merger, Omega acquired 342 facilities, including 341 facilities subject to direct financing leases, one medical office building, two mortgages and other investments. The facilities are located in 31 states and are operated by 38 third-party operators. Omega also assumed certain outstanding equity awards and other debt and liabilities. Based on the closing of the Aviv Merger on April 1, 2015, we estimate the fair value of the consideration exchanged or assumed to be approximately \$3.9 billion. The fair values of Aviv's assets acquired and liabilities assumed on the Aviv Merger date are determined based on certain valuations and analyses that are to be finalized including the values of in place lease assets and liabilities, and accordingly, the assets acquired and liabilities assumed, and the amounts shown below, are subject to adjustment once the analyses are completed.

The following table highlights the preliminary fair value of the assets acquired and liabilities assumed on April 1, 2015.

	(in thousands)
Estimated fair value of assets acquired:	
Land and buildings	\$ 3,108,078
Investment in direct financing leases	26,823
Mortgages notes receivable	19,246
Other investments	23,619
Total investments	3,177,766
Goodwill	630,404
Accounts receivables and other assets	15,500
Cash acquired	84,858
Fair value of total assets acquired	\$ 3,908,528
Estimated fair value of liabilities assumed:	
Accrued expenses and other liabilities	\$ 221,631
Debt	1,410,637
Fair value of total liabilities assumed	1,632,268
Value of shares and OP units exchanged ^(a)	2,276,260
Fair value of consideration	\$ 3,908,528

(a) Includes the fair value of stock compensation plans

We incurred approximately \$52.1 million in acquisition related costs associated with the Aviv Merger. For the year ended December 31, 2015, we recognized approximately \$188.4 million of total revenue in connection with the Aviv Merger.

Within accrued expenses and other liabilities is a \$67.3 million contingent liability related to a leasing arrangement with an operator assumed as a result of the Aviv Merger.

In the fourth quarter of 2015, we adjusted the fair value of the in place lease assets and liabilities that we provisionally recognized on April 1, 2015 in connection with the Aviv Merger. We increased the fair value of the in place lease assets and in place lease liabilities to \$8.2 million and \$105.0 million, respectively, which resulted in a \$79.0 million net increase in goodwill. The change to the provisional amounts resulted in an \$8.2 million increase in net income, of which \$2.7 million relates to the second and third quarters of 2015, respectively.

2014 Acquisitions and

Period	Number of Facilities			Number of Operating Beds	Total Investment	Land	Building & Site Improvements	Furniture & Fixtures
	SNF	ALF	State					
Q1	-	1	AZ	90	\$ 4.7	\$0.4	\$ 3.9	\$ 0.4
Q2/Q3	3	-	GA, SC	345	34.6	0.9	32.1	1.6
Q3	1	-	TX	125	8.2	0.4	7.4	0.4
Q4	-	4	PA,OR,AR	371	84.2	5.1	76.7	2.4
	4	5		931	\$ 131.7	\$6.8	\$ 120.1	\$ 4.8

For the year ended December 31, 2014, we recognized revenue attributable to the acquisitions of approximately \$3.2 million and net income attributable to the acquisitions of approximately \$1.2 million. For the year ended December 31, 2014, we expensed \$3.9 million of acquisition related costs.

Transition of Two West Virginia Facilities to a New Operator

In 2014, we transitioned two West Virginia SNFs that we previously leased to Diversicare Healthcare Services (“Diversicare” and formerly Diversicare HealthCare Services) to a new unrelated third party operator. The two facilities represent 150 operating beds. We amended our Diversicare master lease to transfer the two facilities to the new operator and for the year ended December 31, 2014 recorded a \$0.8 million provision for uncollectible structured notes receivable. Simultaneous with the Diversicare master lease amendment, we entered into a 12-year master lease with a new third party operator.

\$415 Million of Refinancing/Consolidating Mortgage

In June 30, 2014, we entered into an agreement to refinance/consolidate \$117 million in existing mortgages on 17 facilities into one mortgage and to subsequently provide mortgage financing for an additional 14 facilities. The new \$415 million mortgage is secured by 31 facilities totaling 3,430 operating beds located in the state of Michigan. The new loan bears an initial annual cash interest rate of 9.0% and increases by 0.225% per year (e.g., beginning in year 2 the interest rate will be 9.225%, in year 3 the rate will be 9.450%, and in year 4 the rate will be 9.675%).

The existing mortgages that was refinanced/consolidated into the new \$415 million mortgage included annual interest rate escalators and required us to pay a prepayment penalty in the event the mortgage was retired early which required us to record an effective yield interest receivable. With the refinancing/consolidating transaction which was entered into at market terms, the old mortgage was considered to be retired early. The modifications made to the terms of the mortgage were more than minor. As of the date of the refinancing/consolidation transaction, the effective yield interest receivable was approximately \$2.0 million. We forgave the prepayment penalty associated with the retired mortgage and recorded a \$2.0 million provision to write-off the effective yield interest receivable related to the retired mortgage.

\$112.5 Million of New Mortgage

In January 17, 2014, we entered into a \$112.5 million first mortgage loan with an existing operator. The loan is secured by 7 SNFs and 2 ALFs with 9 operating beds located in Pennsylvania (7) and Ohio (2). The loan is cross-defaulted and cross-collateralized with our existing master lease agreement with the existing operator. The loan bears an initial annual cash interest rate of 9.5% and matures in January 2024.

2013 Acquisitions and

Period	Number of Facilities			Number of Operating	Total	Land	Building & Site Improvements		Furniture & Fixtures
	SNF	ALF	State	Beds	Investment		(in millions)		
Q4	-	1	FL	97	\$ 10.3	\$0.6	\$ 9.0	\$ 0.7	
Q4	4	-	IN	384	25.2	(1) 0.7	21.8	2.7	
Total	4	1		481	\$ 35.5	\$1.3	\$ 30.8	\$ 3.4	

er 31, 2013, we recorded approximately \$3.0 million to below market leases as a result of the transaction for a total investment of \$25.2 million.

Transition costs related to the above transactions were expensed as a period cost. For the year ended December 31, 2013, we expensed \$0.2 million of transition costs related to the acquisition of the 11 Arkansas facilities.

Transition of 11 Arkansas Facilities to a New Operator

On August 30, 2013, we transitioned 11 SNFs located in Arkansas that we previously leased to Diversicare Healthcare Services to a new third party operator. The 11 facilities represent 1,084 operating beds. We amended our Diversicare master lease to provide for reduced rent to reflect the transition of the 11 facilities to the new operator, and recorded a \$2.3 million provision for uncollectible straight-line rent receivable. Simultaneously, we entered into a new master lease with the new third party operator of the 11 facilities. The new master lease expires on August 31, 2023 and includes fixed annual rent of \$3.4 million.

\$529 Million Purchase/Leaseback Transaction

On November 27, 2013, we closed on an aggregate \$529 million purchase/leaseback transaction in connection with the acquisition of Ark Holding Inc. (“Ark Holding”) by 4 West Holdings Inc. At closing, we acquired 55 SNFs and 1 ALF operated by Ark Holding and leased the facilities from Ark Holding, now known as New Ark Investment Inc. (“New Ark”), pursuant to four 50-year master leases, with rental payments yielding approximately 5% over the term of the leases. The purchase/leaseback transaction is being accounted for as a direct financing lease. The 56 facilities represent 1,500 stateroom beds located in 12 states, predominantly in the southeastern United States. The 56 facilities are separated by region and divided into four classes of Master Leases. The four regions include the Southeast (39 facilities), the Northwest (7 facilities), Texas (9 facilities) and International (1 facility). The initial year one contractual rent is \$47 million with 2.5% escalators beginning in the second year.

The lease agreements allow the tenant the right to purchase the facilities for a bargain purchase price plus closing costs at the end of the lease term. Commencing in the 41st year of each lease, the tenant will have the right to prepay the remainder of its obligations thereunder for an amount equal to the unamortized portion of the original aggregate \$529 million investment plus the net present value of the remaining payments under the lease plus closing costs. In the event the tenant exercises either of these options, we have the right to purchase the properties for fair value at the time of exercise.

In June and July of 2014, we purchased three facilities and subsequently leased them to New Ark under a twelve-year master lease expiring in 2026. The 2014 three facility lease is being accounted for as an operating lease.

Asset Sales, Impairments and Provisions

In 2013, we sold seven SNFs (four previously held-for-sale) for total cash proceeds of approximately \$41.5 million, generating a gain of approximately \$17.7 million. We also recorded a total of \$17.7 million provision for impairment related to six SNFs to reduce their net book value to their estimated fair value at the time of sale. To estimate the fair value of these facilities we utilized a market approach and Level 3 inputs. Two of the facilities are reclassified from held-for-sale to other assets.

In 2013, we sold four SNFs (three previously held-for-sale) and a parcel of land for total cash proceeds of \$4.1 million, resulting in a \$2.9 million loss. We also recorded a \$3.7 million provision for impairment related to these facilities. To estimate the fair value of these facilities we utilized a market approach and Level 3 inputs.

In 2013, we sold one SNF and a parcel of land for total cash proceeds of \$2.3 million resulting in a \$1.2 million loss.

See “*Note 7 – Assets Held For Sale*” for more information.

As of December 31, 2015, 2014 and 2013, we do not have any material properties or operators with facilities that are not materially

Results of Op

Following is our discussion of the consolidated results of operations, financial position and liquidity and capital resources, which should be read in conjunction with our audited consolidated financial statements and accompanying

Year Ended December 31, 2015 compared to Year Ended December

Operating

Operating revenues for the year ended December 31, 2015, were \$743.6 million, an increase of \$238.8 million over the same period in 2014. Following is a description of certain of the changes in operating revenues for the year ended December 31, 2015 compared to 2014:

Operating income was \$606.0 million, an increase of \$217.5 million over the same period in 2014. The increase was the result of the Aviv Merger and Care Homes Transaction and other acquisitions and lease amendments made throughout 2014 and 2015.

Operating lease income was \$59.9 million, an increase of \$3.2 million over the same period in 2014. The increase was primarily related to two new leases assumed in the Aviv Merger and incremental revenue associated with the New Ark direct financing lease.

Interest income totaled \$68.9 million, an increase of \$15.9 million over the same period in 2014. The increase was primarily due to timing of investments. During the second quarter of 2014, we entered into a \$415 million mortgage with an existing operator. See “*Portfolio and Capital Resources*” above for additional information.

Interest expense totaled \$8.8 million, an increase of \$2.2 million over the same period in 2014. The increase was primarily related to interest on term loans related to the Aviv Merger in April 2015.

Operating

Operating expenses for the year ended December 31, 2015, were \$332.3 million, an increase of approximately \$172.9 million over the same period in 2014. Following is a description of certain of the changes in our operating expenses for the year ended December 31, 2015 compared to 2014:

Depreciation and amortization expense was \$210.7 million for the year ended December 31, 2015, compared to \$123.3 million for the same period in 2014. The increase of \$87.4 million was primarily due to the Aviv Merger and Care Homes Transaction.

Operating and administrative expense, excluding stock-based compensation expense, was \$27.4 million, compared to \$17.3 million for the same period in 2014. The increase is primarily related to the Aviv Merger.

ased compensation expense was \$11.1 million, an increase of \$2.5 million over the same period in 2014. The increase was primarily due to the merger.

acquisition and merger related costs were \$57.5 million, compared to \$3.9 million for the same period in 2014. The \$53.6 million increase was the result of the Aviv Merger in April 2015 and Care Homes Transaction in May 2015.

recorded \$17.7 million of provision for impairment, compared to \$3.7 million for the same period in 2014. The 2015 impairment related to the transition of two facilities to a new operator. We recorded a provision to reduce their net book values to their estimated fair values less costs to sell. In 2014, we closed two SNFs and recorded a \$3.7 million provision for impairment related to these facilities.

on for uncollectible mortgages, notes and accounts receivable was \$7.9 million, compared to \$2.7 million for the same period in 2014. In 2015, we recorded a provision of \$4.7 million of straight line receivable and effective interest balances associated with four leases and three mortgages with an existing operator. We transitioned the facilities to a new operator in January 2016. We also recorded a \$3.0 million provision for a note that we impaired in 2015. In 2014, we recorded \$2.7 million provision for uncollectible receivables related to (i) a write-off of an effective yield interest receivable related to the termination of a mortgage receivable (see \$415 Million of Refinancing/Consolidating Mortgage Loan above) and (ii) a straight-line receivable related to the transition of two facilities from an existing operator to a new operator.

Other Income (

For the year ended December 31, 2015, total other expenses were \$183.1 million, an increase of approximately \$56.3 million over the same period. This \$56.3 million increase was primarily the result of: (i) a \$28.0 million increase in interest expense due to an increase in borrowings outstanding since January 2014 including the April 1, 2015 Aviv Merger and May 1, 2015 Care Homes Transaction and (ii) a \$25.8 million increase in interest expense due to interest refinancing.

20

To qualify as a REIT, we generally are not subject to federal income taxes on the REIT taxable income that we distribute to stockholders, subject to certain exceptions. For tax year 2015, we made common dividend payments of \$358.2 million to satisfy REIT requirements relating to qualifying distributions. Under the limitation under the REIT asset test rules, we are permitted to own up to 100% of the stock of one or more taxable REIT subsidiaries. We have elected for two of our subsidiaries to be treated as TRSs. One of our TRSs is subject to federal, state and local income taxes at the applicable corporate rates and the other is subject to foreign income taxes. As of December 31, 2015, one of our TRSs had a net operating loss carry-forward of approximately \$0.9 million. The loss carry-forward is fully reserved as of December 31, 2015 with a valuation allowance due to uncertainties regarding the realization of the loss.

re

In connection with the Care Homes Transaction in May 2015, we acquired 10 legal entities consisting of 23 facilities. The tax basis in these legal entities for United Kingdom taxes was approximately \$82 million less than the purchase price. We recorded a preliminary initial deferred tax liability associated with the temporary tax basis difference of approximately \$13.5 million.

For the year ended December 31, 2015, we recorded approximately \$1.0 million of state and local income tax provision and approximately \$0.5 million of provision for foreign income taxes.

Ne

Net income for the year ended December 31, 2015 was \$233.3 million compared to \$221.3 million for the same period in 2014.

National Association of Real Estate Investment Trusts Funds From Op

Funds from operations available to common stockholders ("NAREIT FFO"), for the year ended December 31, 2015, was \$455.3 million, compared to \$345.4 million for the same period.

We calculate and report NAREIT FFO in accordance with the definition of Funds from Operations and interpretive guidelines issued by the National Association of Real Estate Investment Trusts ("NAREIT"), and, consequently, NAREIT FFO is defined as net income available to common stockholders for the effects of asset dispositions and certain non-cash items, primarily depreciation and amortization and impairment on real estate assets. NAREIT FFO is an important supplemental measure of our operating performance. Because the historical cost accounting convention for real estate assets requires depreciation (except on land), such accounting presentation implies that the value of real estate assets diminishes predictably over time, while real estate values instead have historically risen or fallen with market conditions. NAREIT FFO was designed by the real estate industry to address this issue. NAREIT FFO herein is not necessarily comparable to NAREIT FFO of other REITs that do not use the same definition or implementation guidelines or interpret the standards differently.

NAREIT FFO is a non-GAAP financial measure. We use NAREIT FFO as one of several criteria to measure the operating performance of our business. We believe that by excluding the effect of depreciation, amortization, impairment on real estate assets and gains or losses from sales of real estate assets based on historical costs and which may be of limited relevance in evaluating current performance, NAREIT FFO can facilitate comparing operating performance between periods and between other REITs. We offer this measure to assist the users of our financial statements in evaluating performance under GAAP, and NAREIT FFO should not be considered a measure of liquidity, an alternative to net income or an indicator of performance measure determined in accordance with GAAP. Investors and potential investors in our securities should not rely on this measure as a substitute for any GAAP measure, including net income.

The following table presents our NAREIT FFO results for the years ended December 31, 2015 and 2014.

	Year Ended December 31, 2015	2014 (in thousands)
Net income	\$233,315	\$226,962
Deduct gain from real estate dispositions	(6,353)	
Elimination of non-cash items included in net income:		
Depreciation and amortization	210,703	
Add back impairments on real estate properties	17,681	
NAREIT FFO ^(a)	\$455,346	\$455,346

(a) Includes amounts allocated to Omega stockholders and Omega OP Unit holders.

Year Ended December 31, 2014 compared to Year Ended December 31, 2013

Operating

Operating revenues for the year ended December 31, 2014, were \$504.8 million, an increase of \$86.1 million over the same period in 2013. For a description of certain of the changes in operating revenues for the year ended December 31, 2014 compared to 2013, see Note 3.

Operating income was \$388.4 million, an increase of \$13.3 million over the same period in 2013. The increase was the result of new investments made and lease amendments made since January 1, 2013.

Direct financing lease income was \$56.7 million, an increase of \$51.5 million over the same period in 2013. The increase was primarily related to the New Ark transaction. The direct financing lease was entered into in November 2013.

Interest income totaled \$53.0 million, an increase of \$23.7 million over the same period in 2013. The increase was primarily due to: (a) a \$298 million in a new mortgage loan (See \$415 Million of Refinancing/Consolidating Mortgage Loans above) we entered into with an existing operator in the second quarter of 2014 and (b) a \$112.5 million mortgage we entered into with an existing operator in the first quarter of 2014.

Other income totaled \$6.6 million, a decrease of \$2.4 million over the same period in 2013. The decrease was primarily related to interest income on a mezzanine loan that was paid off in December 2013.

Operating

g expenses for the year ended December 31, 2014, were \$159.5 million, an increase of approximately \$6.4 million over the same period

Following is a description of certain of the changes in our operating expenses for the year ended December 31, 2014 compared

ation and amortization expense was \$123.3 million for the year ended December 31, 2014, compared to \$128.6 million for the same pe
decrease of \$5.4 million was primarily due to the acquisition of furniture and fixtures that we acquired several years ago as part of the
ce transaction that are now fully depreciated partially offset by the deprecation on fourth quarter of 2013 and 2014 acquisitions and cap
and improvement program.

and administrative expense, excluding stock-based compensation expense, was \$17.3 million, compared to \$15.6 million for the same period in 2013. The increase is primarily related to development costs related to securing additional beds license for future development.

Stock-based compensation expense was \$8.6 million, an increase of \$2.7 million over the same period in 2013. The increase was primarily due to restricted stock units granted to employees in December 2013 and January 2014.

Acquisition costs were \$3.9 million, compared to \$0.2 million for the same period in 2013. The \$3.7 million increase was primarily the result of an increase in acquisition related costs attributed to the Aviv Merger.

We recorded \$3.7 million of provision for impairment, compared to \$0.4 million for the same period in 2013. The \$3.2 million increase in impairment was primarily the result of two facilities that were closed in 2014.

Provision for uncollectible mortgages, notes and accounts receivable was \$2.7 million, compared to \$2.1 million for the same period in 2013. The \$0.6 million increase was primarily the result of a \$2.7 million provision for uncollectible receivables related to (i) a write-off of an effective yield interest receivable related to the refinancing of a mortgage receivable (see \$415 Million of Refinancing/Consolidating Mortgage Loan above) and (ii) a straight-line receivable related to the transfer of two facilities from an existing operator to a new operator.

Other Income (Expense)

For the year ended December 31, 2014, total other expenses were \$126.8 million, an increase of approximately \$34.8 million over the same period in 2013. The \$34.8 million increase was primarily the result of: (i) a \$19.0 million increase in interest expense due to (a) an increase in borrowings outstanding due to the increase in the average rate of the borrowings due to the repayment of lower cost credit facility debt with higher cost long term bond debt and (b) a \$2 million increase in interest refinancing charge. In 2014, we recorded approximately \$3.0 million in refinancing related costs including the write-off of deferred financing costs associated with the termination of our previous \$700 million 2012 Credit Facilities, (b) \$2.0 million write-off of financing costs associated with the termination of our \$200 million unsecured term loan facility and (c) \$1.7 million prepayment penalty on HUD debt in June 2014, partially offset by \$3.3 million gain related to the write-off of premium on the HUD debt paid off in September 2013, we recorded an \$11.1 million gain primarily related to write-off of premium associated with HUD debt that was retired in March 2014.

2014

To qualify as a REIT, we generally are not subject to federal income taxes on the REIT taxable income that we distribute to stockholders, subject to certain exceptions. For tax year 2014, we made common dividend payments of \$258.5 million to satisfy REIT requirements relating to qualifying distributions. For 2014, we have one TRS that is taxable as a corporation and that pays federal, state and local income tax on its net income at the applicable rates. The TRS had a net operating loss carry-forward as of December 31, 2014 of \$1.0 million. The loss carry-forward was fully reserved with a provision for allowance due to uncertainties regarding recovery of the loss carry-forward.

Net income for the year ended December 31, 2014 was \$221.3 million compared to \$172.5 million for the same period

National Association of Real Estate Investment Trusts Funds From Op

IT FFO, for the year ended December 31, 2014, was \$345.4 million, compared to \$302.7 million for the same period in 2013. NAREIT non-GAAP financial measure. See “*National Association of Real Estate Investment Trusts Funds From Operati*

The following table presents our NAREIT FFO results for the years ended December 31, 2014 a

	Year Ended December 31 2014	2013
	(in thousands)	
Net income available to common	\$221,349	\$218,486
(Deduct gain)/add back loss from real estate dispositions	(2,863)	(2,863)
Elimination of non-cash items included in net income:		
Depreciation and amortization	123,257	123,257
Add back impairments on real estate properties	3,660	3,660
NAREIT FFO	\$345,403	\$302,700

Liquidity and Capital R

ember 31, 2015, we had total assets of \$8.0 billion, total equity of \$4.1 billion and debt of \$3.6 billion, with such debt representing approximately 46.5% of total capital

The following table shows the amounts due in connection with the contractual obligations described below as of December

	Payments due by period				
	Total	Less than 1 year	1-3 years	3-5 years	More than 5 years
	(in thousands)				
Debt ⁽¹⁾	\$3,586,204	\$1,249	\$532,616	\$382,782	\$2,621,557
Interest payments on long-term debt	1,298,015	140,760	283,360	261,345	612,550
Operating lease and other obligations	19,183	2,955	5,957	5,366	4,895
Total	\$4,903,402	\$144,964	\$821,933	\$649,493	\$3,487,010

billion of debt outstanding includes: (i) \$230.0 million in borrowings under the Revolving Credit Facility due in June 2018; (ii) \$200 million under the 2015 Term Loan Facility due on June 2019, (iii) \$200 million under the Acquisition Term Loan Facility due June 2017, (iv) \$100 million under the 2017 Term Loan Facility due June 2017, (v) \$180 million GE Term Loan due 2019 at 4%; (vi) \$250 million under the 2015 Term Loan Facility due September 2022, (vii) \$400 million of 5.875% Senior Notes due 2024; (viii) \$400 million of 4.95% Senior Notes due April 2024; (ix) \$250 million of 5.0% Senior Notes due January 2025; (x) \$600 million of 5.25% Senior Notes due 2026; (xi) \$700 million of 4.5% Senior Notes due 2027; (xii) \$100 million of 9.0% subordinated debt maturing in December 2021 and (xiii) \$56 million of HUD debt at 3.06% maturing in July 2044.

Financing Activities and Borrowing Arrangements

HUD Loans

December 31, 2015, we paid approximately \$25.1 million to retire two mortgage loans guaranteed by HUD. The loans were assumed as part of an acquisition in a prior year, and had a blended interest rate of 5.5% per annum with maturities on March 1 and April 1, 2036. The payoff resulted in a \$1.0 million gain on the extinguishment of the debt due to the write-off of the \$2.1 million unamortized fair value adjustment recorded at the time of acquisition, offset by a prepayment fee of approximately \$1.2 million.

December 31, 2015, we paid approximately \$9.1 million to retire one mortgage loan guaranteed by HUD. The loan was assumed as part of an acquisition in a prior year, and had an interest rate of 4.35% per annum with maturity on March 1, 2041. The payoff resulted in a \$1.0 million gain on the extinguishment of the debt due to the write-off of the \$1.5 million unamortized fair value adjustment recorded at the time of acquisition, offset by a prepayment fee of approximately \$0.5 million.

1, 2015, we paid approximately \$154.3 million to retire 21 mortgage loans guaranteed by HUD, totaling approximately \$146.9 million. The loans had a blended interest rate of 5.35% per annum with maturities between January 2040 and January 2045 and three loans had an all-in blended interest rate of 5.35% per annum with maturities between February 2040 and February 2045. The payoff resulted in a \$2.3 million gain on the extinguishment of the loans and the write-off of the \$9.7 million unamortized debt premium recorded at the time of acquisition offset by a prepayment fee of approximately \$0.7 million.

\$250 Million Term Loan

On December 16, 2015, we entered into a \$250 million senior unsecured term loan facility (the “2015 Term Loan Facility”). The 2015 Term Loan Facility has an interest rate at LIBOR plus an applicable percentage (beginning at 180 basis points, with a range of 140 to 235 basis points) based on our rating by Standard & Poor’s, Moody’s and/or Fitch Ratings. The 2015 Term Loan Facility may be increased to an aggregate amount of \$400 million. We have used proceeds from this loan to repay existing indebtedness and for general corporate purposes. The 2015 Term Loan Facility matures on December 15, 2022, with interest payments due monthly. We had a total of \$250 million outstanding under the 2015 Term Loan Facility as of December 31, 2015.

As a result of exposure to interest rate movements associated with the 2015 Term Loan Facility, on December 16, 2015, we entered into forward-starting interest rate swap arrangements, which effectively converted \$250 million of our variable-rate debt based on one-month LIBOR to a fixed rate of approximately 3.8005% effective December 30, 2016. The effective fixed rate achieved by the combination of the 2015 Term Loan Facility and the interest rate swaps could vary up by 55 basis points or down by 40 basis points based on future changes to our credit ratings. Each swap has a term of 6 years on December 30, 2016 and matures on December 15, 2022. On the date of inception, we designated the interest rate swaps as cash flow hedges in accordance with accounting guidance for derivatives and hedges and linked the interest rate swaps to the 2015 Term Loan Facility. Because the terms of the interest rate swaps and the 2015 Term Loan Facility coincide, the hedges are expected to exactly offset changes in expected cash flows due to fluctuations in 1-month LIBOR over the term of the hedges. The purpose of entering into the swaps was to reduce our exposure to future changes in interest rates. The interest rate swaps settle on a monthly basis when interest payments are made. These settlements will occur through the 2015 Term Loan Facility. The interest rate for the 2015 Term Loan Facility is not hedged for the portion of the term prior to December 30, 2016.

\$575 Million 6.75% Senior Notes due 2022 Redeemed

On December 26, 2015, we redeemed all of our outstanding 6.75% Senior Notes due 2022 (the “2022 Notes”). As a result of the redemption, during 2015, we recorded approximately \$21.3 million in redemption related costs and write-offs, including \$19.4 million for the early redemption premium and \$1.9 million in net write-offs associated with unamortized deferred financing costs and original issuance premiums/costs.

\$600 Million 5.25% Senior Notes

On December 23, 2015, we sold \$600 million aggregate principal amount of our 5.250% Senior Notes due 2026 (the “2026 Notes”). The 2026 Notes were issued at an issue price of 99.717% of their face value before the initial purchasers’ discount. Our total net proceeds from the offering, after deducting the initial purchasers’ discounts and other offering expenses, were approximately \$594.4 million. The net proceeds of the offering were used to repay our outstanding aggregate principal amount 6.75% Senior Notes due 2022 and for general corporate purposes. The 2026 Notes mature on January 15, 2026 and will pay interest semi-annually on January 15th and July 15th.

\$500 Million Equity Shelf

On December 3, 2015, we entered into separate Equity Distribution Agreements (collectively, the “Equity Shelf Agreements”) to sell shares of our common stock having an aggregate gross sales price of up to \$500 million (the “2015 Equity Shelf Program”) with several financial institutions, each as a principal (collectively, the “Managers”). Under the terms of the Equity Shelf Agreements, we may sell shares of our common stock, from time to time, through or to the Managers having an aggregate gross sales price of up to \$500 million. Sales of the shares, if any, will be made by means of open market transactions on the New York Stock Exchange at market prices, or as otherwise agreed with the applicable Manager. We will pay each Manager a commission for sales of the shares equal to 2% of the gross sales price per share of shares sold through such Manager under the applicable Equity Shelf Agreement. As of December 31, 2015, we did not issue any shares under the 2015 Equity Shelf Program.

\$250 Million Equity Shelf Program Termination

On September 3, 2015, we terminated our \$250 million Equity Shelf Program (the “2013 Equity Shelf Program”) that we entered into with various financial institutions on March 18, 2013. In 2015, we did not issue any shares under the 2013 Equity Shelf Program.

For the year ended December 31, 2014, we issued approximately 1.8 million shares under the 2013 Equity Shelf Program, at an average price of \$35.28 per share, generating gross proceeds of approximately \$63.5 million, before \$1.5 million of commissions and other expenses.

Under the terms of the 2013 Equity Shelf Program, we sold a total of 7.4 million shares of common stock generating total gross proceeds of \$233.0 million, before \$4.7 million of commissions. As a result of the termination of the 2013 Equity Shelf Program, no additional shares were issued under the 2013 Equity Shelf Program.

Credit Facilities

On December 27, 2014, we entered into a credit agreement (as amended, the “2014 Credit Agreement”) providing us with \$1.2 billion unsecured credit facilities, consisting of a \$1 billion senior unsecured revolving credit facility (the “Revolving Credit Facility”) and a \$200 million senior unsecured term loan facility (the “Term Loan Facility” or “Tranche A-1 Term Loan Facility,” and, collectively, the “2014 Credit Facilities”).

On January 1, 2015, we entered into a First Amendment to Credit Agreement (the “First Amendment to Omega Credit Agreement”) which amends the 2014 Credit Facilities. Under the First Amendment to Omega Credit Agreement, the Company (i) increased the aggregate revolving commitment amount under the Revolving Credit Facility from \$1 billion to \$1.25 billion and (ii) obtained a \$200 million senior unsecured incremental term loan facility (the “Acquisition Term Loan Facility” or “Tranche A-2 Term Loan Facility”).

Borrowings under the Revolving Credit Facility bear interest at LIBOR plus an applicable percentage (beginning at 130 basis points, with a range of 130 to 150 basis points) based on our ratings from Standard & Poor’s, Moody’s and/or Fitch Ratings, plus a facility fee based on the same ratings (initially 12.5 to 30 basis points, with a range of 12.5 to 30 basis points). The Revolving Credit Facility is used for acquisitions and general corporate purposes. At December 31, 2015, we had a total of \$230.0 million borrowings outstanding under the Revolving Credit Facility. The Revolving Credit Facility matures on June 27, 2019, subject to a one-time option by us to extend such maturity date by one year.

The Tranche A-1 Term Loan Facility bears interest at LIBOR plus an applicable percentage (beginning at 150 basis points, with a range of 100 to 150 basis points) based on our ratings from Standard & Poor’s, Moody’s and/or Fitch Ratings. At December 31, 2015, we had a total of \$200.0 million in borrowings outstanding under the Tranche A-1 Term Loan Facility. The Tranche A-1 Term Loan Facility matures on June 27, 2019.

The Tranche A-2 Term Loan Facility bears interest at LIBOR plus an applicable percentage (beginning at 150 basis points, with a range of 100 to 195 basis points) based on our ratings from Standard & Poor's, Moody's and/or Fitch Ratings. At December 31, 2015, we had a total of \$200.0 million in loans outstanding under the Tranche A-2 Term Loan Facility. The Tranche A-2 Term Loan Facility matures on June 27, 2017, subject to Omega's option to extend the maturity date of the Tranche A-2 Term Loan Facility twice, the first extension until June 27, 2018 and the second extension until June 27, 2019.

On January 29, 2016, Omega entered into a Third Amendment to Credit Agreement (the "Third Amendment to Omega Credit Agreement"), which amended the First Amendment to Omega Credit Agreement to provide, among other things, for a \$350 million senior unsecured incremental term loan facility (the "Tranche A-3 Term Loan Facility," and together with the Tranche A-1 Term Loan Facility and the Tranche A-2 Term Loan Facility, the "Tranche A-1 to A-3 Term Loan Facilities"), which was borrowed in full at closing. The Tranche A-3 Term Loan Facility matures on January 29, 2021. The proceeds from the Tranche A-3 Term Loan Facility were used to pay down the Revolving Credit Facility and for general corporate purposes. The Tranche A-3 Term Loan Facility bears interest at a rate of LIBOR plus an applicable percentage (beginning at 150 basis points, with a range of 100 to 195 basis points) based on our ratings from Standard & Poor's and/or Fitch Ratings. The Third Amendment to Omega Credit Agreement also permits Omega, subject to compliance with customary conditions, to increase the amount of the Revolving Credit Facility or to add one or more tranches of incremental term loans, or both, by an aggregate principal amount not to exceed \$250 million.

Omega OP Term Loan

2015, Omega OP entered into a credit agreement (the “Omega OP Credit Agreement”) providing it with a \$100 million senior unsecured term loan facility (the “Omega OP Term Loan Facility”). The Omega OP Term Loan Facility bears interest at LIBOR plus an applicable percentage (beginning in 2016, with a range of 100 to 195 basis points) based on our ratings from Standard & Poor’s, Moody’s and/or Fitch Ratings. The Omega OP Term Loan Facility matures on June 27, 2017, subject to Omega OP’s option to extend such maturity date twice, the first extension until June 27, 2018 and the second extension until June 27, 2019. At December 31, 2015, we had a total of \$100.0 million borrowings outstanding under the Omega OP Term Loan Facility.

General Electric Term Loan

2015, as a result of the Aviv Merger, we assumed a \$180 million secured term loan with General Electric Capital Corporation (“GE”). The loan is secured by real estate assets having a net carrying value of \$295.5 million at December 31, 2015. On each payment date, we pay interest only (in arrears) on the outstanding principal balance until February 1, 2017 when principal and interest will be paid in arrears based on a thirty year amortization schedule. The interest rate is based on LIBOR, with a floor of 50 basis points, plus a margin of 350 basis points. The interest rate at December 31, 2015 was 4.6%. The term expires in December 2019 with the full balance of the loan due at that time.

Other Aviv Debt Repayment

In connection with the Aviv Merger on April 1, 2015, we assumed notes payable with a face amount of \$650 million and a revolving credit facility with an outstanding balance of \$525 million. We repaid this debt assumed from Aviv on April 1, 2015. Due to the contractual requirements of the debt; we paid approximately \$705.6 million to retire the \$650 million notes assumed. The amount repaid in connection with the revolving credit facility was \$525 million.

Increase of Authorized Omega Common Stock

On June 27, 2015, we amended our charter to increase the number of authorized shares of Omega capital stock from 220 million to 370 million and the number of authorized shares of Omega common stock from 200 million to 350 million.

\$700 Million 4.5% Senior Notes

On March 18, 2015, we sold \$700 million aggregate principal amount of our 4.5% Senior Notes due 2027 (the “2027 Notes”). The 2027 Notes were sold at a price of 98.546% of their face value before the initial purchasers’ discount. Our total net proceeds from the offering, after deducting initial placement agent fees, commissions, underwriting discounts and other offering expenses, were approximately \$683 million. The net proceeds of the offering were used for general corporate purposes, including the repayment of Aviv indebtedness on April 1, 2015 in connection with the Aviv Merger, and repayment of future maturities of our other outstanding debt. The 2027 Notes mature on April 1, 2027 and pay interest semi-annually on April 1st and October 1st.

\$200 Million 7.5% Senior Notes due 2020 Redeemed

On March 13, 2015, Omega redeemed all of its outstanding \$200 million 7.5% Senior Notes due 2020 (the “2020 Notes”) at a redemption price of approximately \$208.7 million, consisting of 103.750% of the principal amount, plus accrued and unpaid interest on such notes to, but not including, the date of redemption.

In connection with the redemption, we recorded approximately \$11.7 million redemption related costs and write-offs, including \$7.5 million in premium amortization for early redemption and \$4.2 million of write-offs associated with unamortized deferred financing costs and discount. The consideration for the redemption of the 2020 Notes was funded from the net proceeds of the 10.925 million share common stock offering.

Issuance of 10.925 Million Shares of Common Stock

On July 9, 2015, we completed an underwritten public offering of 10.925 million shares of our common stock at \$42.00 per share before underwriting and offering expenses. The Company's total net proceeds from the offering were approximately \$440 million, after deducting underwriting and commissions and other estimated offering expenses.

To qualify as a REIT, we are required to distribute dividends (other than capital gain dividends) to our stockholders in an amount at least equal to the sum of (i) 90% of our "REIT taxable income" (computed without regard to the dividends paid deduction and our net capital gain), and (ii) the amount of net capital gain (after tax), if any, from foreclosure property, minus (B) the sum of certain items of non-cash income. In addition, if we dispose of an asset during a recognition period, we will be required to distribute at least 90% of the built-in gain (after tax), if any, recognized on the disposition. Such distributions must be paid in the taxable year to which they relate, or in the following taxable year if declared before we timely file our tax return for such year and paid on or before the first regular dividend payment after such declaration. In addition, such distributions are required to be made with no preference to any share of stock as compared with other shares of the same class, and with no preference to one class of stock as compared to another class except to the extent that such class is entitled to such a preference. To the extent that we do not distribute all of our net capital gain, we will distribute at least 90%, but less than 100% of our "REIT taxable income" as adjusted, we will be subject to tax thereon at regular ordinary and capital gains corporate income tax rates.

In 2015, we paid dividends of \$358.2 million to our common stockholders.

Common Stock Dividends

On February 14, 2016, the Board of Directors declared a common stock dividend of \$0.57 per share, increasing the quarterly common dividend by \$0.02 per share over the prior quarter, which was paid February 16, 2016 to common stockholders of record on February 12, 2016.

On November 14, 2015, the Board of Directors declared a common stock dividend of \$0.56 per share, increasing the quarterly common dividend by \$0.01 per share over the previous quarter. The common dividends were paid November 16, 2015 to common stockholders of record on November 12, 2015.

On August 14, 2015, the Board of Directors declared a common stock dividend of \$0.55 per share, increasing the quarterly common dividend rate by \$0.01 per share over the prior quarter, which was paid on August 17, 2015 to common stockholders of record on July 30, 2015.

April 15, 2015, the Board of Directors declared a prorated dividend of \$0.18 per share of Omega's common stock in view of the recently closed quarter. The per share dividend amount payable by Omega represents dividends for April 2015, at a quarterly dividend rate of \$0.54 per share of common stock, increasing the quarterly common dividend rate by \$0.01 per share over the prior quarter. The \$0.18 dividend was paid in cash on May 15, 2015 to stockholders of record as of the close of business on April 15, 2015.

February 5, 2015, the Board of Directors declared a prorated dividend of \$0.36 per share of Omega's common stock in view of the pending acquisition of Omega pursuant to the Aviv Merger. The per share dividend amount represented dividends for February and March 2015, at a quarterly dividend rate of \$0.72 per share of common stock, increasing the quarterly common dividend rate by \$0.01 per share over the prior quarter. The dividend was paid in cash on February 7, 2015 to stockholders of record as of the close of business on March 5, 2015.

February 14, 2015, the Board of Directors declared a common stock dividend of \$0.53 per share, increasing the quarterly common dividend rate of \$0.53 per share over the prior quarter, which was paid February 16, 2015 to common stockholders of record on February 14, 2015.

our liquidity and various sources of available capital, including cash from operations, our existing availability under our 2014 Credit Facility and expected proceeds from mortgage payoffs are more than adequate to finance operations, meet recurring debt service requirements and fund future investments through the next twelve months.

regularly review our liquidity needs, the adequacy of cash flow from operations, and other expected liquidity sources to meet these needs. We believe our principal short-term liquidity needs are:

- normal recurring expenses
- debt service payments
- capital improvement projects
- common stock dividends
- growth through acquisitions of additional properties

Our primary source of liquidity is our cash flows from operations. Operating cash flows have historically been determined by: (i) the number of mortgages on; (ii) rental and mortgage rates; (iii) our debt service obligations; and (iv) general and administrative expenses. The timing of cash flows provided by/used in financing activities and used in investing activities are sensitive to the capital markets environment, and changes in interest rates. Changes in the capital markets environment may impact the availability of cost-effective capital and affect our acquisition and disposition activities.

Cash equivalents totaled \$5.4 million as of December 31, 2015 an increase of \$0.9 million as compared to the balance at December 31, 2014. The following is a discussion of changes in cash and cash equivalents due to operating, investing and financing activities, which are presented in the Consolidated Statement of Cash Flows.

Operating Activities – Operating activities generated \$463.9 million of net cash flow for the year ended December 31, 2015, as compared to \$337.5 million for the same period in 2014, an increase of \$126.4 million. The increase was primarily due to the additional cash flow generated from new investments, primarily the Aviv Merger and Care Homes Transaction, including the facilities acquired and leased throughout 2014 and 2015.

Investing Activities – Net cash flow from investing activities was an outflow of \$397.4 million for the year ended December 31, 2015, as compared to an outflow of \$547.9 million for the same period in 2014. The \$150.5 million decrease in cash outflow from investing activities related primarily to: (i) an increase of \$84.9 million of cash acquired with the Aviv Merger in 2015; (ii) an increase of \$37.5 million in proceeds from the sale of real estate to the same period in 2014; (iii) \$12.7 million of net mortgage investment made in 2015 compared to \$406.6 million of net mortgage investment in the same period of 2014, offset by (i) an increase of \$164.2 million investment in construction in progress in 2015 as compared to the same period of 2014, (ii) an increase of \$162.5 million in acquisitions in 2015 compared to the same period of 2014, (iii) an increase of \$8.5 million in other investing activities.

on program investment compared to the same period of 2014 and (iv) an increase of \$6.8 million investment in direct financing leases in 2015 compared to the same period in 2014.

Financing Activities – Net cash flow from financing activities was an outflow of \$65.3 million for the year ended December 31, 2015 as compared to an outflow of \$212.3 million for the same period in 2014. The \$277.6 million change in cash flow from financing activities was primarily a result of (i) an increase in net proceeds of \$386 million on the credit facility in 2015 compared to the same period in 2014; (ii) an increase in net proceeds of \$377.4 million from issuance common stock in 2015 as compared to the same period in 2014; (iii) an increase in net proceeds of \$79.4 million from our stock repurchase plan in 2015 compared to the same period in 2014, offset by (i) an increase of \$948.8 million net payments in long term borrowing in 2015 compared to the same period in 2014; (ii) dividend payments increased by \$99.7 million due to an increase in number of shares outstanding and an increase in the common dividends; (iii) an increase of \$37.0 million in refinancing related costs compared to the same period in 2014; and (iv) \$11.6 million distributions to Omega OP Units.

Critical Accounting Policies and Estimates

Preparation of financial statements in conformity with generally accepted accounting principles (“GAAP”) in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the end of the reporting period, and the reported amounts of revenues and expenses during the reporting period. Our significant accounting policies are described in *Note 2 – Summary of Significant Accounting Policies*.” These policies were followed in preparing the consolidated financial statements for the periods presented. Actual results could differ from those expected.

We have identified four significant accounting policies that we believe are critical accounting policies. These critical accounting policies are those that have the most impact on the reporting of our financial condition and those requiring significant assumptions, judgments and estimates. With respect to these critical accounting policies, we believe the application of judgments and assessments is consistently applied and produces financial information that faithfully presents the results of operations for all periods presented. The four critical accounting policies are:

Lease Accounting

At the inception of the lease and during the amendment process, we evaluate each lease to determine if the lease should be considered an operating lease or a direct financing lease. We have determined that all but seven of our leases should be accounted for as operating leases. The other seven leases are accounted for as direct financing leases.

Leases accounted for as operating leases, we retain ownership of the asset and record depreciation expense. We also record lease revenue based on the contractual terms of the operating lease agreement which often includes annual rent escalators, see “*Revenue Recognition and Allowance for Doubtful Accounts*” below for further discussion regarding the recordation of revenue on our operating leases.

Leases accounted for as direct financing leases, we record the present value of the future minimum lease payments (utilizing a constant interest rate from the lease agreement) as a receivable and record interest income based on the contractual terms of the lease agreement. As of December 31, 2019, \$3.3 million and \$3.4 million, respectively, of unamortized direct costs related to originating the direct financing leases have been deferred and recorded in our Consolidated Balance Sheet as a contra liability.

Revenue Recognition and Allowance for Doubtful Accounts

We have various different investments that generate revenue, including leased and mortgaged properties, as well as, other investments, including loans. We recognized rental income and mortgage interest income and other investment income as earned over the terms of the related investments.

respectively. Interest income is recorded on an accrual basis to the extent that such amounts are expected to be collected using the effective interest method. In applying the effective interest method, the effective yield on a loan is determined based on its contractual payment terms, adjusted for any prepayments.

Generally all of our leases contain provisions for specified annual increases over the rents of the prior year and are generally computed in accordance with specific provisions of each lease as follows: (i) a specific annual increase over the prior year's rent, generally between 2.0% and 3.0%; (ii) a percentage increase based on the change in pre-determined formulas from year to year (i.e., such as increases in the Consumer Price Index); or (iii) specific annual increases over prior years. Revenue under lease arrangements with fixed and determinable increases is recognized over the term of the lease on a straight-line basis. The authoritative guidance does not provide for the recognition of contingent revenue until all possible contingencies have been eliminated. We consider the operating history of the lessee, the payment history, the general condition of the industry and various other factors in determining whether all possible contingencies have been eliminated. We do not include contingent rents as income until the contingencies are eliminated.

In addition to the recognition of rental revenue recognized on a straight-line basis, we generally record reserves against earned revenues from leases when collection is doubtful or when negotiations for restructurings of troubled operators result in significant uncertainty regarding ultimate collection. The amount of the reserve is estimated based on what management believes will likely be collected. We continually evaluate the collectability of our straight-line rental revenue. If it appears that we will not collect future rent due under our leases, we will record a provision for loss related to the straight-line rental revenue.

Record direct financing lease income on a constant interest rate basis over the term of the lease. The costs related to originating the direct financing lease have been deferred and are being amortized on a straight-line basis as a reduction to income from direct financing leases over the term of the lease.

Mortgage interest income is recognized as earned over the terms of the related mortgage notes, using the effective yield method. Allowances are provided for unearned revenues from mortgage interest when collection of amounts due becomes questionable or when negotiations for restructurings of mortgages lead to lower expectations regarding ultimate collection. When collection is uncertain, mortgage interest income on impaired mortgages is recognized as received after taking into account application of security.

We review our accounts receivable as well as our straight-line rents receivable and lease inducement assets to determine their collectability. The determination of collectability of these assets requires significant judgment and is affected by several factors relating to the credit quality of our tenants. We regularly monitor, including (i) payment history, (ii) the age of the contractual receivables, (iii) the current economic conditions and reimbursement, (iv) the ability of the tenant to perform under the terms of their lease and/or contractual loan agreements and (v) the value of the underlying asset under the agreement. If we determine collectability of any of our contractual receivables is at risk, we estimate the potential uncollectible amount and provide an allowance. In the case of a lease recognized on a straight-line basis or existence of lease inducements, we generally provide an allowance for the straight-line accounts receivable and/or the lease inducements when certain conditions or indicators of adverse collectability are present.

Gains on sales of real estate assets are recognized in accordance with the authoritative guidance for sales of real estate. The specific timing of the sale and the related gain is measured against the various criteria in the guidance related to the terms of the transactions and any contingencies or involvement associated with the assets sold. To the extent the sales criteria are not met, we defer gain recognition until the sales criteria are met.

Depreciation and Asset Impairment

In accordance with GAAP, real estate assets are stated at the lower of depreciated cost or fair value, if deemed impaired. Depreciation is computed on a straight-line basis over the estimated useful lives of 20 to 40 years for buildings, eight to 15 years for site improvements, and three to 10 years for furniture, fixtures and equipment. Management evaluates our real estate investments for impairment indicators, including the evaluation of our assets' useful lives. The determination of the existence of impairment indicators is based on factors such as, but not limited to, market conditions, operator performance and legal proceedings. If indicators of impairment are present, management evaluates the carrying value of the related real estate investments in relation to the future undiscounted cash flows of the underlying facilities. Provisions for impairment losses related to long-lived assets are recognized when expected future undiscounted cash flows are determined to be less than the carrying values of the assets. An adjustment is made to the net carrying value of the leased properties and long-lived assets for the excess of historical cost over fair value. The fair value of the real estate investment is determined by market research, including the property as a nursing home as well as other alternative uses. All impairments are taken as a period cost at that time, and depreciation is adjusted going forward to reflect the new value assigned to the asset.

When we decide to sell rental properties or land holdings, we evaluate the recoverability of the carrying amounts of the assets. If the evaluation indicates that the carrying value is not recoverable from estimated net sales proceeds, the property is written down to estimated fair value less costs to sell. Our estimated

and fair values of the properties are based on current market conditions and consider matters such as rental rates and occupancies for comparable properties, recent sales data for comparable properties, and, where applicable, contracts or the results of negotiations with purchasers or prospective purchasers.

For the periods ended December 31, 2015, 2014, and 2013, we recognized impairment losses of \$17.7 million, \$3.7 million and \$0.4 million, respectively. These impairments are primarily the result of closing facilities or updating the estimated proceeds we expect for the sale of closed facilities.

Loan and Direct Financing Lease Im

ment evaluates our outstanding mortgage notes, direct financing leases and other notes receivable. When management identifies potential financing lease impairment indicators, such as non-payment under the loan documents, impairment of the underlying collateral, financial difficulties or other circumstances that may impair full execution of the loan documents or direct financing leases, and management believes it is probable that amounts will not be collected under the contractual terms of the loan or direct financing leases, the loan or direct financing lease is written down to the fair value of the expected future cash flows. In cases where expected future cash flows are not readily determinable, the loan or direct financing lease is written down to the fair value of the collateral. The fair value of the loan or direct financing leases is determined by market research, which includes valuing the property as a nursing home as well as other alternative

currently account for impaired loans and direct financing leases using (a) the cost-recovery method, and/or (b) the cash basis method. We use the cost recovery method for impaired loans or direct financing leases for which impairment reserves were recorded. We utilize the cash basis method for impaired loans or direct financing leases for which no impairment reserves were recorded because the net present value of the discounted cash flows under the loan or direct financing lease and or the underlying collateral supporting the loan or direct financing lease were equal to or exceeded the fair value of the loans or direct financing leases. Under the cost recovery method, we apply cash received against the outstanding loan balance on direct financing leases prior to recording interest income. Under the cash basis method, we apply cash received to principal or interest income based on the method of payment. As of December 31, 2015 we had \$3.0 million of reserves on our loans and no reserves on our direct financing leases. As of December 31, 2014, we had no reserves on our loans or direct financing leases.

Item 7A - Quantitative and Qualitative Disclosure about Mar

posed to various market risks, including the potential loss arising from adverse changes in interest rates. We do not enter into derivative financial instruments for trading or speculative purposes, but we seek to mitigate the effects of fluctuations in interest rates by matching the term of our investments with new long-term fixed rate borrowing to the extent

ing disclosures of estimated fair value of financial instruments are subjective in nature and are dependent on a number of important assumptions, including estimates of future cash flows, risks, discount rates and relevant comparable market information associated with each financial instrument. We caution that many of the statements contained in these paragraphs are forward-looking and should be read in conjunction with our disclosures under the heading “Forward-looking Statements, Reimbursement Issues and Other Factors Affecting Future Results” set forth above. The use of these assumptions and estimation methodologies may have a material effect on the reported estimated fair value amounts. Accordingly, the amounts presented below are not necessarily indicative of the amounts we would realize in a current market environment.

notes receivable - The fair value of mortgage notes receivable is estimated by discounting the future cash flows using the current rates of interest on similar loans would be made to borrowers with similar credit ratings and for the same remaining term.

Financing Leases - The fair value of direct financing receivable is estimated by discounting the future cash flows using the current rates at which similar leases would be made to borrowers with similar credit ratings and for the same remaining term.

Notes Receivable - The fair value of notes receivable is estimated by discounting the future cash flows using the current rates at which similar loans would be made to borrowers with similar credit ratings and for the same remaining term.

Debt under variable rate agreements - Our variable rate debt as of December 31, 2015 includes our credit facilities and term loans. The fair value of debt under variable rate agreements is estimated using an expected present value technique based on expected cash flows discounted at the current credit-adjusted risk-free rate.

Senior unsecured notes -The fair value of the senior unsecured notes is estimated based on open market trading activity provided by third parties.

The market value of our long-term fixed rate borrowings and mortgages is subject to interest rate risks. Generally, the market value of fixed rate borrowings will decrease as interest rates rise and increase as interest rates fall. The estimated fair value of our total long-term borrowings at December 31, 2015 was approximately \$3.6 billion. A one percent increase in interest rates would result in a decrease in the fair value of long-term borrowings of approximately \$182 million at December 31, 2015. The estimated fair value of our total long-term borrowings at December 31, 2014 was approximately \$3.5 billion. A one percent increase in interest rates would result in a decrease in the fair value of long-term borrowings by approximately \$164 million at December 31, 2014.

We enter into certain types of derivative financial instruments to further reduce interest rate risk. We use interest rate swap agreements, for example, to convert some of our variable rate debt to a fixed-rate basis or to hedge anticipated financing transactions. We use derivatives for hedging purposes only and do not enter into financial instruments for trading purposes. As of December 31, 2015, we were party to interest rate swap agreements that will effectively fix the rate on the 2015 Term Loan Facility at 3.8005% beginning December 2016 through its maturity date and extension period. The forward-starting swap contract was deemed to be a highly effective cash flow hedge and we elected to designate the forward-starting swap contract as an accounting hedge.

Item 8 - Financial Statements and Supplemental Data

Our consolidated financial statements and the report of Ernst & Young LLP, Independent Registered Public Accounting Firm, on such financial statements are included as part of this report beginning on page F-1. The summary of unaudited quarterly results of operations for the years ended December 31, 2015 and 2014 is included in “*Note 19 - Summary of Quarterly Results (Unaudited)*” to our audited consolidated financial statements, which is incorporated by reference in response to Item 302 of Regulation S-K.

Item 9 - Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

Item 9A - Controls and Procedures

Evaluation of Disclosure Controls and Procedures

the controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), other procedures of an issuer that are designed to ensure that information required to be disclosed by the issuer in the reports that it files or the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosures.

In connection with the preparation of our Form 10-K as of and for the year ended December 31, 2015, we evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of December 31, 2015. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of December 31, 2015.

Management’s Report on Internal Control over Financial Reporting

Management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is defined in Rule 13a-15(f) or 15d-15(f) promulgated under the Exchange Act as a process designed by, or under the supervision of, a company’s principal executive and principal financial officers, or persons performing similar functions, and effected by a company’s board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP and includes those policies and procedures that:

the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the company;

reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles and that receipts and expenditures of the company are being made only in accordance with authorizations of management and other personnel of the company; and

provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the company's assets that could have a material effect on the financial statements.

Internal control systems, no matter how well designed, have inherent limitations and can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of the control system must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our company have been detected. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation.

In connection with the preparation of our Form 10-K, our management assessed the effectiveness of our internal control over financial reporting as of December 31, 2015. In making that assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadwell Commission (COSO) in Internal Control-Integrated Framework (2013 framework). Based on management's assessment, management believes that as of December 31, 2015, our internal control over financial reporting was effective based on those criteria.

In accordance with Section 404 of the Sarbanes-Oxley Act of 2002, we have included above a report of management's assessment of the design and effectiveness of our internal controls as part of this Annual Report on Form 10-K for the fiscal year ended December 31, 2015. Our independent registered public accounting firm also reported on the effectiveness of internal control over financial reporting. The independent registered public accounting firm's attestation report is included in our 2015 financial statements under the caption entitled "Report of Independent Registered Public Accounting Firm" and is incorporated by reference herein.

Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting during the quarter ended December 31, 2015 identified in connection with the evaluation of our disclosure controls and procedures described above that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Item 10 – Directors, Executive Officers and Corporate Governance

Information required by this item is incorporated herein by reference to our Company’s definitive proxy statement for the 2016 Annual Meeting of Stockholders, to be filed with the SEC pursuant to Regulation S-K.

For information regarding executive officers of our Company, see “*Item 1 – Business – Executive Officers of Omega Therapeutics*.”

Business Conduct and Ethics. We have adopted a written Code of Business Conduct and Ethics (“Code of Ethics”) that applies to all of our employees, including our chief executive officer, chief financial officer, chief accounting officer and controller. A copy of our Code of Ethics is available on our website at www.omegahealthcare.com, and print copies are available upon request without charge. You can request print copies from our Chief Financial Officer in writing at Omega Healthcare Investors, Inc., 200 International Circle, Suite 3500, Hunt Valley, Maryland 21084, or by telephone at 410-427-1700. Any amendment to our Code of Ethics or any waiver of our Code of Ethics will be disclosed on our website at www.omegahealthcare.com promptly following the date of such amendment or the date of the disclosure.

Item 11 - Executive Compensation

Information required by this item is incorporated herein by reference to our Company’s definitive proxy statement for the 2016 Annual Meeting of Stockholders, to be filed with the SEC pursuant to Regulation S-K.

Item 12 - Security Ownership of Certain Beneficial Owners and Management

Information required by this item is incorporated herein by reference to our Company’s definitive proxy statement for the 2016 Annual Meeting of Stockholders, to be filed with the SEC pursuant to Regulation S-K.

Item 13 - Certain Relationships and Related Transactions, and Director Independence

Information required by this item, if any, is incorporated herein by reference to our Company's definitive proxy statement for the 2016 Annual Meeting of Stockholders, to be filed with the SEC pursuant to Regulation S-K.

Item 14 - Principal Accounting Fees and Expenses

Information required by this item is incorporated herein by reference to our Company's definitive proxy statement for the 2016 Annual Meeting of Stockholders, to be filed with the SEC pursuant to Regulation S-K.

Item 15 - Exhibits and Financial Statement S

(a)(1) Listing of Consolidated Financial S

Title of Document	Page Number
<u>Reports of Independent Registered Public Accounting Firm</u>	F-1
<u>Consolidated Balance Sheets as of December 31, 2015 and 2014</u>	F-3
<u>Consolidated Statements of Operations and Comprehensive Income for the years ended December 31, 2015, 2014 and 2013</u>	F-4
<u>Consolidated Statements of Changes in Equity for the years ended December 31, 2015, 2014 and 2013</u>	F-5
<u>Consolidated Statements of Cash Flows for the years ended December 31, 2015, 2014 and 2013</u>	F-6
<u>Notes to Consolidated Financial Statements</u>	F-8

(a)(2) Listing of Financial Statement Schedules. The following consolidated financial statement schedules are included:

Schedule III –
Real Estate
and F-52
Accumulated
Depreciation
Schedule IV –
Mortgage F-53
Loans on
Real Estate

Schedules for which provision is made in the applicable accounting regulation of the Securities and Exchange Commission are not required, are not applicable, or are inapplicable or have been omitted because sufficient information has been included in the notes to the Consolidated Financial Statements.

(a)(3) Listing of Exhibits — See “*Index to Exhibits*” beginning on Page I-1.

(b) Exhibits — See “*Index to Exhibits*” beginning on Page I-1.

(c) Financial Statement Schedules — The following consolidated financial statement schedules are included:

Schedule III — Real Estate and Accumulated Depreciation

Schedule IV — Mortgage Loans on Real Estate

Report of Independent Registered Public Accountants

The Board of Directors and Stockholders of Omega Healthcare Investors, Inc.

We audited the accompanying consolidated balance sheets of Omega Healthcare Investors, Inc. as of December 31, 2015 and 2014, and the consolidated statements of operations and comprehensive income, changes in equity and cash flows for each of the three years in the period ended December 31, 2015. Our audits also included the financial statement schedules listed in the Index at Item 15(a)(2). These financial statements and schedules are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements and schedules based on our audits.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit involves examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting policies used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the consolidated financial position of Omega Healthcare Investors, Inc. at December 31, 2015 and 2014, and the consolidated results of its operations and its cash flows for each of the three years in the period ended December 31, 2015, in conformity with U.S. generally accepted accounting principles. Also, in our opinion, the related financial statement schedules, when considered in relation to the basic financial statements taken as a whole, presents fairly in all material respects the information set forth therein.

We have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), Omega Healthcare Investors, Inc.'s internal control over financial reporting as of December 31, 2015, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) and our report dated February 26, 2016 expressed an unqualified opinion on the effectiveness of Omega Healthcare Investors, Inc.'s internal control over financial reporting.

/s/ Ernst & Young

Baltimore, MD

February 26, 2016

Report of Independent Registered Public Accountants

The Board of Directors and Stockholders of Omega Healthcare Investors, Inc.

We have audited Omega Healthcare Investors, Inc.'s internal control over financial reporting as of December 31, 2015, based on criteria established by COSO's Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the "COSO Framework"). Omega Healthcare Investors, Inc.'s management is responsible for maintaining effective internal control over financial reporting, and for the design and implementation of the effectiveness of internal control over financial reporting included in the accompanying Management's Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company's internal control over financial reporting based on our audit.

We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material aspects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

A company's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit the preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are supported by valid and supporting documentation in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of the effectiveness of internal control over financial reporting to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

In our opinion, Omega Healthcare Investors, Inc. maintained, in all material respects, effective internal control over financial reporting as of December 31, 2015, based on the COSO Framework.

We also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the consolidated balance sheet of Omega Healthcare Investors, Inc. as of December 31, 2015 and 2014, and the related consolidated statements of operations and comprehensive income, equity, and cash flows for each of the three years in the period ended December 31, 2015 and our report dated February 26, 2016 expressed our opinion on those financial statements.

unqualified opinion

/s/ Ernst & YC

Baltimore, MD

February

OMEGA HEALTHCARE INVESTOR

CONSOLIDATED BALANCE SHEET

(in thousands, except per share amounts)

	December 31,	
	2015	2014
Properties		
Buildings	\$6,743,958	\$3,200,000
Accumulated depreciation	(1,019,150)	(820,000)
Properties – net	5,724,808	2,380,000
Leases in direct financing leases – net	587,701	530,000
Notes receivable	679,795	640,000
Investments	6,992,304	3,500,000
Investments for sale – net	89,299	48,000
Investments	7,081,603	3,600,000
Investments for sale – net	6,599	12,000
Investments	7,088,202	3,600,000
Cash equivalents	5,424	4,400
Cash	14,607	29,000
Accounts receivable – net	203,862	160,000
Prepaid expenses	645,683	—
Other assets	61,231	68,000
Total assets	\$8,019,009	\$3,900,000
LIABILITIES AND EQUITY		
Accounts payable	\$230,000	\$85,000
Accounts payable	750,000	200,000
Accruals – net	236,204	25,000
Borrowings – net	2,352,882	1,800,000
Provisions and other liabilities	333,706	14,000
Income taxes	15,352	—
Other liabilities	3,918,144	2,500,000
Total liabilities	8,626,288	5,400,000
Common stock \$.10 par value authorized – 350,000 shares, issued and outstanding – 187,399 shares as of December 31, 2015 and 187,399 shares as of December 31, 2014	18,740	12,000
Additional paid-in capital	4,609,474	2,100,000
Retained earnings	1,372,522	1,100,000
Dividends paid	(2,254,038)	(1,100,000)
Accumulated other comprehensive loss	(8,712)	—
Total equity	3,737,986	1,400,000

ing interest	362,879	—
ies and equity	4,100,865	1,4
	\$8,019,009	\$3,9

See accompany

OMEGA HEALTHCARE INVESTOR
CONSOLIDATED STATEMENTS OF OPERATIONS
AND COMPREHENSIVE INCOME

(in thousands, except per share amounts)

	Year Ended December 31,		
	2015	2014	2013
Revenue			
Rental income	\$605,991	\$388,443	\$388,443
Income from direct financing leases	59,936	56,719	56,719
Mortgage interest income	68,910	53,007	28,000
Other investment income – net	8,780	6,618	9,999
Total operating revenues	743,617	504,787	440,879
Expenses			
Depreciation and amortization	210,703	123,257	118,257
General and administrative	38,568	25,888	25,888
Acquisition and merger related costs	57,525	3,948	2,000
Impairment loss on real estate properties	17,681	3,660	4,000
Provisions for uncollectible mortgages, notes and accounts receivable	7,871	2,723	2,000
Total operating expenses	332,348	159,476	142,145
Income before other income and expense	411,269	345,311	298,734
Other income (expense)			
Interest income	285	44	4,000
Interest expense	(147,381)	(119,369)	(119,369)
Interest – amortization of deferred financing costs	(6,990)	(4,459)	(4,459)
Interest – refinancing (costs) gain	(28,837)	(3,041)	-
Realized loss on foreign exchange	(173)	-	-
Total other expense	(183,096)	(126,825)	(119,828)
Income before gain (loss) on assets sold	228,173	218,486	178,906
Gain (loss) on assets sold – net	6,353	2,863	(1,000)
Income from continuing operations before income taxes	234,526	221,349	177,906
Income taxes	(1,211)	-	-
Net income	233,315	221,349	177,906
Net income attributable to noncontrolling interest	(8,791)	-	-
Net income available to common stockholders	\$224,524	\$221,349	\$177,906
Net income	\$233,315	\$221,349	\$177,906
Other comprehensive loss - foreign currency translation	(8,413)	-	-
Other comprehensive loss - cash flow hedges	(718)	-	-
Total comprehensive income	224,184	221,349	177,906

Edgar Filing: ROYAL CARIBBEAN CRUISES LTD - Form 10-K

Add: other comprehensive loss attributable to noncontrolling interest	419	-	-
Comprehensive income attributable to common stockholders	\$224,603	\$221,349	\$1
Income per common share available to common stockholders:			
Basic:			
Net income available to common stockholders	\$1.30	\$1.75	\$1
Diluted:			
Net income	\$1.29	\$1.74	\$1
Weighted-average shares outstanding, basic	172,242	126,550	1
Weighted-average shares outstanding, diluted	180,508	127,294	1

See accompany

OMEGA HEALTHCARE INVESTORS

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY

(in thousands, except per share amounts)

	Common Stock Par Value	Additional Paid-in Capital	Cumulative Net Earnings	Cumulative Dividends Paid	Accumulated Other Comprehensive Loss	Total Stockholders' Equity	Noncontrolling Interest	Total
December 31, 2012 (112,393 shares)	\$ 11,239	\$ 1,664,855	754,128	(1,418,893)	\$ —	\$ 1,011,329	\$ —	\$ 1,011,329
Restricted stock to company (2,875 shares at \$30.33 per share)	2	(2)	—	—	—	—	—	—
Issuance of restricted stock	—	5,817	—	—	—	5,817	—	5,817
Restricted stock shares surrendered for tax withholding (193 shares)	(19)	(5,755)	—	—	—	(5,774)	—	(5,774)
Investment plan (1,930 shares at \$28.87 per share)	193	55,632	—	—	—	55,825	—	55,825
Stock as payment of directors' fees (6,504 shares at an average of \$31.21 per share)	—	187	—	—	—	187	—	187
Employee Stock Purchase Program (6,504 shares at \$29.21 per share, net of issuance costs)	650	193,149	—	—	—	193,799	—	193,799
Issuance of common stock (2,875 shares at \$29.44 per share)	288	84,286	—	—	—	84,574	—	84,574
Dividends (\$1.86 per share)	—	—	—	(218,175)	—	(218,175)	—	(218,175)
	—	—	172,521	—	—	172,521	—	172,521
December 31, 2013 (123,530 shares)	12,353	1,998,169	926,649	(1,637,068)	—	1,300,103	—	1,300,103
Restricted stock to company (2,875 shares at \$35.79 per share)	1	(1)	—	—	—	—	—	—
Issuance of restricted stock	—	8,382	—	—	—	8,382	—	8,382
Restricted stock to company (net of tax withholdings) (126 shares)	13	(3,590)	—	—	—	(3,577)	—	(3,577)
Investment plan (2,084 shares at \$34.52 per share)	208	71,279	—	—	—	71,487	—	71,487
Stock as payment of directors' fees (6,504 shares at an average of \$35.52 per share)	1	199	—	—	—	200	—	200
Employee Stock Purchase Program (1,848 shares at \$33.01 per share, net of issuance costs)	185	61,796	—	—	—	61,981	—	61,981
Dividends (\$2.02 per share).	—	—	—	(258,598)	—	(258,598)	—	(258,598)
	—	—	221,349	—	—	221,349	—	221,349

Edgar Filing: ROYAL CARIBBEAN CRUISES LTD - Form 10-K

December 31, 2014 (127,606 shares)	12,761	2,136,234	1,147,998	(1,895,666)	—	1,401,327	—	1,401,327
Restricted stock to company (shares at \$35.70 per share)	2	(2)	—	—	—	—	—	—
Issuance of restricted stock	—	11,133	—	—	—	11,133	—	11,133
Equity compensation plan, net holdings (941 shares)	94	(26,800)	—	—	—	(26,706)	—	(26,706)
Investment plan (4,184 shares per share)	418	150,429	—	—	—	150,847	—	150,847
Assumed options in Merger	—	109,346	—	—	—	109,346	—	109,346
Assumed other equity	—	12,644	—	—	—	12,644	—	12,644
Stock plan in Merger	—	—	—	—	—	—	—	—
Stock as payment of directors (shares at an average of \$35.94 per share)	1	312	—	—	—	313	—	313
Compensation directors	—	1,444	—	—	—	1,444	—	1,444
Common stock (10,925 shares at \$40.32 per share)	1,093	438,229	—	—	—	439,322	—	439,322
Common stock – Merger – (13 shares)	4,371	1,776,505	—	—	—	1,780,876	—	1,780,876
Dividends (\$2.18 per share)	—	—	—	(358,372)	—	(358,372)	—	(358,372)
Advance (9,165 units)	—	—	—	—	—	—	373,394	373,394
Issuance of OP units (209 units)	—	—	—	—	—	—	(7,251)	(7,251)
Contributions	—	—	—	—	—	—	(11,636)	(11,636)
Currency translation	—	—	—	—	(8,027)	(8,027)	(386)	(8,413)
Warrants	—	—	—	—	(685)	(685)	(33)	(718)
	—	—	224,524	—	—	224,524	8,791	233,315
December 31, 2015 (187,399 OP Units)	\$ 18,740	\$ 4,609,474	\$ 1,372,522	\$ (2,254,038)	\$ (8,712)	\$ 3,737,986	362,879	\$ 4,105,615

See accompanying notes

OMEGA HEALTHCARE INVESTOR
CONSOLIDATED STATEMENTS OF CASH
(in th

	Year Ended December 31,		
	2015	2014	2013
Cash flows from operating activities			
Net income	\$233,315	\$221,349	\$187,100
Adjustment to reconcile net income to net cash provided by operating activities:			
Depreciation and amortization	210,703	123,257	110,000
Provision for impairment on real estate properties	17,681	3,660	4,000
Provision for uncollectible mortgages, notes and accounts receivable	7,871	2,723	2,000
Amortization of deferred financing costs and refinancing costs	35,827	7,500	(1,000)
Accretion of direct financing leases	(11,007)	(9,787)	(1,000)
Restricted stock amortization expense	11,133	8,592	5,000
(Gain) loss on assets sold – net	(6,353)	(2,863)	1,000
Amortization of acquired in-place leases - net	(13,846)	(4,986)	(1,000)
Change in operating assets and liabilities – net of amounts assumed/acquired:			
Accounts receivable, net	248	(2,264)	8,000
Straight-line rent receivables	(36,057)	(20,956)	(1,000)
Lease inducements	994	2,656	3,000
Effective yield receivable on mortgage notes	(4,065)	(2,878)	(1,000)
Other operating assets and liabilities	17,441	11,537	8,000
Net cash provided by operating activities	463,885	337,540	210,000
Cash flows from investing activities			
Acquisition of real estate – net of liabilities assumed and escrows acquired	(294,182)	(131,689)	(1,000)
Cash acquired in merger	84,858	—	—
Investment in construction in progress	(164,226)	—	—
Investment in direct financing leases	(6,793)	—	(1,000)
Placement of mortgage loans	(14,042)	(529,548)	(1,000)
Proceeds from sale of real estate investments	41,543	4,077	2,000
Capital improvements to real estate investments	(26,397)	(17,917)	(1,000)
Proceeds from other investments	45,871	13,589	3,000
Investments in other investments	(65,402)	(9,441)	(1,000)
Collection of mortgage principal	1,359	122,984	4,000
Net cash used in investing activities	(397,411)	(547,945)	(1,000)
Cash flows from financing activities			
Proceeds from credit facility borrowings	1,826,000	900,000	5,000
Payments on credit facility borrowings	(1,681,000)	(1,141,000)	(1,000)
Receipts of other long-term borrowings	1,838,124	842,148	1,000
Payments of other long-term borrowings	(2,187,314)	(242,544)	(1,000)
Payments of financing related costs	(54,721)	(17,716)	(1,000)
Receipts from dividend reinvestment plan	150,847	71,487	5,000
Payments for exercised options and restricted stock – net	(26,706)	(3,577)	(1,000)

Edgar Filing: ROYAL CARIBBEAN CRUISES LTD - Form 10-K

Net proceeds from issuance of common stock	439,322	61,981	2
Dividends paid	(358,232)	(258,501)	(
Distributions to OP Unit Holders	(11,636)	—	—
Net cash (used in) provided by financing activities	(65,316)	212,278	3
Increase in cash and cash equivalents	1,158	1,873	9
Effect of foreign currency translation on cash and cash equivalents	(223)	—	—
Cash and cash equivalents at beginning of year	4,489	2,616	1
Cash and cash equivalents at end of year	\$5,424	\$4,489	\$2
Interest paid during the year, net of amounts capitalized	\$145,929	\$110,919	\$1

Non-cash investing and financing a

	Year Ended December	
	2015	2014
Non-cash investing activities		
Non-cash acquisition of business (see Note 3 for details)	\$ (3,602,040)	\$ -
Total	\$ (3,602,040)	\$ -
Non-cash financing activities		
Assumed Aviv debt	\$ 1,410,637	\$ -
Stock exchanged in Merger	1,902,866	-
OP Units exchanged in Merger	373,394	-
Cash flow hedges	718	-
Total	\$ 3,687,615	\$ -

See accompany

OMEGA HEALTHCARE INVESTORS

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 - ORGANIZATION AND BASIS OF PRESENTATION

Org

Healthcare Investors, Inc. (“Omega,” “we,” “our” or the “Company”) has one reportable segment consisting of investments in healthcare facilities located in the United States and the United Kingdom. Our core business is to provide financing and capital to the long-term healthcare facilities with a particular focus on skilled nursing facilities (“SNFs”). Our core portfolio consists of long-term leases and mortgage agreements. All of our leases are “net” leases, which require the tenants to pay all property-related expenses. Our mortgage revenue derives from fixed rate mortgage loans secured by first mortgage liens on the underlying real estate and personal property of the mortgagor.

Omega was formed as a real estate investment trust (“REIT”) and incorporated in the State of Maryland on March 31, 1992. In April 2015, Aviv Real Estate, a Maryland corporation (“Aviv”), merged (the “Aviv Merger”) with and into a wholly-owned subsidiary of Omega, pursuant to the terms of the Merger Agreement and Plan of Merger, dated as of October 30, 2014 (the “Merger Agreement”), by and among the Company, Aviv, OHI Healthcare Properties, Inc., a Delaware corporation and a direct wholly-owned subsidiary of Omega (“Merger Sub”), OHI Healthcare Properties Limited Partnership, a Delaware limited partnership (“Omega OP”), and Aviv Healthcare Properties Limited Partnership, a Delaware limited partnership (the “Aviv OP”).

Effective on or to April 1, 2015 and in accordance with the Merger Agreement, Omega restructured the manner in which it holds its assets by converting its umbrella partnership real estate investment trust structure (the “UPREIT Conversion”). As a result of the UPREIT Conversion and the consummation of the Aviv Merger, substantially all of the Company’s assets are held by OHI Healthcare Properties, Inc.

Omega is governed by the Second Amended and Restated Agreement of Limited Partnership of OHI Healthcare Properties Limited Partnership, dated 2015 (the “Partnership Agreement”). Pursuant to the Partnership Agreement, the Company and Merger Sub are the general partners of Omega OP with exclusive control over Omega OP’s day-to-day management. As of December 31, 2015, the Company owned approximately 95% of the Omega OP outstanding units of partnership interest in Omega OP (“Omega OP Units”), and other investors owned approximately 5% of the Omega OP Units.

Cons

consolidated financial statements include the accounts of (i) Omega, (ii) Omega OP and (iii) all direct and indirect wholly-owned subsidiaries. All inter-company transactions and balances have been eliminated in consolidation, and our net earnings are reduced by the portion of net earnings attributable to noncontrolling interests.

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Accounting Principles

The preparation of financial statements in conformity with U.S. generally accepted accounting principles (“GAAP”) requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Fair Value Measurements

The Company measures and discloses the fair value of nonfinancial and financial assets and liabilities utilizing a hierarchy of valuation techniques. The inputs to a fair value measurement are considered to be observable or unobservable in a marketplace. Observable inputs reflect market data from independent sources, while unobservable inputs reflect the Company's market assumptions. This hierarchy requires the use of observable market data when available. These inputs have created the following fair value hierarchy:

Level 1 - quoted prices for identical instruments in active markets;

OMEGA HEALTHCARE INVESTOR

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - C

quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and
valued valuations in which significant inputs and significant value drivers are observable in active markets; and

Level 3 - fair value measurements derived from valuation techniques in which one or more significant inputs or significant value drivers
unobservable.

Company measures fair value using a set of standardized procedures that are outlined herein for all assets and liabilities which are requ
dured at fair value. When available, the Company utilizes quoted market prices from an independent third party source to determine fair
es such items in Level 1. In some instances where a market price is available, but the instrument is in an inactive or over-the-counter m

Company consistently applies the dealer (market maker) pricing estimate and classifies such items in

and market prices or inputs are not available, fair value measurements are based upon valuation models that utilize current market or indepe
sourced market inputs, such as interest rates, option volatilities, credit spreads and or market capitalization rates. Items valued u
generated valuation techniques are classified according to the lowest level input that is significant to the fair value measurement. As a res
be classified in either Level 2 or Level 3 even though there may be some significant inputs that are readily observable. Internal fair valu
and techniques used by the Company include discounted cash flow and Monte Carlo valuation

Risks and Unc

Company is subject to certain risks and uncertainties affecting the healthcare industry as a result of healthcare legislation and growing regul
al, state and local governments. Additionally, we are subject to risks and uncertainties as a result of changes affecting operators of nurs
ilities due to the actions of governmental agencies and insurers to limit the rising cost of healthcare services (see Note 9 – Concentratio

Business Com

the purchase of properties to net tangible and identified intangible assets acquired and liabilities assumed at their fair value. In making
value for purposes of recording the purchase, we utilize a number of sources, including independent appraisals that may be obtained in co
acquisition or financing of the respective property and other market data. We also consider information obtained about each property as a

acquisition due diligence, marketing and leasing activities as well as other critical valuation metrics such as capitalization rates and discounts to determine the fair value of the tangible and intangible assets acquired (Level 3). When liabilities are assumed as part of a transaction, we use the information obtained about the liabilities and use similar valuation metrics (Level 3). In some instances when debt is assumed and an identifiable market for similar debt is present, we use market interest rates for similar debt to estimate the fair value of the debt assumed (Level 2). The market rate determines fair value as

Land is determined based on third party appraisals.

Land site improvements acquired are valued using a combination of discounted cash flow projections that assume certain future revenues and expenses and capitalization and discount rates using current market conditions as well as replacement cost analysis.

Furniture and fixture is determined based on third party appraisals.

Leases acquired are valued using a combination of discounted cash flow projections as well as other valuation techniques based on current market rates for the intangible asset being acquired. When evaluating below market leases we consider extension options controlled by the lessee in determining fair value. For additional information regarding above and below market leases assumed as part of an acquisition see "In-Place Leases" below.

Accounts receivable, prepaid expenses, other current assets acquired and liabilities assumed are typically valued at stated amounts, which approximate fair value on the date of the acquisition.

OMEGA HEALTHCARE INVESTOR

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - C

Assumed debt balances are valued by discounting the remaining contractual cash flows using a current market rate of interest.

Stock based compensation and noncontrolling interests are valued using a stock price on the acquisition date.

represents the purchase price in excess of the fair value of assets acquired and liabilities assumed and the cost associated with expanding portfolio. Goodwill is not amortized.

Real Estate Investments and Dep

of significant improvements, renovations and replacements, including interest are capitalized. In addition, we capitalize leasehold improvements when certain criteria are met, including when we supervise construction and will own the improvement. Expenditures for maintenance and repairs are charged to operations as they are

depreciation is computed on a straight-line basis over the estimated useful lives ranging from 20 to 40 years for buildings, eight to 15 years for equipment, and three to 10 years for furniture, fixtures and equipment. Leasehold interests are amortized over the shorter of the estimated useful life or the term of

As of December 31, 2015 and 2014, we had identified conditional asset retirement obligations primarily related to the future removal and disposal of asbestos that is contained within certain of our real estate investment properties. The asbestos is appropriately contained, and we believe we are in compliance with current environmental regulations. If these properties undergo major renovations or are demolished, certain environmental regulations are required to specify the manner in which asbestos must be handled and disposed. We are required to record the fair value of these conditional liabilities if the amount is reasonably estimated. As of December 31, 2015 and 2014, sufficient information was not available to estimate our liability for conditional asset retirement obligations as the obligations to remove the asbestos from these properties have indeterminable settlement dates. As such, no liability for conditional asset retirement obligations was recorded on our accompanying Consolidated Balance Sheets as of December 31, 2015 and 2014.

Lease Ac

ception of the lease and during the amendment process, we evaluate each lease to determine if the lease should be considered an operating lease, or direct financing lease. We have determined that all but seven of our leases should be accounted for as operating leases. The other leases are accounted for as direct financing

accounted for as operating leases, we retain ownership of the asset and record depreciation expense, see “Business Combinations” and “Assets and Depreciation” above for additional information regarding our investment in real estate leased under operating lease agreements. Lease revenue based on the contractual terms of the operating lease agreement which often includes annual rent escalators, see “Revenue Recognition” below for further discussion regarding the recordation of revenue on our operating

accounted for as direct financing leases, we record the present value of the future minimum lease payments (utilizing a constant interest rate of the lease agreement) as a receivable and record interest income based on the contractual terms of the lease agreement. Certain direct financing leases include annual rent escalators; see “Revenue Recognition” below for further discussion regarding the recording of interest income on direct financing leases. As of December 31, 2015 and 2014, \$3.3 and \$3.4 million, respectively, of unamortized direct costs related to originating direct financing leases have been deferred and recorded in our Consolidated Balance Sheet

In-Place

Lease assets and liabilities result when we assume a lease as part of a facility purchase or business combination. The fair value of in-place leases is determined by the following components, as applicable (1) the estimated cost to replace the leases, and (2) the above or below market cash flow of the leases. We determine the fair value of in-place leases by comparing the projected cash flows of the leases in place at the time of acquisition to projected cash flows of comparable market-rate leases (classified as Lease Intangibles). Lease Intangible assets and liabilities are classified as lease contracts above and below market value, respectively, and “accrued expenses and other liabilities,” and amortized on a straight-line basis as decreases and increases, respectively, to rental income over the estimated remaining term of the underlying leases. Should a tenant terminate the lease, the unamortized portion of the Lease Intangible is recorded as a liability and immediately as income or expense

OMEGA HEALTHCARE INVESTO

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - C

December 31, 2015 and 2014, we had \$110.2 million and \$20.4 million, respectively, of below market lease liabilities and \$7.8 million on, respectively, of above market lease assets recorded on our Consolidated Balance Sheets. We expect net amortization of the in-place increase rental in

	(in m
2016	\$ 10
2017	14
2018	13
2019	12
2020	11
Thereafter	34
Total	\$ 10

years ended December 31, 2015, 2014 and 2013, we have amortized \$13.8 million, \$5.0 million and \$5.1 million, respectively, as a net rental income. Amounts presented above include the preliminary purchase accounting for the Aviv Merger, see Note 3 - Properties. For information, see Note 8 – I

Asset Im

nt evaluates our real estate investments for impairment indicators, including the evaluation of our assets' useful lives. The judgment reg of impairment indicators is based on factors such as, but not limited to, market conditions, operator performance and legal structure. If i nt are present, management evaluates the carrying value of the related real estate investments in relation to the future undiscounted cash underlying facilities. Provisions for impairment losses related to long-lived assets are recognized when expected future undiscounted cash d to be less than the carrying values of the assets. An adjustment is made to the net carrying value of the real estate investments for the ue over fair value. The fair value of the real estate investment is determined by market research, which includes valuing the property as ell as other alternative uses. All impairments are taken as a period cost at that time, and depreciation is adjusted going forward to refle value assigned to

decide to sell real estate properties or land holdings, we evaluate the recoverability of the carrying amounts of the assets. If the evaluation he carrying value is not recoverable from estimated net sales proceeds, the property is written down to estimated fair value less costs to cash flows and fair values of the properties are based on current market conditions and consider matters such as rental rates and occup

comparable properties, recent sales data for comparable properties, and, where applicable, contracts or the results of negotiations with purchasers of comparable properties, and prospective purchasers.

For the years ended December 31, 2015, 2014 and 2013, we recognized impairment losses of \$17.7 million, \$3.7 million and \$0.4 million, respectively. Impairments are primarily the result of closing facilities or updating the estimated proceeds we expect to receive for the sale of closed facilities. For additional information, see Note 3 – Properties and Note 7 – Assets Held for Sale.

Loan and Direct Financing Lease Impairment

Management evaluates our outstanding mortgage notes, direct financing leases and other notes receivable for impairment. When management identifies potential loan or direct financing lease impairment indicators, such as non-payment under the loan documents, impairment of the underlying collateral, financial difficulty of the operator or other circumstances that may impair full execution of the loan documents or direct financing leases, and management determines it is probable that all amounts will not be collected under the contractual terms of the loan or direct financing lease, the loan or direct financing lease is written down to the present value of the expected future cash flows. In cases where expected future cash flows are not readily determinable, the direct financing lease is written down to the fair value of the collateral. The fair value of the loan or direct financing lease is determined by management, which includes valuing the property as a nursing home as well as other alternative uses.

OMEGA HEALTHCARE INVESTOR

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - C

ount for impaired loans and direct financing leases using (a) the cost-recovery method, and/or (b) the cash basis method. We generally use the cost-recovery method for impaired loans or direct financing leases for which impairment reserves were recorded. We utilize the cash basis method for impaired loans or direct financing leases for which no impairment reserves were recorded because the net present value of the discounted cash flows under the loan or direct financing lease and or the underlying collateral supporting the loan or direct financing lease were equal to or exceeded the carrying amount of the loans or direct financing leases. Under the cost-recovery method, we apply cash received against the outstanding loan balance or direct financing lease prior to recording interest income. Under the cash basis method, we apply cash received to principal or interest income based on the contractual terms of the instrument. As of December 31, 2015 we had \$3.0 million of reserves on our loans and no reserves on our direct financing leases. As of December 31, 2014 we had no reserves on our loans or direct financing leases. For additional information, see Note 4 – Direct Financing Leases, Note 5 – Mortgage Receivable and Note 6 – Other Investments.

Assets Held for Sale

er properties to be assets held for sale when (1) management commits to a plan to sell the property; (2) it is unlikely that the disposal plan will be significantly modified or discontinued; (3) the property is available for immediate sale in its present condition; (4) actions required to complete the sale of the property have been initiated; (5) sale of the property is probable and we expect the completed sale will occur within one year; and (6) the property is actively being marketed for sale at a price that is reasonable given our estimate of current market value. Upon designation of a property as an asset held for sale, we record the property's value at the lower of its carrying value or its estimated fair value, less estimated costs to sell, and we cease depreciating the property. For additional information, see Note 7 – Assets Held for Sale.

Cash and Cash Equivalents

h and cash equivalents consist of cash on hand and highly liquid investments with a maturity date of three months or less when purchased. Investments are stated at cost, which approximates fair value. The majority of our cash and cash equivalents are held at major commercial banks.

Restricted Cash

d cash consists primarily of funds escrowed for tenants' security deposits required by us pursuant to certain contractual terms (see Note 4 – Direct Financing Leases and Mortgage Receivable).

Accounts R

ts receivable includes: contractual receivables, effective yield interest receivables, straight-line rent receivables and lease inducements, and provision for losses related to uncollectible and disputed accounts. Contractual receivables relate to the amounts currently owed to us under the lease agreement. Effective yield interest receivables relate to the difference between the interest income recognized on an effective yield basis for the term of the loan agreement and the interest currently due to us according to the contractual agreement. Straight-line receivables relate to the difference between the rental revenue recognized on a straight-line basis and the amounts due to us contractually. Lease inducements result from amounts provided by us to the lessee at the inception or renewal of the lease are amortized as a reduction of rental revenue over the non cancellable lease term.

On a quarterly basis, we review our accounts receivable to determine their collectability. The determination of collectability of these assets is based on our judgment and is affected by several factors relating to the credit quality of our operators that we regularly monitor, including (i) payment history, (ii) the age of the contractual receivables, (iii) the current economic conditions and reimbursement environment, (iv) the ability of the tenant to pay under the terms of their lease and/or contractual loan agreements and (v) the value of the underlying collateral of the agreement. If we determine that the collectability of any of our contractual receivables is at risk, we estimate the potential uncollectible amounts and provide an allowance. In the case of straight-line receivables or lease inducements, we generally provide an allowance for straight-line accounts receivable and lease inducements when certain conditions or indicators of adverse collectability are present.

OMEGA HEALTHCARE INVESTOR

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - C

A summary of our net receivables by type is as

	December 31,	
	2015	2014
	(in thousands)	
Contractual receivables	\$8,452	\$4,799
Effective yield interest receivables	9,028	6,232
Straight-line receivables	175,709	143,652
Lease inducements	10,982	13,571
Allowance	(309)	(78)
Accounts receivable – net	\$203,862	\$168,176

continuously evaluate the payment history and financial strength of our operators and have historically established allowance reserves for straight-line receivables from operators that do not meet our requirements. We consider factors such as payment history, the operator's financial condition, and current and future anticipated operating trends when evaluating whether to establish allowance

We wrote-off \$3.2 million of straight-line rent receivables and \$1.5 million of effective yield interest receivables associated with four facilities that will transition to a new operator and three mortgages that will be repaid prior to their maturity. This transaction closed

We wrote-off (i) \$0.8 million of straight-line rent receivables associated with a lease amendment to an existing operator for two facilities that transitioned to a new operator and (ii) \$2.0 million of effective yield interest receivables associated with the termination of a mortgage note that matured in November 2021. See Note 3 – Properties and Note 5 – Mortgage Notes Receivable for additional information.

Goodwill Impairment

We evaluate our goodwill for potential impairment during the fourth quarter of each fiscal year, or during the year if an event or other circumstance indicates that we may not be able to recover the carrying amount of the net assets of the reporting unit. In evaluating goodwill for impairment, we first assess qualitative factors to determine whether it is more likely than not (that is, a likelihood of more than 50 percent) that the fair value of the reporting unit is less than its carrying amount.

ing amount. If we conclude that it is more likely than not that the fair value of the reporting unit is less than its carrying value, then we p
goodwill impairment test to identify potential impairment and measure the amount of impairment we will recognize, if any. We do not e
of the goodwill to be deductible for tax

t step of the two-step goodwill impairment test (“Step 1”), we compare the fair value of the reporting unit to its net book value, includin
company has only one reporting unit, the fair value of the reporting unit is determined by reference to the market capitalization of the Co
through quoted market prices and adjusted for other relevant factors. A potential impairment exists if the fair value of the reporting uni
book value. The second step (“Step 2”) of the process is only performed if a potential impairment exists, and it involves determining the
e fair value of the reporting unit's net assets other than goodwill and the fair value of the reporting unit. If the difference is less than the
ue of goodwill, impairment exists and is recorded. In the event that the Company determines that the value of goodwill has become imp
ill record an accounting charge for the amount of impairment during the fiscal quarter in which the determination is made. The Compan
ed to perform Step 2 of the process because the fair value of the reporting unit has significantly exceeded its book value at the measure
There was no impairment of goodwill dur

Incon

rganized to qualify for taxation as a REIT under Section 856 through 860 of the Internal Revenue Code (“Code”). As long as we qualify
t be subject to federal income taxes on the REIT taxable income that we distributed to stockholders, subject to certain exceptions. How
certain of our subsidiaries that have elected to be treated as taxable REIT subsidiaries (“TRSs”), we record income tax expense or bene
entities are subject to federal income tax similar to regular corp

OMEGA HEALTHCARE INVESTOR

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - C

account for deferred income taxes using the asset and liability method and recognize deferred tax assets and liabilities for the expected effects of events that have been included in our financial statements or tax returns. Under this method, we determine deferred tax assets and liabilities based on the differences between the financial reporting and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Any increase or decrease in the deferred tax liability that results from a change in circumstances, and that cannot be recognized in our judgment about expected future tax consequences of events, is included in the tax provision when such changes occur. Deferred income taxes also reflect the impact of operating loss and tax credit carryforwards. A valuation allowance is provided if we believe it is more likely than not that the realization of the deferred tax asset will not be realized. Any increase or decrease in the valuation allowance that results from a change in circumstances, which causes us to change our judgment about the realizability of the related deferred tax asset, is included in the tax provision when such change occurs.

For additional information on income taxes, see Note 1.

Revenue Recognition

We have various different investments that generate revenue, including leased and mortgaged properties, as well as other investments, including real estate. We recognize rental income and other investment income as earned over the terms of the related leases and notes, respectively. Interest income is recorded on an accrual basis to the extent that such amounts are expected to be collected using the effective interest method. In applying the effective interest method, the effective yield on a loan is determined based on its contractual payment terms, adjusted for prepayment penalties.

Most of our operating leases contain provisions for specified annual increases over the rents of the prior year and are generally computed using different methods depending on specific provisions of each lease as follows: (i) a specific annual increase over the prior year's rent, generally between 2% and 5%; (ii) an increase based on the change in pre-determined formulas from year to year (e.g. increases in the Consumer Price Index); or (iii) a percentage increase over prior years. Revenue under lease arrangements with minimum fixed and determinable increases is recognized over the non-cancellable term of the lease on a straight-line basis. The authoritative guidance does not provide for the recognition of contingent revenue until all contingencies have been eliminated. We consider the operating history of the lessee, the payment history, the general condition of the industry and other factors when evaluating whether all possible contingencies have been eliminated. We do not recognize contingent rents as income until all contingencies have been eliminated.

When we recognize rental revenue on a straight-line basis, we generally record reserves against earned revenues from leases when collection is doubtful or when negotiations for restructurings of troubled operators result in significant uncertainty regarding ultimate collection. The amount of the reserve is estimated based on what management believes will likely be collected. We continually evaluate the collectability of our straight-line rental revenue. If it appears that we will not collect future rent due under our leases, we will record a provision for loss related to the straight-line rental revenue.

cord direct financing lease income on a constant interest rate basis over the term of the lease. The costs related to originating the direct financing lease have been deferred and are being amortized on a straight-line basis as a reduction to income from direct financing leases over the term of the lease.

Mortgage interest income is recognized as earned over the terms of the related mortgage notes, using the effective yield method. Allowances are established for unearned revenues from mortgage interest when collection of amounts due becomes questionable or when negotiations for restructurings of mortgage loans lead to lower expectations regarding ultimate collection. When collection is uncertain, mortgage interest income on impaired mortgage notes is recognized as received after taking into account application of security.

Gains on sales of real estate assets are recognized in accordance with the authoritative guidance for sales of real estate. The specific timing of the sale and the related gain is measured against the various criteria in the guidance related to the terms of the transactions and any conditions of involvement associated with the assets sold. To the extent the sales criteria are not met, we defer gain recognition until the sales criteria are met.

OMEGA HEALTHCARE INVESTOR

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - C

Stock-Based Comp

e recognize stock-based compensation expense adjusted for estimated forfeitures to employees and directors, in “general and administrative expenses” in our Consolidated Statements of Operations and Comprehensive Income on a straight-line basis over the requisite service period of the awards, see Note 10 – Stock-Based Compensation for additional information.

Deferred Financing Costs and Original Issuance Premium and/or Discounts for Debt

al costs incurred from placement of our debt are capitalized and amortized on a straight-line basis over the terms of the related borrowings. We also use the effective interest method. The deferred financing costs are included in “other assets” in our Consolidated Balance Sheets. Original issuance premium or discounts reflect the difference between the face amount of the debt issued and the cash proceeds received and are amortized on a straight-line basis over the term of the related borrowings. All premium and discounts are recorded as an addition to or reduction from debt in our Consolidated Balance Sheets. Amortization of financing costs and original issuance premium or discounts total \$7.0 million, \$4.5 million and \$2.8 million in 2015, 2014 and 2013, respectively, and are classified as “interest - amortization of deferred financing costs” in our Consolidated Statements of Operations and Comprehensive Income. When financings are terminated, unamortized deferred financing costs and unamortized premium or discounts, as well as charges incurred on the extinguishment, are recognized as expense or income at the time the termination is made. Gains and losses from the extinguishment of debt are presented as “interest-refinancing (costs) gain” in our Consolidated Statements of Operations and Comprehensive Income.

Earnings P

arnings per common share (“EPS”) is computed by dividing net income available to common stockholders by the weighted-average number of common shares outstanding during the year. Diluted EPS is computed using the treasury stock method, which is net income divided by the weighted-average number of common shares plus the effect of dilutive common equivalent shares during the respective period. Common shares reflect the assumed issuance of additional common shares pursuant to certain of our share-based compensation plans, including restricted stock and performance restricted stock units and the assumed issuance of additional shares related to Omega OP Units held by employees. All outstanding unvested share-based payment awards that contain rights to non-forfeitable dividends or dividend equivalents that participate in the company's earnings with common stockholders are considered participating securities that shall be included in the two-class method of computing diluted EPS. The impact of the two class method is immaterial. For additional information, see Note 20 – Earnings

Redeemable Limited Partnership Unitholder Interests and Noncontrolling

April 1, 2015 and after giving effect to the Aviv Merger, the Company owned approximately 138.8 million Omega OP Units and Aviv owned approximately 52.9 million Omega OP Units. Each of the Omega OP Units (other than the Omega OP Units owned by Omega) is redeemable at the option of the Omega OP Unit holder for cash equal to the then-fair market value of one share of Omega common stock, par value \$0.10 per share ("Omega OP Units"), subject to the Company's election to exchange the Omega OP Units tendered for redemption for unregistered shares of Omega Common Stock on a one-for-one basis, subject to adjustment as set forth in the Partnership Agreement. Effective June 30, 2015, the Company (through Merger Sub, as the general partner of Aviv OP) caused Aviv OP to make a distribution of Omega OP Units held by Aviv OP (or equivalent value) to the other investors (the "Aviv OP Distribution") in connection with the liquidation of Aviv OP. As a result of the Aviv OP Distribution, Omega directly owns approximately 95% of the outstanding Omega OP Units, and the other investors own approximately 5% of the outstanding Omega OP Units. As of the end of the Aviv OP Distribution, Omega settled approximately 0.2 million units via cash settlement. As of December 31, 2015, Omega directly owns approximately 95% of the outstanding Omega OP Units, and the other investors own approximately 5% of the outstanding Omega OP Units.

Noncontrolling

Noncontrolling interests is the portion of equity in the Omega OP not attributable to the Company. We present the portion of any equity that we own in related entities as noncontrolling interests and classify those interests as a component of total equity, separate from total stockholders' equity, on our Consolidated Balance Sheets. We include net income attributable to the noncontrolling interests in net income in our Consolidated Statements of Operations and Comprehensive Income.

OMEGA HEALTHCARE INVESTOR

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - C

ownership of a controlled subsidiary increases or decreases, any difference between the aggregate consideration paid to acquire the noncontrolling interest and our noncontrolling interest balance is recorded as a component of equity in additional paid-in capital, so long as we maintain a controlling ownership.

Foreign Operations

The U.S. dollar is the functional currency for our consolidated subsidiaries operating in the United States. The functional currency for our consolidated subsidiaries operating in countries other than the United States is the principal currency in which the entity primarily generates and expends cash. For consolidated subsidiaries whose functional currency is not the U.S. dollar, we translate their financial statements into the U.S. dollar. We translate assets and liabilities at the exchange rate in effect as of the financial statement date. Gains and losses resulting from this translation are included in accumulated other comprehensive loss ("AOCL") as a separate component of equity and a proportionate amount of gain or loss is allocated to noncontrolling interest. Revenue and expense accounts, primarily equity and capital-related accounts, are translated using an average exchange rate for the period.

For certain of our consolidated subsidiaries may have intercompany and third-party debt that is not denominated in the entity's functional currency. When the debt is remeasured against the functional currency of the entity, a gain or loss can result. The resulting adjustment is reflected in earnings, unless it is intercompany debt that is deemed to be long-term in nature and then the adjustments are included in AOCL.

Derivative Instruments

In the normal course of business, we may use certain types of derivative instruments for the purpose of managing interest rate and currency risk. For hedge accounting, derivative instruments used for risk management purposes must effectively reduce the risk exposure that they are designed to hedge. In addition, at inception of a qualifying cash flow hedging relationship, the underlying transaction or transactions, must be, and are expected to be, probable of occurring in accordance with the Company's related assertions. The Company recognizes all derivative instruments, including those that are not designated in hedging relationships or that do not meet the criteria of hedge accounting are recognized in earnings. For derivatives designated as qualifying cash flow hedging relationships, the change in fair value of the effective portion of the derivatives is recognized in AOCL as a separate component of equity and a proportionate amount of gain or loss is allocated to noncontrolling interest, whereas the change in fair value of the ineffective portion is recognized in earnings. We formally document all relationships between hedging instruments and hedged items, as well as our risk management objectives and strategy for undertaking various hedge transactions. This process includes designating all derivatives that are

relationship to specific forecasted transactions as well as recognized obligations or assets in the Consolidated Balance Sheets. We also a
ent, both at inception of the hedging relationship and on a quarterly basis thereafter, whether the derivatives are highly effective in offs
ignated risks associated with the respective hedged items. If it is determined that a derivative ceases to be highly effective as a hedge, o
ble the underlying forecasted transaction will not occur, we discontinue hedge accounting prospectively and record the appropriate adju
ased on the current fair value of the derivative. As a matter of policy, we do not use derivatives for trading or speculative purposes. At L
, we had \$0.7 million of qualifying cash flow hedges recorded at fair value in accrued expenses and other liabilities on our Consolidated

Related Party Tran

any has a policy which generally requires related party transactions to be approved or ratified by the Audit Committee. As part of our ac
es owning 143 skilled nursing facilities in June 2010, we acquired entities owning skilled nursing facilities with existing leases in place
ties, LLC (“LHCC”) a subsidiary of Laurel Healthcare Holdings, Inc. (“Laurel”). A member of the Board of Directors of the Company,
bers of his immediate family, beneficially owned approximately 34% of the equity of Laurel. Our lease with LHCC generated approxin
llion of rental income in both 2014 and 2013. In connection with the Aviv Merger, we acquired operating leases with LHCC for an add
Together, our leases with LHCC generated approximately \$23.0 million of rental income in 2015. In 2016, the Company acquired 10 S
an unrelated third party acquired all of the outstanding equity interests of Laurel, including the interests previously owned by the direct
family as further described within Note 22 –Subsequ

OMEGA HEALTHCARE INVESTOR

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - C

Reclas

Certain prior year amounts have been reclassified to conform with the current year pres

Recent Accounting Pronoun

The Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, *Revenue from Contracts with Customers* (“ASU 2014-09”), which outlines a comprehensive model for entities to use in accounting for revenue arising from contracts with customers. ASU 2014-09 requires that “an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration that the entity expects to be entitled in exchange for those goods or services.” While ASU 2014-09 specifically references contracts with customers, it also applies to certain other transactions such as the sale of real estate or equipment. ASU 2014-09 is effective for the Company beginning January 1, 2015. We are continuing to evaluate this guidance; however, we do not expect its adoption to have a significant impact on our consolidated financial statements because a substantial portion of our revenue consists of rental income from leasing arrangements, which are specifically excluded from ASU 2014-09.

In February 2015, the FASB issued ASU 2015-02, *Amendments to the Consolidation Analysis* (“ASU 2015-02”), which makes certain changes to the variable interest model and the voting model, including changes to (1) the identification of variable interests (fees paid to a decision maker or a service provider), (2) the variable interest entity characteristics for a limited partnership or similar entity and (3) the primary beneficiary determination. ASU 2015-02 is effective for the Company beginning January 1, 2016. We are continuing to evaluate this guidance; however, we do not expect its adoption to have a significant impact on our consolidated financial statements.

In March 2015, the FASB issued ASU 2015-03, *Simplifying the Presentation of Debt Issuance Costs* (“ASU 2015-03”), which requires that debt issued as a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with the treatment of discounts. The recognition and measurement guidance for debt issuance costs are not affected. Upon adoption, we will apply the new guidance on a prospective basis and adjust the balance sheet of each individual period presented to reflect the period-specific effects of applying the new guidance. Additionally, since ASU 2015-03 did not address presentation or subsequent measurement of debt issuance costs related to line-of-credit arrangements, we adopted ASU 2015-15, *Interest—Imputation of Interest* (“ASU 2015-15”) in August 2015. Under ASU 2015-15, an entity may present debt issued as a liability to a line-of-credit arrangement as an asset and subsequently amortize the deferred debt issuance costs ratably over the term of the line-of-credit arrangement. This guidance is effective for the Company beginning January 1, 2016. We are continuing to evaluate this guidance; however, we do not expect its adoption to have a significant impact on our consolidated financial statements.

st 2015, the FASB issued ASU 2015-16, *Simplifying the Accounting for Measurement-Period Adjustments* (“ASU 2015-16”), which eliminates the requirement that an acquirer in a business combination account for measurement-period adjustments retrospectively. Instead, an acquirer will recognize a measurement-period adjustment during the period in which it determines the amount of the adjustment. The acquirer must still disclose the amount of the adjustment for adjustments to provisional amounts and the amount of the adjustment reflected in the current-period income statement that would have been recognized in previous periods if the adjustment to provisional amounts had been recognized as of the acquisition date. We adopted ASU 2015-16 in December 2015, and disclosed the impact of measurement-period adjustments resulting from a business combination in Note 3 –

OMEGA HEALTHCARE INVESTOR

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - C

NOTE 3 - PROP

Leased

leased real estate properties, represented by 782 SNFs, 85 ALFs, 16 specialty facilities and one medical office building at December 31, under provisions of single leases and master leases with initial terms typically ranging from 5 to 15 years, plus renewal options. Substantia leases and master leases provide for minimum annual rentals that are typically subject to annual increases. Under the terms of the leases, is responsible for all maintenance, repairs, taxes and insurance on the leased p

A summary of our investment in leased real estate properties is as

	December 31,	
	2015	2014
	(in thousands)	
Buildings	\$5,514,820	\$2,745,872
Site improvements and equipment	558,222	227,411
Land	670,916	250,502
	6,743,958	3,223,785
Less accumulated depreciation	(1,019,150)	(821,712)
Total	\$5,724,808	\$2,402,073

ber 31, 2015, we have approximately \$194.3 million of projects currently under development which includes \$3.7 million of capitalized

The future minimum estimated contractual rents due for the remainder of the initial terms of the leases are as follows at December

	(in thousands)
2016	\$ 628,906

2017	638,232
2018	619,251
2019	592,657
2020	600,652
Thereafter	3,198,157
Total	\$ 6,277,855

ing tables summarize the significant transactions that occurred from 2013 to 2015. The 2015 table excludes the acquisition of Care Home United Kingdom and the Aviv Merger in the second quarter of 2015, which are discussed separately.

OMEGA HEALTHCARE INVESTOR

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - C

2015 Acquisitions a

Period	Number of Facilities			Number of Operating Beds	Total Investment		Land	Building & Site Improvements	Furniture & Fixtures
	SNF	ALF	State						
Q1	1	-	TX	93	\$ 6.8		\$0.1	\$ 6.1	\$ 0.6
Q3	6	-	NE	530	15.0		1.4	12.1	1.5
Q3	1	2	WA	136	18.0		2.2	14.9	0.9
Q3	-	2	GA	125	10.8		1.2	9.0	0.6
Q3	1	-	VA	300	28.5	(1)	1.9	24.2	2.4
Q3	2	-	FL	260	32.0	(4)	1.4	29.0	1.6
Q3	-	-	NY	-	111.7	(2)(3)	111.7	-	-
Q4	1	-	AZ	6	0.6	(3)	0.3	0.3	-
Q4	1	-	TX	92	5.3		1.8	3.0	0.5
Total	13	4		1,542	\$ 228.7		\$122.0	\$ 98.6	\$ 8.1

(1) In July 2015, we leased the facility to a new operator with an initial lease term of 10 years.

(2) In July 2015, we purchased five buildings located in New York City, New York for approximately \$111.7 million. We and our operator plan to build a 201,000 square-foot assisted living and memory care facility. The properties were added to the operator's existing master lease. The land is held for a 5% annual cash yield on the land during the construction phase. Upon issuance of a certification of occupancy, the annual cash yield will increase to 7% in year one and 8% in year two with annual 2.5% annual escalators thereafter.

(3) Accounted for as an asset acquisition.

(4) Management has estimated the fair value of the assets acquired on the acquisition date based on certain valuation analyses that have yet to be finalized. Accordingly, the assets acquired, as detailed, are subject to adjustment once the analyses are completed.

As of the period ended December 31, 2015, we recognized revenue attributable to the aforementioned acquisitions of approximately \$4.9 million and net income attributable to the acquisitions of approximately \$2.3 million. Acquisition costs related to the above were expensed as period costs. For the year ended December 31, 2015, we expensed \$2.2 million of acquisition related costs. No goodwill was recorded in connection with these acquisitions.

Acquisition of Care Homes in the United States

On May 1, 2015, we closed on a purchase/leaseback Care Homes Transaction (the “Care Homes Transaction”) for 23 care homes located in the United Kingdom and operated by Healthcare Homes Holding Limited (“Healthcare Homes”). As part of the transaction, we acquired title to the 23 care homes, including 1,000 assisted living beds and leased them back to Healthcare Homes pursuant to a 12-year master lease agreement with an initial annual cash yield of 2.5% and annual escalators of 2.5%. The care homes, comparable to assisted living facilities (“ALFs”) in the United States, are located throughout the United Kingdom (north of London) of the United Kingdom. Healthcare Homes is headquartered in Colchester (Essex County), England. We recorded approximately \$152.1 million of assets consisting of land (\$20.7 million), building and site improvements (\$152.1 million), furniture and fixtures (\$5.3 million) and goodwill (\$15.7 million).

We incurred approximately \$3.2 million in acquisition related costs associated with the Care Homes Transaction. For the year ended December 31, 2015, we recognized approximately \$9.5 million of rental revenue in connection with the Care Homes Transaction.

Aviv

On April 1, 2015, Omega completed the Aviv Merger, which was structured as a stock-for-stock merger. Under the terms of the Merger Agreement, one share of Aviv common stock was converted into 0.90 of a share of Omega common stock. In connection with the Aviv Merger, Omega issued approximately 43.7 million shares of common stock to former Aviv stockholders. As a result of the Aviv Merger, Omega acquired 342 facilities, including 342 facilities subject to direct financing leases, one medical office building, two mortgages and other investments. The facilities are located in 31 states and are operated by 38 third-party operators. Omega also assumed certain outstanding equity awards and other debt and liabilities. Based on the closing of the Aviv Merger on April 1, 2015, we estimate the fair value of the consideration exchanged or assumed to be approximately \$3.9 billion. The fair values of Aviv’s assets acquired and liabilities assumed on the Aviv Merger date are determined based on certain valuations and analyses that have not yet finalized its analysis of the fair value of acquired land and buildings and intangible assets and liabilities. As such the amounts reported below for those items are subject to further adjustment. Any change may have an impact on the reported amounts.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - C

The following table highlights the preliminary fair value of the assets acquired and liabilities assumed on April 30, 2015.

	(in thousands)
Estimated fair value of assets acquired:	
Land and buildings	\$ 3,108,078
Investment in direct financing leases	26,823
Mortgages notes receivable	19,246
Other investments	23,619
Total investments	3,177,766
Goodwill	630,404
Accounts receivables and other assets	15,500
Cash acquired	84,858
Fair value of total assets acquired	\$ 3,908,528
Estimated fair value of liabilities assumed:	
Accrued expenses and other liabilities	\$ 221,631
Debt	1,410,637
Fair value of total liabilities assumed	1,632,268
Value of shares and OP units exchanged ^(a)	2,276,260
Fair value of consideration	\$ 3,908,528

(a) Includes the fair value of stock compensation plans as of April 30, 2015.

We incurred approximately \$52.1 million in acquisition related costs associated with the Aviv Merger. For the year ended December 31, 2015, we recognized approximately \$188.4 million of total revenue in connection with the Aviv Merger.

Within accrued expenses and other liabilities is a \$67.3 million contingent liability related to a leasing arrangement with an operator assumed as a result of the Aviv Merger.

In the fourth quarter of 2015, we adjusted the preliminary fair value of the in place lease assets and liabilities that we provisionally recognized in connection with the Aviv Merger. We increased the fair value of the in place lease assets and in place lease liabilities to \$8.2 million as of April 30, 2015.

respectively which resulted in a \$79.0 million net increase in goodwill (see Note 8 – Intangibles). The change to the provisional amounts
an \$8.2 million increase in rental income, of which \$2.7 million relates to the second and third quarters of 2015, resp

OMEGA HEALTHCARE INVESTOR

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - C

2014 Acquisitions a

Period	Number of Facilities			Number of Operating Beds	Total Investment	Land (in millions)	Building & Site Improvements	Furniture & Fixtures
	SNF	ALF	State					
Q1	-	1	AZ	90	\$ 4.7	\$0.4	\$ 3.9	\$ 0.4
Q2/Q3	3	-	GA, SC	345	34.6	0.9	32.1	1.6
Q3	1	-	TX	125	8.2	0.4	7.4	0.4
Q4	-	4	PA,OR,AR	371	84.2	5.1	76.7	2.4
	4	5		931	\$ 131.7	\$6.8	\$ 120.1	\$ 4.8

For the year ended December 31, 2014, we recognized revenue attributable to the acquisitions of approximately \$3.2 million and net income attributable to the acquisitions of approximately \$1.2 million. Acquisition costs related to the above transactions were expensed as period costs. For the year ended December 31, 2014, we expensed \$3.9 million of acquisition related costs.

Transition of Two West Virginia Facilities to a New

For the year ended December 31, 2014, we transitioned two West Virginia SNFs that we previously leased to Diversicare Healthcare Services (“Diversicare” and formerly Diversicare West Virginia) to a new unrelated third party operator. The two facilities represent 150 operating beds. We amended our Diversicare master lease to transfer the two facilities to the new operator and for the year ended December 31, 2014 recorded a \$0.8 million provision for uncollectible receivables. Simultaneous with the Diversicare master lease amendment, we entered into a 12-year master lease with a new third party operator.

2013 Acquisitions a

Number of Facilities	Number of Operating	Total	Land	Building & Site Improvements	Furniture & Fixtures

Period	SNF	ALF	State	Beds	Investment	(in millions)		
Q4	-	1	FL	97	\$ 10.3	\$0.6	\$ 9.0	\$ 0.7
Q4	4	-	IN	384	25.2	(1) 0.7	21.8	2.7
Total	4	1		481	\$ 35.5	\$1.3	\$ 30.8	\$ 3.4

er 31, 2013, we recorded approximately \$3.0 million to below market leases as a result of the transaction for a total investment of \$25.3

ition costs related to the above transactions were expensed as a period cost. For the year ended December 31, 2013, we expensed \$0.2 million in acquisition related

Transition of 11 Arkansas Facilities to a New

August 30, 2013, we transitioned 11 SNFs located in Arkansas that we previously leased to Diversicare Healthcare Services to a new third party operator. The 11 facilities represent 1,084 operating beds. We amended our Diversicare master lease to provide for reduced rent to reflect the transition of the 11 facilities to the new operator, and recorded a \$2.3 million provision for uncollectible straight-line rent receivable. Simultaneously with the amendment to the Diversicare master lease, we entered into a new master lease with the new third party operator of the 11 facilities. The new master lease expires on August 31, 2023 and includes fixed annual rent of

OMEGA HEALTHCARE INVESTOR

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - C

Pro Forma Acquisitions

ities acquired in 2015 and 2014 are included in our results of operations from the dates of acquisition. The following unaudited pro forma information is presented to illustrate the impact of the acquisitions as if they occurred on January 1, 2014. In the opinion of management, all significant necessary adjustments have been made to give effect to the effect of the acquisitions have been made. The following pro forma information is not indicative of future operations.

	Pro Forma Year Ended December 31,	
	2015	2014
	(in thousands, except per share amounts, unaudited)	
Pro forma revenues	\$ 817,642	\$ 789,270
Pro forma net income	\$ 258,927	\$ 318,271
Earnings per share – diluted:		
Net income – as reported	\$ 1.29	\$ 1.74
Net income – pro forma	\$ 1.33	\$ 1.74

Asset Sales, Impairments and

we sold seven SNFs (four previously held-for-sale) for total cash proceeds of approximately \$41.5 million, generating a gain of approximately \$17.7 million. We also recorded a total of \$17.7 million provision for impairment related to six SNFs to reduce their net book value to their estimated fair value for sale. To estimate the fair value of these facilities we utilized a market approach and Level 3 inputs. Two of the facilities are reclassified from held-for-sale to held-for-sale.

We sold four SNFs (three previously held-for-sale) and a parcel of land for total cash proceeds of \$4.1 million, resulting in a \$2.9 million gain. We also recorded a \$3.7 million provision for impairment related to these facilities. To estimate the fair value of these facilities we utilized a market approach and Level 3 inputs. See Note 7 – Assets Held For Sale for more information.

In 2013, we sold one SNF and a parcel of land for total cash proceeds of \$2.3 million resulting in a \$1.2 million gain.

NOTE 4 – DIRECT FINANCING LEASES

The components of investment in direct financing leases consist of the following:

	December 31,	
	2015	2014
	(in thousands)	
Minimum lease payments receivable	\$4,320,876	\$4,244,067
Less unearned income	(3,733,175)	(3,704,835)
Investment in direct financing leases - net	\$587,701	\$539,232
Properties subject to direct financing leases	59	56

OMEGA HEALTHCARE INVESTOR

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - C

December 31, 2015 and 2014 we had seven direct financing leases with four different operators. The following table summarizes the investment in direct financing leases by

	December 31,	
	2015	2014
	(in thousands)	
New Ark	\$560,308	\$539,232
Reliance Health Care Management, Inc.	15,509	-
Sun Mar Healthcare	11,381	-
Markleysburg Healthcare Investors, LP	503	-
Investment in direct financing leases - net	\$587,701	\$539,232

New Ark Invest

On December 27, 2013, we closed an aggregate \$529 million purchase/leaseback transaction in connection with the acquisition of Ark Holding Company ("Ark Holding") by 4 West Holdings Inc. At closing, we acquired 55 SNFs and 1 ALF operated by Ark Holding and leased the facilities to a company now known as New Ark Investment Inc. ("New Ark"), pursuant to four 50-year master leases with rental payments yielding 10.6% per annum over the term of the leases. The purchase/leaseback transaction is being accounted for as a direct financing lease.

The lease agreements allow the tenant the right to purchase the facilities for a bargain purchase price plus closing costs at the end of the lease term. Commencing in the 41st year of each lease, the tenant will have the right to prepay the remainder of its obligations thereunder for an amount equal to the unamortized portion of the original aggregate \$529 million investment plus the net present value of the remaining payments under the lease plus closing costs. In the event the tenant exercises either of these options, we have the right to purchase the properties for fair value at the time of purchase.

The facilities represent 5,623 licensed beds located in 12 states, predominantly in the southeastern United States. The 56 facilities are separated into four regions and divided amongst four cross-defaulted master leases. The four regions include the Southeast (39 facilities), the Northwest (7 facilities), the Midwest (7 facilities) and Indiana (1 facility).

y, in June and July of 2014, we purchased three facilities and subsequently leased them to New Ark under a twelve-year master lease ex
2026. The 2014 three facility lease is being accounted for as an operat

Avi

On April 1, 2015, we acquired two additional direct financing leases as a result of the Avi

As of December 31, 2015, the following minimum rents are due under our direct financing leases for the next five years (in th

Year 1	Year 2	Year 3	Year 4	Year 5
\$50,141	\$50,647	\$51,905	\$53,180	\$54,475

OMEGA HEALTHCARE INVESTOR

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - C

NOTE 5 - MORTGAGE NOTES RECEIVABLE

As of December 31, 2015, mortgage notes receivable relate to 26 fixed rate mortgages on 58 long-term care facilities. The mortgage notes are secured by mortgage liens on the borrowers' underlying real estate and personal property. The mortgage notes receivable relate to facilities located in the United States and are owned and operated by eight independent healthcare operating companies. We monitor compliance with mortgages and when necessary have initiated court proceedings for foreclosure and other proceedings with respect to certain outstanding

The outstanding principal amounts of mortgage notes receivable, net of allowances, were as follows:

	December 31, 2015	December 31, 2014
	(in thousands)	
Mortgage note due 2023; interest at 11.00%	\$69,928	\$112,500
Mortgage note due 2024; interest at 9.64%	112,500	413,399
Mortgage note due 2029; interest at 9.23%	413,399	83,968
Other mortgage notes outstanding ⁽¹⁾	83,968	679,795
Mortgage notes receivable, gross	679,795	—
Allowance for loss on mortgage notes receivable	—	\$679,795
Total mortgages — net	\$679,795	\$—

Other mortgage notes outstanding have stated interest rates ranging from 8.35% to 12.0% and maturity dates through 2046.

Mortgage Note

A \$112.5 million mortgage note is secured by seven facilities located in Maryland. The interest rate will accrue at a fixed rate of 11% per year through April 2018. After April 2018, the interest rate will increase to 13.75% per year. The mortgage note matures in December 2024.

\$112.5 Million of Mortgage Note

17, 2014, we entered into a \$112.5 million first mortgage loan with an existing operator. The loan is secured by 7 SNFs and 2 ALFs tot operating beds located in Pennsylvania (7) and Ohio (2). The loan is cross-defaulted and cross-collateralized with our existing master lease

\$415 Million of Refinancing/Consolidating Mortgage Loans

, 2014, we entered into an agreement to refinance/consolidate \$117 million in existing mortgages with maturity dates ranging from 202 ties into one mortgage and simultaneously provide mortgage financing for an additional 14 facilities. The new \$415 million mortgage n secured by 31 facilities totaling 3,430 licensed beds all located in the state of Michigan. The new loan bore an initial annual cash intere 9.0% and increases by 0.225% per year (e.g., beginning in year 2 the interest rate will be 9.225%, in year 3 the rate will be 9.4

existing mortgages that was refinanced/consolidated into the new \$415 million mortgage included annual interest rate escalators and rec e to pay a prepayment penalty in the event the mortgage was retired early which resulted in us recording an effective yield interest rece with the refinancing/consolidating transaction which was entered into at market terms, the old mortgage was considered to be retired e fications made to the terms of the mortgage were more than minor. As of the date of the refinancing/consolidation transaction, the effec receivable was approximately \$2.0 million. We forgave the prepayment penalty associated with the retired mortgage and recorded a \$2. provision to write-off the effective yield interest receivable related to the retired r

OMEGA HEALTHCARE INVESTO

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - C

NOTE 6 - OTHER INVEST

A summary of our other investments is as

	December 2015 (in thousand)
Other investment note due 2015; interest at 10.00%	\$—
Other investment note due 2020; interest at 10.00%	23,000
Other investment note due 2023; interest at 9.00%	5,470
Other investment note due 2030; interest at 6.66%	26,966
Other investment notes outstanding ⁽¹⁾	36,823
Other investments, gross	92,259
Allowance for loss on other investments	(2,960)
Total other investments	\$89,299

(1) Other investment notes have maturity dates through 2027 and interest rates ranging from 6.50% to 12.0%.

Other Investment Note

December 2015, we amended our five year \$28.0 million loan agreement with an existing operator. The amendment permits the operator to remain under the original loan agreement. Omega funded \$6.0 million to the operator in December 2015. The loan bears interest at 10% per annum and the maturity date was extended from 2017 to 2020. As of December 31, 2015, approximately \$23.0 million remains outstanding.

Other Investment Note

December 2015, we entered into a \$50.0 million revolving credit facility with an operator. The note bears interest at approximately 6.66% and matures in 2030. As of December 31, 2015, approximately \$27.0 million has been drawn and remains outstanding.

NOTE 7 – ASSETS HELD FOR

	Number of Properties	Properties Held-For-Sale Net Book Value (in thousands)
December 31, 2013 ⁽¹⁾	4	\$ 1,356
Properties sold ⁽²⁾	(3)	(686)
Properties added	3	12,122
December 31, 2014 ⁽¹⁾	4	\$ 12,792
Properties sold/other ⁽³⁾	(5)	(16,877)
Properties added ⁽⁴⁾	4	10,684
December 31, 2015 ⁽⁵⁾	3	\$ 6,599

⁽¹⁾Includes one parcel of land and three facilities.

⁽²⁾In 2014, we sold these facilities for approximately \$2.8 million in net proceeds recognizing a gain on sale of approximately \$2.0 million. One parcel of land was reclassified to closed facilities. In addition, we sold four facilities for approximately \$25.5 million in net proceeds recognizing a gain on sale of approximately \$8.8 million.

We recorded a \$3.0 million impairment charge on a SNF in New Mexico to reduce its net book value to its estimated fair value less costs to sell.

⁽⁵⁾Includes three facilities.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - C

NOTE 8 – INTANGIBLE

The following is a summary of our intangibles as of December 31, 2015 and

	December 31,	
	2015	2014
	(in thousands)	
Assets:		
Goodwill	\$645,683	\$—
Above market lease intangibles	\$21,901	14,576
In-place lease intangibles	386	—
Accumulated amortization	(14,162)	(12,166)
Net intangible assets	\$8,125	\$2,410
Liabilities:		
Below market lease intangibles	\$165,331	\$59,785
Accumulated amortization	(55,131)	(39,352)
Net intangible liabilities	\$110,200	\$20,433

will was recorded in connection with the Aviv Merger and Care Homes Transaction and is shown as a separate line on our Consolidated Balance Sheets. Above market lease intangibles and in-place lease intangibles, net of accumulated amortization, are included in other assets on our Consolidated Balance Sheets. Below market lease intangibles are included in accrued expenses and other liabilities on our Consolidated Balance Sheets. As discussed in Note 3 – Properties, the amounts presented above are subject to further adjustment upon completion of purchase accounting for the Aviv Merger.

For the years ended December 31, 2015, 2014 and 2013, our net amortization related to intangibles was \$13.9 million, \$5.0 million and \$5.0 million, respectively. The estimated net amortization related to these intangibles for the subsequent five years is as follows: 2016 – \$16.1 million; 2017 – \$15.1 million; 2018 – \$13.1 million; 2019 – \$12.0 million and 2020 - \$11.7 million. As of December 31, 2015 the weighted average remaining amortization period for above market lease assets and in place lease liabilities is 5.6 years and 8.2 years, respectively.

The following is a reconciliation of our goodwill as of December

	(in tho
Balance as of December 31, 2014	\$ —
Balance as of March 31, 2015	—
Add: Aviv Merger	526,
Add: acquisition of Care Homes	15,7
Add: foreign currency translation	585
Balance as of June 30, 2015	543,
Add: additional valuation adjustments related to preliminary valuations (see Note 3 – Aviv Merger)	12,2
Less: foreign currency translation	(605
Balance as of September 30, 2015	554,
Add: additional valuation adjustments related to preliminary valuations (see Note 3 – Aviv Merger)	91,3
Add: additional valuation adjustments related to preliminary valuations (see Note 3 – Care Homes acquisition)	5
Less: foreign currency translation	(407
Balance as of December 31, 2015	\$ 645,

OMEGA HEALTHCARE INVESTOR

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - C

NOTE 9 - CONCENTRATION C

December 31, 2015, our portfolio of real estate investments consisted of 949 healthcare facilities, located in 42 states and the United Kingdom, operated by 83 third party operators. Our gross investment in these facilities, net of impairments and before reserve for uncollectible loans, was approximately \$8.0 billion at December 31, 2015, with approximately 99% of our real estate investments related to long-term care facilities. Our portfolio consisted of 782 SNFs, 85 ALFs, 16 specialty facilities, one medical office building, fixed rate mortgages on 56 SNFs and two ALFs, and seven SNFs held-for-sale. At December 31, 2015, we also held miscellaneous investments of approximately \$89.3 million, consisting primarily of loans to third-party operators of our

December 31, 2015, the three states in which we had our highest concentration of investments were Ohio (10%), Texas (9%) and Florida (9%). No operator or manager generated more than 8% of our total revenues for the year ended December

NOTE 10 - LEASE AND MORTGAGE DE

Our liquidity deposits, security deposits and letters of credit from most operators pursuant to our lease and mortgage agreements with the operators generally represent the rental and mortgage interest for periods ranging from three to six months with respect to certain of our investments. At December 31, 2015, we held \$5.8 million in liquidity deposits, \$50.6 million in security deposits and \$68.7 million in letters of credit. The liquidity deposits and the letters of credit may be used in the event of lease and or loan defaults, subject to applicable limitations under bankruptcy law for operators filing under Chapter 11 of the United States Bankruptcy Code. Liquidity deposits are recorded as restricted cash on our Consolidated Balance Sheets with the offset recorded as a liability in accrued expenses and other liabilities on our Consolidated Balance Sheets. Security deposits received from the operator are recorded in accrued expenses and other liabilities on our Consolidated Balance Sheets. Additional security provided by operators is provided by covenants regarding minimum working capital and net worth, liens on accounts receivable and other operating assets of the operators, provisions for cross default, provisions for cross-collateralization and by corporate or personal guaranties.

OMEGA HEALTHCARE INVESTOR

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - C

NOTE 11 - BORROWING ARRANGEMENTS

The following is a summary of our long-term borrowings:

		Rate as of	December 31,	
	Maturity	December 31,	2015	2016
		2015	(in thousands)	
Secured borrowings:				
GE term loan	2019	4.00	% \$180,000	\$—
HUD mortgages assumed June 2010	—	—	—	12
HUD mortgages assumed October 2011	—	—	—	24
HUD mortgages assumed December 2011 ⁽¹⁾	2044	3.06	% 56,204	57
HUD mortgages assumed December 2012	—	—	—	35
			236,204	23
Premium – net			—	13
Total secured borrowings			236,204	25
Unsecured borrowings:				
Revolving line of credit	2018	1.72	% 230,000	85
Tranche A-1 term loan	2019	1.92	% 200,000	20
Tranche A-2 term loan	2017	1.77	% 200,000	—
Omega OP term loan	2017	1.77	% 100,000	—
2015 term loan	2022	2.14	% 250,000	—
			980,000	28
2020 notes	—	—	—	20
2022 notes	—	—	—	57
2024 notes	2024	5.875	% 400,000	40
2024 notes	2024	4.95	% 400,000	40
2025 notes	2025	4.50	% 250,000	25
2026 notes	2026	5.25	% 600,000	—
2027 notes	2027	4.50	% 700,000	—
Subordinated debt	2021	9.00	% 20,000	20
			2,370,000	1,

Discount - net	(17,118)	(2
Total unsecured borrowings	3,332,882	2,
Total – net	\$3,569,086	\$2,

Reflects the weighted average annual contractual interest rate on the mortgages at December 31, 2015 excluding a third-party administrative fee of approximately 0.5%. Secured by real estate assets with a net carrying value of \$95.4 million.

Secured Bo

General Electric T

2015, as a result of the Aviv Merger, we assumed a \$180 million secured term loan with General Electric Capital Corporation (“GE”). The loan is secured by real estate assets having a net carrying value of \$295.5 million at December 31, 2015. On each payment date, we pay interest only (in arrears) on the outstanding principal balance until February 1, 2017 when principal and interest will be paid in arrears based on a thirty year amortization schedule. The interest rate is based on LIBOR, with a floor of 50 basis points, plus a margin of 350 basis points. The interest rate at December 31, 2015 was 4.0%. The initial term expires in December 2019 with the full balance of the loan due at that time.

OMEGA HEALTHCARE INVESTOR

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - C

HUD Mortgages Loa

December 31, 2015, we paid approximately \$25.1 million to retire two mortgage loans guaranteed by the U.S. Department of Housing and Urban Development (“HUD”). The loans were assumed as part of an acquisition in a prior year, and had a blended interest rate of 5.5% per annum with maturities on April 1, 2036. The payoff resulted in a \$0.9 million gain on the extinguishment of the debt due to the write-off of the \$2.1 million unamortized fair value adjustment recorded at the time of acquisition offset by a prepayment fee of approximately \$1.2 million.

December 31, 2015, we paid approximately \$9.1 million to retire one mortgage loan guaranteed by HUD. The loan was assumed as part of an acquisition in a prior year, and had an interest rate of 4.35% per annum with maturity on March 1, 2041. The payoff resulted in a \$1.0 million gain on the extinguishment of the debt due to the write-off of the \$1.5 million unamortized fair value adjustment recorded at the time of acquisition offset by a prepayment fee of approximately \$0.4 million.

December 31, 2015, we paid approximately \$154.3 million to retire 21 mortgage loans guaranteed by HUD, totaling approximately \$146.9 million. The loans had a blended interest rate of 5.35% per annum with maturities between January 2040 and January 2045 and three loans had an all-in blended interest rate of 5.5% per annum with maturities between February 2040 and February 2045. The payoff resulted in a \$2.3 million gain on the extinguishment of the debt due to the write-off of the \$9.7 million unamortized debt premium recorded at the time of acquisition offset by a prepayment fee of approximately \$0.7 million.

*Unsecured Bo**Unsecured Credi*

On December 27, 2014, we entered into a credit agreement (as amended, the “2014 Credit Agreement”) providing us with \$1.2 billion unsecured credit facilities consisting of a \$1 billion senior unsecured revolving credit facility (the “Revolving Credit Facility”) and a \$200 million senior unsecured term loan facility (the “Tranche A-1 Term Loan Facility” or “Tranche A-1 Term Loan Facility,” and, collectively, the “2014 Credit Facilities”). The 2014 Credit Facilities replaced our previous \$700 million senior unsecured credit facility (the “2012 Credit

On June 1, 2015, we entered into a First Amendment to Credit Agreement (the “First Amendment to Omega Credit Agreement”) which amended the terms of our credit facilities. Under the First Amendment to Omega Credit Agreement, the Company (i) increased the aggregate revolving commitment amount under the Revolving Credit Facility from \$1 billion to \$1.25 billion and (ii) obtained a \$200 million senior unsecured incremental term loan facility, which may be used for “Acquisition Term Loan Facility” or “Tranche A-2 Term Loan Facility”.

Loans under the Revolving Credit Facility bear interest at LIBOR plus an applicable percentage (beginning at 130 basis points, with a range of 130 to 300 basis points) based on our ratings from Standard & Poor’s, Moody’s and/or Fitch Ratings, plus a facility fee based on the same ratings (initially ranging from 12.5 to 30 basis points). The Revolving Credit Facility is used for acquisitions and general corporate purposes. The Revolving Credit Facility matures on June 27, 2018, subject to a one-time option by us to extend such maturity date by up to 18 months.

The Tranche A-1 Term Loan Facility bears interest at LIBOR plus an applicable percentage (beginning at 150 basis points, with a range of 150 to 300 basis points) based on our ratings from Standard & Poor’s, Moody’s and/or Fitch Ratings. The Tranche A-1 Term Loan Facility matures on June 27, 2018.

The Tranche A-2 Term Loan Facility bears interest at LIBOR plus an applicable percentage (beginning at 150 basis points, with a range of 150 to 300 basis points) based on our ratings from Standard & Poor’s, Moody’s and/or Fitch Ratings. The Tranche A-2 Term Loan Facility matures on June 27, 2018, subject to an option to extend the maturity date of the Tranche A-2 Term Loan Facility twice, the first extension until June 27, 2019 and the second extension until June 27, 2020.

OMEGA HEALTHCARE INVESTOR

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - C

Omega OP Term Loan

2015, Omega OP entered into a credit agreement (the “Omega OP Credit Agreement”) providing it with a \$100 million senior unsecured term loan facility (the “Omega OP Term Loan Facility”). The Omega OP Term Loan Facility bears interest at LIBOR plus an applicable percentage (beginning at 180 basis points, with a range of 100 to 195 basis points) based on our ratings from Standard & Poor’s, Moody’s and/or Fitch Ratings. The Omega OP Term Loan Facility matures on June 27, 2017, subject to Omega OP’s option to extend such maturity date twice, the first extension until June 27, 2018 and the second extension until June 27, 2019.

\$250 Million Term Loan

On December 16, 2015, we entered into a \$250 million senior unsecured term loan facility (the “2015 Term Loan Facility”). The 2015 Term Loan Facility bears interest at LIBOR plus an applicable percentage (beginning at 180 basis points, with a range of 140 to 235 basis points) based on our ratings from Standard & Poor’s, Moody’s and/or Fitch Ratings. The 2015 Term Loan Facility may be increased to an aggregate amount of \$400 million. We intend to use the proceeds from this loan to repay existing indebtedness and for general corporate purposes. The 2015 Term Loan Facility matures on December 15, 2022.

As a result of exposure to interest rate movements associated with the 2015 Term Loan Facility, on December 16, 2015, we entered into interest rate swap arrangements, which effectively converted \$250 million of our variable-rate debt based on one-month LIBOR to a fixed rate of approximately 3.8005% effective December 30, 2016. The effective fixed rate achieved by the combination of the 2015 Term Loan Facility and the interest rate swaps could vary up by 55 basis points or down by 40 basis points based on future changes to our credit ratings. Each swap has a notional amount of \$250 million, a term of 6 years on December 30, 2016 and matures on December 15, 2022. On the date of inception, we designated the interest rate swaps as cash flow hedges in accordance with accounting guidance for derivatives and hedges and linked the interest rate swaps to the 2015 Term Loan Facility. Because the interest rate swaps and 2015 Term Loan Facility coincide, the hedges are expected to exactly offset changes in expected cash flows associated with fluctuations in 1-month LIBOR over the term of the hedges. The purpose of entering into the swaps was to reduce our exposure to future changes in interest rates. The interest rate swaps settle on a monthly basis when interest payments are made. These settlements will occur through the 2015 Term Loan Facility. The interest rate for the 2015 Term Loan Facility is not hedged for the portion of the term prior to December 15, 2022.

\$575 Million 6.75% Senior Notes due 2022

er 26, 2015, we redeemed all of our outstanding 6.75% Senior Notes due 2022 (the “2022 Notes”). As a result of the redemption, during 2015, we recorded approximately \$21.3 million in redemption related costs and write-offs, including \$19.4 million for the early redemption premiums and \$1.9 million in net write-offs associated with unamortized deferred financing costs and original issuance premiums/c

\$600 Million 5.25% Senior Notes

ember 23, 2015, we sold \$600 million aggregate principal amount of our 5.250% Senior Notes due 2026 (the “2026 Notes”). The 2026 Notes were issued at an issue price of 99.717% of their face value before the initial purchasers’ discount. Our total net proceeds from the offering, after deducting initial purchasers’ discounts and other offering expenses, were approximately \$594.4 million. The net proceeds of the offering were used to repay our outstanding aggregate principal amount 6.75% Senior Notes due 2022 and for general corporate purposes. The 2026 Notes mature on January 15, 2026 and pay interest semi-annually on January 15th and July 15th.

December 31, 2015, our subsidiaries that are not guarantors of our 5.25% Senior Notes due 2026 accounted for approximately \$598.6 million of our total debt.

\$700 Million 4.5% Senior Notes

April 8, 2015, we sold \$700 million aggregate principal amount of our 4.5% Senior Notes due 2027 (the “2027 Notes”). The 2027 Notes were issued at a price of 98.546% of their face value before the initial purchasers’ discount. Our total net proceeds from the offering, after deducting initial purchasers’ discounts and other offering expenses, were approximately \$683 million. The net proceeds of the offering were used for general corporate purposes, including the repayment of Aviv indebtedness on April 1, 2015 in connection with the Aviv Merger, and repayment of future maturities of our outstanding debt. The 2027 Notes mature on April 1, 2027 and pay interest semi-annually on April 1st and October 1st.

December 31, 2015, our subsidiaries that are not guarantors of our 4.5% Senior Notes due 2027 accounted for approximately \$598.6 million of our total debt.

OMEGA HEALTHCARE INVESTOR

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - C

\$200 Million 7.5% Senior Notes due 2020 Re

On March 13, 2015, Omega redeemed all of its outstanding \$200 million 7.5% Senior Notes due 2020 (the “2020 Notes”) at a redemption price of approximately \$208.7 million, consisting of 103.750% of the principal amount, plus accrued and unpaid interest on such notes to, but not including interest accrued to the date of redemption.

In connection with the redemption, we recorded approximately \$11.7 million redemption related costs and write-offs, including \$7.5 million in premium amortization for early redemption and \$4.2 million of write-offs associated with unamortized deferred financing costs and discount. The consideration for the redemption of the 2020 Notes was funded from the net proceeds of the 10.925 million share common stock offering. See Note 15 – Stockholders’ Equity for additional information.

\$250 Million 4.5% Senior Notes

On November 11, 2014, we sold \$250 million aggregate principal amount of our 4.5% Senior Notes due 2025 (the “2025 Notes”). The 2025 Notes were sold at a price of 99.131% of their face value before the initial purchasers’ discount resulting in gross proceeds of approximately \$247.8 million. The 2025 Notes mature on January 15, 2025 and pay interest semi-annually on January 15 and July 15 of each year.

As of December 31, 2015, our subsidiaries that are not guarantors of the 2025 Notes accounted for approximately \$598.6 million of our total debt.

\$400 Million 4.95% Senior Notes

On November 11, 2014, we sold \$400 million aggregate principal amount of our 4.95% Senior Notes due 2024 (the “2024 Notes”). These notes were sold at a price of 98.58% of the principal amount of the notes, before the initial purchasers’ discount resulting in gross proceeds of approximately \$394.3 million. The 2024 Notes mature on April 1, 2024 and pay interest semi-annually on April 1 and October 1 of each year.

of December 31, 2015, our subsidiaries that are not guarantors of the 2024 Notes accounted for approximately \$598.6 million of our total

\$400 Million 5.875% Senior Notes

In 2012, we issued \$400 million aggregate principal amount of our 5.875% Senior Notes due 2024. These notes mature on March 15, 2024, and pay interest semi-annually on March 15 and September 15 of each year.

As of December 31, 2015, our subsidiaries that are not guarantors of the \$400 million 5.875% Senior Notes due 2024 accounted for approximately \$598.6 million of our total

Other Debt

In connection with the Aviv Merger on April 1, 2015, we assumed notes payable with a face amount of \$650 million and a revolving credit facility with an outstanding balance of \$525 million. In connection with the Aviv Merger, we repaid this debt assumed from Aviv on April 1, 2015. Due to the covenants and requirements for early repayments; the Company paid approximately \$705.6 million to retire the \$650 million notes assumed. The amount of cash paid in connection with the revolving credit facility was \$525 million.

All of our other secured and unsecured borrowings are subject to customary affirmative and negative covenants, including financial covenants. As of December 31, 2015 and 2014, we were in compliance with all affirmative and negative covenants, including financial covenants, for our secured and unsecured borrowings.

The required principal payments, excluding the premium or discount on our secured and unsecured borrowings, for each of the five years ending December 31, 2015 and the aggregate due thereafter are set forth below:

	(in thousands)
2016	\$ 1,249
2017	301,288
2018	231,328
2019	381,370
2020	1,412
Thereafter	2,669,557

Totals \$ 3,586,204

The following summarizes the refinancing rela

	Year Ended December	
	2015	2014
	(in thousands)	
Write off of deferred financing cost and unamortized premiums due to refinancing ^{(1) (2)(3)}	\$(7,134)	\$1,180
Prepayment and other costs associated with refinancing ⁽⁴⁾	35,971	1,861
Total debt extinguishment costs (gain)	\$28,837	\$3,041

we recorded: (a) \$4.2 million of write-offs of unamortized deferred financing costs and discount associated with the early redemption of our 2012 Notes, (b) \$1.9 million in net write-offs associated with unamortized deferred financing costs and original issuance premiums/discounts associated with the early redemption of our 2012 Notes, offset by (c) \$13.2 million gain related to the early extinguishment of debt from the write off of unamortized premium on the HUD debt paid off in March, April and December 2015.

we recorded: (a) \$2.6 million write-off of deferred financing costs associated with the termination of the 2012 Credit Facilities, (b) \$2.0 million of deferred financing costs associated with the termination of our 2013 Term Loan Facility offset by (c) \$3.5 million gain related to the extinguishment of debt from the write off of unamortized premium on the HUD debt paid off in September and December 2014.

OMEGA HEALTHCARE INVESTOR

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - C

we recorded an \$11.3 million interest refinancing gain associated with the write-off of the unamortized premium for debt assumed on 1 loans that we paid off in May 2013.

we made: (a) \$7.5 million of prepayment penalties associated with the early redemption of our 2020 Notes, (b) \$19.4 million of prepayment penalties associated with the early redemption of our 2022 Notes and (c) \$9.1 million of prepayment penalties associated with 24 HUD mortgage loans paid off in March, April and December 2015. In 2014, we made prepayment penalties of \$1.9 million associated with five HUD mortgage loans paid off in September and October 2014. In 2013, we made prepayment penalties of \$0.2 million associated with 11 HUD mortgage loans paid off in May 2013.

NOTE 12 - FINANCIAL INSTRUMENTS

At December 31, 2015 and 2014, the carrying amounts and fair values of our financial instruments were as follows:

	2015		2014	
	Carrying	Fair	Carrying	Fair
	Amount	Value	Amount	Value
	(in thousands)			
Assets:				
Cash and cash equivalents	\$5,424	\$5,424	\$4,489	\$4,489
Restricted cash	14,607	14,607	29,076	29,076
Investments in direct financing leases – net	587,701	584,358	539,232	539,232
Mortgage notes receivable – net	679,795	687,130	648,079	648,079
Other investments – net	89,299	90,745	48,952	48,952
Totals	\$1,376,826	\$1,382,264	\$1,269,828	\$1,269,828
Liabilities:				
Revolving line of credit	\$230,000	\$230,000	\$85,000	\$85,000
Tranche A-1 term loan	200,000	200,000	200,000	200,000
Tranche A-2 term loan	200,000	200,000	—	—
Omega OP term loan	100,000	100,000	—	—
2015 term loan	250,000	250,000	—	—
7.50% notes due 2020 – net	—	—	198,235	198,235
6.75% notes due 2022 – net	—	—	580,410	580,410
5.875% notes due 2024 – net	400,000	429,956	400,000	400,000
4.95% notes due 2024 – net	395,333	403,064	394,768	394,768

Edgar Filing: ROYAL CARIBBEAN CRUISES LTD - Form 10-K

4.50% notes due 2025 – net	248,099	242,532	247,889	24
5.25% notes due 2026 – net	598,343	612,760	—	—
4.50% notes due 2027 – net	690,494	667,651	—	—
GE term loan due 2019	180,000	180,000	—	—
HUD debt – net	56,204	52,678	251,454	20
Subordinated debt – net	20,613	24,366	20,747	20
Totals	\$3,569,086	\$3,593,007	\$2,378,503	\$2

value estimates are subjective in nature and are dependent on a number of important assumptions, including estimates of future cash flow, discount rates and relevant comparable market information associated with each financial instrument (see Note 2 – Summary of Significant Accounting Policies). The use of different market assumptions and estimation methodologies may have a material effect on the reported estimated fair value.

The following methods and assumptions were used in estimating fair value disclosures for financial instruments:

Cash equivalents and restricted cash: The carrying amount of cash and cash equivalents and restricted cash reported in the Consolidated Balance Sheet approximates fair value because of the short maturity of these instruments (i.e., less than 90 days) (Level 1).

OMEGA HEALTHCARE INVESTOR

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - C

financing leases: The fair value of the investments in direct financing leases are estimated using a discounted cash flow analysis, using interest rates being offered for similar leases to borrowers with similar credit ratings (Level 3).

notes receivable: The fair value of the mortgage notes receivables are estimated using a discounted cash flow analysis, using interest rates being offered for similar loans to borrowers with similar credit ratings (Level 3).

investments: Other investments are primarily comprised of notes receivable. The fair values of notes receivable are estimated using a discounted cash flow analysis, using interest rates being offered for similar loans to borrowers with similar credit ratings (Level 3).

line of credit and term loans: The fair value of our borrowings under variable rate agreements are estimated using an expected present value technique based on expected cash flows discounted using the current market rates (Level 3).

senior and subordinated debt: The fair value of our borrowings under fixed rate agreements are estimated using an expected present value technique based on open market trading activity provided by a third party (Level 2).

The fair value of our borrowings under HUD debt agreements are estimated using an expected present value technique based on quotes from independent debt brokers (Level 2).

NOTE 13

organized, have operated, and intend to continue to operate in a manner that enables us to qualify for taxation as REIT under Sections 856 through 860 of the Internal Revenue Code of 1986, as amended (the "Code"). On a quarterly and annual basis we perform several analyses to test our compliance with the REIT taxation rules. In order to qualify as a REIT, in addition to other requirements, we must: (i) distribute dividends (other than capital gains) to our stockholders in an amount at least equal to (A) the sum of (a) 90% of our "REIT taxable income" (computed without regard to the tax on the distribution and our net capital gain), and (b) 90% of the net income (after tax), if any, from foreclosure property, minus (B) the sum of certain expenses on an annual basis, (ii) ensure that at least 75% and 95%, respectively of our gross income is generated from qualifying sources as defined in the REIT tax law, (iii) ensure that at least 75% of our assets consist of qualifying assets, such as real property, mortgages, and other securities as described in the REIT tax law, (iv) ensure that we do not own greater than 10% in voting power or value of securities of any one issuer, (v) we do not own either debt or equity securities of another company that are in excess of 5% of our total assets and (vi) ensure that no more than 100 persons are invested in one or more taxable REIT subsidiaries (and with respect to taxable years beginning after December 31, 2017, no more than 50 persons). In addition to the above requirements, the REIT rules require that no less than 100 stockholders own shares or an interest in the REIT and that five percent of the stockholders do not own (directly or indirectly) more than 50% of the shares or proportionate interest in the REIT. If we fail to meet the above or

nts for qualification as a REIT in any tax year, we will be subject to federal income tax on our taxable income at regular corporate rates
to qualify as a REIT for the four subsequent years, unless we qualify for certain relief provisions that are available in the event we fail
any of these require

also subject to federal taxation of 100% of the derived net income if we sell or dispose of property, other than foreclosure property, that
rily for sale to customers in the ordinary course of a trade or business. We believe that we do not hold assets for sale to customers in the
of business and that none of the assets currently held for sale or that have been sold would be considered a prohibited transaction within
taxat

s we qualify as a REIT under the Code, we generally will not be subject to federal income taxes on the REIT taxable income that we dis
stockholders, subject to certain exceptions. In 2015 and 2014, we distributed dividends in excess of our taxable

ear 2000, the definition of foreclosure property has included any “qualified health care property,” as defined in Code Section 856(e)(6)
ult of the termination or expiration of a lease of such property. We have from time to time operated qualified healthcare facilities acquir
for up to two years (or longer if an extension was granted). Properties that we had taken back in a foreclosure or bankruptcy and operate
t were treated as foreclosure properties for income tax purposes, pursuant to Code Section 856(e). Gross income from foreclosure prop
“good income” for purposes of the annual REIT income tests upon making the election on the tax return. Once made, the income was c
for a period of three years, or until the properties were no longer operated for our own account. In all cases of foreclosure property, we
endent contractor to conduct day-to-day operations to maintain REIT status. In certain cases, we operated these facilities through a taxa
For those properties operated through the taxable REIT subsidiary, we formed a new entity (TC Healthcare) on our behalf through the
eligible independent contractor to conduct day-to-day operations to maintain REIT status. As a result of the foregoing, we do not believ
ion in the operation of nursing homes increased the risk that we would fail to qualify as a REIT. Through our 2015 taxable year, we had
any tax on our foreclosure property because those properties had been produc

OMEGA HEALTHCARE INVESTORS

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - C

As a result of our UPREIT Conversion, our Company and its subsidiaries may be subject to income or franchise taxes in certain states and municipalities. As a result of our UPREIT Conversion, we created five subsidiary REITs that are subject to all of the REIT qualification rules set forth in the Internal Revenue Code. In December 2015, we consolidated the five subsidiary REITs into one subsidiary REIT.

Due to the limitation under the REIT asset test rules, we are permitted to own up to 100% of the stock of one or more taxable REIT subsidiaries. We have elected for two of our active subsidiaries to be treated as TRSs. One of our TRSs is subject to federal, state and local income taxes at the applicable corporate rates and the other is subject to foreign income taxes. As of December 31, 2015, our TRS that is subject to federal, state and local income taxes at the applicable corporate rates had a net operating loss carry-forward of approximately \$0.9 million. The loss carry-forward is fully reserved as of December 31, 2015 with a valuation allowance due to uncertainties regarding realization.

In connection with our acquisition of Care Homes in May 2015, we acquired 10 legal entities consisting of 23 facilities. The tax basis in these legal entities for United Kingdom taxes was approximately \$82 million less than the purchase price. We recorded an initial deferred tax liability associated with the temporary tax basis difference of approximately \$1.0 million.

For the year ended December 31, 2015, we recorded approximately \$1.0 million of state and local income tax provision and approximately \$0.1 million of provision for foreign income taxes.

NOTE 14 - RETIREMENT ARRANGEMENTS

Our Company has a 401(k) Profit Sharing Plan covering all eligible employees. Under this plan, employees are eligible to make contributions, and, at our discretion, may match contributions and make a profit sharing contribution. Amounts charged to operations with respect to these retirement arrangements totaled approximately \$0.4 million, \$0.3 million, \$0.2 million in 2015, 2014 and 2013, respectively.

In addition, we have a deferred stock compensation plan that allows employees and directors the ability to defer the receipt of stock awards. The awards (units) participate in future dividends as well as the change in the value of the Company's common stock. As of December 31, 2015, the Company had 400,814 and 398,373 deferred stock units outstanding.

\$500 Million Equity Shelf

On December 3, 2015, we entered into separate Equity Distribution Agreements (collectively, the “Equity Shelf Agreements”) to sell shares of our common stock having an aggregate gross sales price of up to \$500 million (the “2015 Equity Shelf Program”) with several financial institutions, each as a principal (collectively, the “Managers”). Under the terms of the Equity Shelf Agreements, we may sell shares of our common stock, from time to time, through or to the Managers having an aggregate gross sales price of up to \$500 million. Sales of the shares, if any, will be made by means of primary market transactions on the New York Stock Exchange at market prices, or as otherwise agreed with the applicable Manager. We will pay each Manager a commission for sales of the shares equal to 2% of the gross sales price per share of shares sold through such Manager under the applicable Equity Shelf Agreements. As of December 31, 2015, we did not issue any shares under the 2015 Equity Shelf Program.

OMEGA HEALTHCARE INVESTOR

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - C

\$250 Million Equity Shelf Program Termination

On September 3, 2015, we terminated our \$250 million Equity Shelf Program (the “2013 Equity Shelf Program”) that we entered into with financial institutions on March 18, 2013. In 2015, we did not issue any shares under the 2013 Equity Shelf Program.

For the year ended December 31, 2014, we issued approximately 1.8 million shares under the 2013 Equity Shelf Program, at an average price of \$35.28 per share, generating gross proceeds of approximately \$63.5 million, before \$1.5 million of commissions and expenses.

At the inception of the 2013 Equity Shelf Program, we sold a total of 7.4 million shares of common stock generating total gross proceeds of \$233.3 million, before \$4.7 million of commissions. As a result of the termination of the 2013 Equity Shelf Program, no additional shares will be issued under the 2013 Equity Shelf Program.

\$245 Million Equity Shelf Program Termination

On March 18, 2013, we terminated our previous \$245 million Equity Shelf Program (the “2012 Equity Shelf Program”) that we entered into with financial institutions on June 19, 2012. For the year ended December 31, 2013, we issued approximately 1.0 million shares under the 2012 Equity Shelf Program at an average price of \$28.29 per share, generating gross proceeds of approximately \$27.8 million, before \$0.6 million of commissions. As a result of the termination of the 2012 Equity Shelf Program, no additional shares will be issued under the 2012 Equity Shelf Program.

Increase of Authorized Omega Common Stock

On December 27, 2015, we amended our charter to increase the number of authorized shares of Omega capital stock from 220 million to 370 million and the number of authorized shares of Omega common stock from 200 million to 350 million.

10.925 Million Common Stock

On July 9, 2015, we completed an underwritten public offering of 10.925 million shares of our common stock at \$42.00 per share before underwriting offering expenses. The Company's total net proceeds from the offering were approximately \$440 million, after deducting underwriting discounts and commissions and other estimated offering expenses.

2.875 Million Common Stock

On October 7, 2013, we sold 2.875 million shares of common stock in an underwritten public offering at a price of \$29.48 per share, after underwriting discounts but before expenses. Our total net proceeds from the offering, after underwriting discounts and expenses were approximately \$84.0 million.

Dividend Reinvestment and Common Stock Purchase Plan

Dividend Reinvestment and Common Stock Purchase Plan (the "DRSPP") that allows for the reinvestment of dividends and the option to purchase common stock. For the year ended December 31, 2015, we issued 4.2 million shares of common stock for gross proceeds of approximately \$176.4 million. For the year ended December 31, 2014, we issued 2.1 million shares of common stock for gross proceeds of approximately \$71.5 million. For the year ended December 31, 2013, we issued 1.9 million shares of common stock for gross proceeds of approximately \$55.8 million.

OMEGA HEALTHCARE INVESTOR

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - C

NOTE 16 – STOCK-BASED COMPEN

Restricted Stock and Restricted Sto

Restricted stock and restricted stock units (“RSUs”) are subject to forfeiture if the holder’s service to us terminates prior to vesting, subject to certain qualifying terminations of employment or a change in control of the Company. Prior to vesting, ownership of the shares/units is not transferred. The restricted stock has the same dividend and voting rights as our common stock. RSUs accrue dividend equivalents but have no voting rights. Restricted stock and RSUs are valued at the price of our common stock on the date of grant. We expense the cost of these awards ratably over the vesting period.

RSUs assumed from Aviv as part of the Aviv Merger were valued at the closing price of our stock on the date of the transaction. The portion of the expense accruing prior to the acquisition was recorded as part of the purchase price consideration. The expense associated with the vesting that will occur after the date of the transaction will be recorded as stock compensation expense ratably over the remaining life of the award.

The following table summarizes the activity in restricted stock and RSUs for the years ended December 31, 2013, 2014 and 2015:

	Number of Shares/Units	Weighted - Average Grant- Date Fair Value per Share	Compe Cost (1) (in mil
Non-vested at December 31, 2012	459,502	\$ 22.33	
Granted during 2013	241,699	29.87	\$ 7.2
Vested during 2013	(444,003)	22.38	
Non-vested at December 31, 2013	257,198	\$ 29.32	
Granted during 2014	143,637	30.70	\$ 4.4
Vested during 2014	(90,901)	28.87	
Non-vested at December 31, 2014	309,934	\$ 30.08	

Granted during 2015	232,533	39.25	\$ 9.3
Assumed in Aviv Merger ⁽²⁾	38,268	23.50	\$ 0.9
Cancelled during 2015	(61,911)	33.77	
Vested during 2015	(106,146)	28.72	
Non-vested at December 31, 2015	412,678	\$ 34.44	

Total compensation cost to be recognized on the awards based on grant date fair value, which is based on the market price of the Company's common stock on the date of grant.

Stock price on April 1, 2015 was \$40.74. The weighted average stock price indicated in the table above represents the expense per unit of award related to the assumed Aviv RSUs.

Performance Restricted Stock

Performance restricted stock units ("PRSUs") and long term incentive plan units ("LTIP Units") are subject to forfeiture if the performance requirements are not achieved or if the holder's service to us terminates prior to vesting, subject to certain exceptions for certain qualifying terminations of employment or a change of control of the Company. The PRSUs awarded in January 2011, January 2013, December 2013, January 2014, March 2015, April 2015 and July 2015 and the LTIP Units awarded in March 2015, April 2015 and July 2015 have varying degrees of performance requirements to achieve vesting. Each PRSU and LTIP Units award represents the right to a variable number of shares of common stock or partnership units (each LTIP Unit once vested is convertible into one Omega OP Unit in Omega OP, subject to certain conditions). The vesting requirements are based on either the (i) total shareholder return ("TSR") of Omega or (ii) Omega's TSR relative to other real estate investment trusts in the MSCI U.S. REIT Index ("Relative TSR"). We expense the cost of these awards ratably over their service period.

Upon vesting and the distribution of shares, ownership of the PRSUs cannot be transferred. The dividends on the PRSUs accumulate and if vested, the dividends are distributed to the employee. While each LTIP Unit is unearned, the employee receives a partnership distribution equal to 10% of the quarterly approved regular periodic distributions per Omega OP Unit. The remaining partnership distributions (which in the case of normal distributions is equal to the total approved quarterly dividend on Omega's common stock) on the LTIP Units accumulate, and if the LTIP Units are vested, the accumulated distributions are distributed to the employee.

OMEGA HEALTHCARE INVESTOR

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - C

used a Monte Carlo model to estimate the fair value for the PRSUs and LTIP Units granted to the employees. The following are the assumptions used in estimating the value of the awards for grants made on the following

	January 1, 2012	January 1, 2013	December 31, 2013 and January 1, 2014	March 31, 2015	April 1, 2015	July 31, 2015
Price on date of grant	\$19.35	\$23.85	\$29.80	\$40.57	\$40.74	\$36.26
Volatility	8.27%	4.24%	6.44%	5.23%	5.20%	6.07%
Interest rate at time of	0.03% to 0.35%	0.05% to 0.43%	0.04% to 0.86%	0.10% to 0.94%	0.09% to 0.91%	0.13% to
	35.64% to 38.53%	15.56% to 23.83%	24.16% to 25.86%	20.06% to 21.09%	20.06% to 21.08%	20.06% to 20.21%

The following table summarizes the activity in PRSUs for the years ended December 31, 2013, 2014 and

	Number of Shares	Weighted- Average Grant- Date Fair Value per Share	Compe Cost (1) (in mil
Non-vested at December 31, 2012	372,735	\$ 11.36	
Granted during 2013	665,289	10.36	\$ 6.9
Vested during 2013 ⁽²⁾	-	-	
Non-vested at December 31, 2013	1,038,024	\$ 10.72	
Granted during 2014	309,168	11.46	\$ 3.5
Vested during 2014 ⁽²⁾	(496,979)	10.75	
Non-vested at December 31, 2014	850,213	\$ 10.97	
Granted during 2015	537,923	18.51	\$ 10.
Cancelled during 2015	(165,570)	14.11	
Forfeited during 2015	(128,073)	12.04	
Vested during 2015 ⁽²⁾	(181,406)	10.10	
Non-vested at December 31, 2015	913,087	\$ 14.87	

Total compensation cost to be recognized on the awards was based on the grant date fair value or the modification date fair value. PRSUs are shown as vesting in the year that the Compensation Committee determines the level of achievement of the applicable performance measures.

OMEGA HEALTHCARE INVESTOR

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - C

The following table summarizes our total unrecognized compensation cost as of December 31, 2015 associated with restricted stock, restricted stock units, performance restricted stock units, performance restricted stock units with PRSU awards, and LTIP Unit awards to employees.

	Grant Year	Shares/ Units	Grant Date Average Fair Value Per Unit/ Share	Total Compensation Cost (in millions) (1)	Weighted Average Period of Expense Recognition (in months)	Unrecognized Compensation Cost (in millions)	Performance Period	Vesting Dates
	2013	195,822	\$ 29.80	\$ 5.8	36	\$ 1.9	N/A	12/31/14 - 12/31/2016
	2014	106,778	29.80	3.2	36	1.1	N/A	12/31/2016
	2015	109,585	40.57	4.4	33	3.2	N/A	12/31/2017
	2015	39,914	40.74	1.6	33	1.2	N/A	12/31/2017
Dividend RSUs	2015	10,644	12.36	0.1	9	-	N/A	12/31/2015
Dividend RSUs	2015	19,825	24.92	0.5	21	0.3	N/A	12/31/2016
Dividend RSUs	2015	7,799	35.08	0.3	33	0.2	N/A	12/31/15-12/31/2017
	2015	23,902	36.26	0.9	5	-	N/A	12/31/2015
Restricted Stock Units Total		514,269	\$ 32.78	\$ 16.8		\$ 7.9		
Restricted Stock and LTIP Units								
Performance Relative TSR (2)	2013	67,885	7.47	0.5	24	-	12/31/2013-12/31/2015	12/31/2015
Performance Relative TSR	2013	101,591	8.67	0.9	36	0.3	12/31/2013-12/31/2016	12/31/2016
	2014	135,634	8.67	1.2	48	0.6	1/1/2014-12/31/2016	Quarterly
7 LTIP Units	2015	137,249	14.66	2.0	45	1.6	1/1/2015-12/31/2017	Quarterly
7 LTIP Units	2015	54,151	14.80	0.8	45	0.6	1/1/2015-12/31/2017	Quarterly
5 Transition TSR	2015	9,484	27.20	0.3	5	-	12/31/2013-12/31/2015	12/31/2015
5 Transition TSR	2015	22,091	18.51	0.4	5	-	12/31/2013-12/31/2016	12/31/2016
7 LTIP Units	2015	5,823	8.78	0.1	5	-	1/1/2015-12/31/2017	12/31/2017
Restricted Stock & LTIP Total		533,908	\$ 11.42	\$ 6.2		\$ 3.1		
Performance Relative PRSUs								
Performance Relative TSR	2013	67,884	13.05	0.9	24	-	12/31/2013-12/31/2015	12/31/2015
Performance Relative TSR	2013	101,588	14.24	1.4	36	0.5	12/31/2013-12/31/2016	12/31/2016
Performance Relative TSR	2014	135,634	14.24	1.9	48	1.0	1/1/2014-12/31/2016	Quarterly
7 Relative TSR	2015	137,249	22.50	3.1	45	2.5	1/1/2015-12/31/2017	Quarterly

Edgar Filing: ROYAL CARIBBEAN CRUISES LTD - Form 10-K

17 Relative TSR	2015	54,151	22.91	1.2	45	1.0	1/1/2015-12/31/2017	Quarterly i
5 Relative TSR	2015	9,484	18.85	0.2	5	-	1/1/2014-12/31/2015	12/31/2015
6 Relative TSR	2015	22,100	19.60	0.4	5	-	1/1/2014-12/31/2016	12/31/2016
7 Relative TSR	2015	5,826	17.74	0.1	5	-	1/1/2015-12/31/2017	12/31/2017
PRSU Total		533,916	\$ 17.44	\$ 9.2		\$ 5.0		
		1,582,093	\$ 20.39	\$ 32.2		\$ 16.0		

(1)

Total compensation costs are net of shares cancelled.

shares/unit information includes 30,872 shares/units that were determined to be forfeited because the performance goal was not achieved.

shares/unit information includes 4,231 shares/units that were determined to be forfeited because the performance goal was not achieved.

shares/unit information includes 67,884 shares/units that were determined to be forfeited because the performance goal was not achieved.

shares/unit information includes 9,484 shares/units that were determined to be forfeited because the performance goal was not achieved.

OMEGA HEALTHCARE INVESTOR

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - C

Stock Options and Tax With

of the Aviv Merger, we assumed approximately 5.7 million Aviv employee stock options that were fully vested prior to the merger. Omega Aviv stock options were converted into Omega stock options at an exchange ratio of 0.9 resulting in issuance of approximately 5.1 million Omega stock options. The intrinsic value of the stock option assumed on April 1, 2015 was approximately \$99.2 million and was recorded as pre-tax expense provided in the merger. For the year ended December 31, 2015, approximately 2.6 million options have been exercised at a weighted average exercise price of \$19.38 per share. At December 31, 2015, approximately 2.5 million options remain outstanding and exercisable. Options outstanding as of December 31, 2015 had a weighted average exercise price of \$19.38. The aggregate intrinsic value of these options is \$39.2 million and represents the total pre-tax intrinsic value (the difference between the Company's closing stock price on the last trading day of 2015 of \$34.98 and the exercise price) for all in-the-money options as of December 31, 2015. Options outstanding have no contractual term limit.

withheld to pay minimum statutory tax withholdings for equity instruments granted under stock-based payment arrangements for the year ended December 31, 2015, 2014 and 2013, was \$26.7 million, \$3.6 million and \$5.8 million, respectively.

Shares Available for Issuance for Compensation

In 2013, at our Company's Annual Meeting, our stockholders approved the 2013 Stock Incentive Plan (the "2013 Plan"), which amended our Company's 2004 Stock Incentive Plan. The 2013 Plan is a comprehensive incentive compensation plan that allows for various types of equity-based compensation, including restricted stock units (including performance-based restricted stock units and LTIP units), stock awards, deferred restricted stock units, incentive stock options, non-qualified stock options, stock appreciation rights, dividend equivalent rights and certain cash-based awards (including performance-based cash awards). The 2013 Plan increased the number of shares reserved for issuance for compensation purposes by 3

As of December 31, 2015, 2,139,785 shares of common stock were reserved for issuance to our employees, directors and consultants under our stock incentive plans. Awards under our stock incentive plans may be in the form of stock, stock options, restricted stock, and performance restricted stock.

Director Restricted Stock

13, 2014 and 2015, we issued 27,958, 21,500 and 30,500 shares of restricted stock to members of our Board of Directors. The fair value was approximately \$0.8 million, \$0.8 million and \$1.1 million, respectively, for 2013, 2014 and 2015. As of December 31, 2015, we had restricted stock outstanding to directors. The directors' restricted shares are scheduled to vest over the next three years. As of December 31, 2015, the unrecognized compensation cost associated with outstanding director restricted stock grants is approximately \$1.4 million.

OMEGA HEALTHCARE INVESTOR

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - C

NOTE 17 - DIV

Common L

y 14, 2016, the Board of Directors declared a common stock dividend of \$0.57 per share, increasing the quarterly common dividend by share over the prior quarter, which was paid February 16, 2016 to common stockholders of record on February

r 14, 2015, the Board of Directors declared a common stock dividend of \$0.56 per share, increasing the quarterly common dividend by share over the previous quarter. The common dividends were paid November 16, 2015 to common stockholders of record on November

2015, the Board of Directors declared a common stock dividend of \$0.55 per share, increasing the quarterly common dividend rate by share over the prior quarter, which was paid on August 17, 2015 to common stockholders of record on July

il 15, 2015, the Board of Directors declared a prorated dividend of \$0.18 per share of Omega's common stock in view of the recently cl The per share dividend amount payable by Omega represents dividends for April 2015, at a quarterly dividend rate of \$0.54 per share of increasing the quarterly common dividend rate by \$0.01 per share over the prior quarter. The \$0.18 dividend was paid in cash on May 15 stockholders of record as of the close of business on April

n 5, 2015, the Board of Directors declared a prorated dividend of \$0.36 per share of Omega's common stock in view of the pending acq ant to the Aviv Merger. The per share dividend amount represented dividends for February and March 2015, at a quarterly dividend rate common stock, increasing the quarterly common dividend rate by \$0.01 per share over the prior quarter. The dividend was paid in cash 7, 2015 to stockholders of record as of the close of business on March

14, 2015, the Board of Directors declared a common stock dividend of \$0.53 per share, increasing the quarterly common dividend rate per share over the prior quarter, which was paid February 16, 2015 to common stockholders of record on February

Per Share Dist

Per share distributions by our Company were characterized in the following manner for income tax purposes (un

	Year Ended December 31,		
	2015	2014	2013
Common			
Ordinary income	\$ 1.133	\$ 1.834	\$ 1.536
Return of capital	1.047	0.186	0.324
Total dividends paid	\$ 2.180	\$ 2.020	\$ 1.860

For additional information regarding dividends, see Note 1

NOTE 18 - LITIG

subject to various legal proceedings, claims and other actions arising out of the normal course of business. While any legal proceeding or
 ment of uncertainty, management believes that the outcome of each lawsuit, claim or legal proceeding that is pending or threatened, or al
 combined, will not have a material adverse effect on our consolidated financial position or results of op

OMEGA HEALTHCARE INVESTOR

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - C

NOTE 19 - SUMMARY OF QUARTERLY RESULTS (UNAU

The following summarizes quarterly results of operations for the years ended December 31, 2015 a

	March 31	June 30	September 30	Decem
	(in thousands, except per share amounts)			
2015				
Revenues	\$133,420	\$197,711	\$ 201,974	\$ 210
Net income	43,052	43,466	83,254	63,
Net income available to common stockholders	43,052	41,428	79,402	60,
Net income available to common per share:				
Basic	\$0.32	\$0.23	\$ 0.43	\$ 0.3
Net income per share:				
Diluted	\$0.32	\$0.22	\$ 0.43	\$ 0.3
Cash dividends paid on common stock	\$0.53	\$0.54	\$ 0.55	\$ 0.5
2014				
Revenues	\$121,001	\$121,800	\$ 130,665	\$ 131
Net income	55,829	46,817	61,713	56,
Net income available to common stockholders	55,829	46,817	61,713	56,
Net income available to common per share:				
Basic	\$0.45	\$0.37	\$ 0.48	\$ 0.4
Net income per share:				
Diluted	\$0.45	\$0.37	\$ 0.48	\$ 0.4
Cash dividends paid on common stock	\$0.49	\$0.50	\$ 0.51	\$ 0.5

OMEGA HEALTHCARE INVESTOR

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - C

NOTE 20 - EARNINGS PER

The following tables set forth the computation of basic and diluted earnings per

	Year Ended December 31,		
	2015	2014	2013
	(in thousands, except per share amounts)		
Numerator:			
Net income	\$ 233,315	\$ 221,349	\$ 173,111
Less: Net income attributable to noncontrolling interests	(8,791)	—	—
Net income available to common stockholders	\$ 224,524	\$ 221,349	\$ 173,111
Denominator:			
Denominator for basic earnings per share	172,242	126,550	111,111
Effect of dilutive securities:			
Common stock equivalents	1,539	744	84
Noncontrolling interest – OP units	6,727	—	—
Denominator for diluted earnings per share	180,508	127,294	111,111
Earnings per share - basic:			
Net income available to common stockholders	\$ 1.30	\$ 1.75	\$ 1.56
Earnings per share - diluted:			
Net income	\$ 1.29	\$ 1.74	\$ 1.54

NOTE 21– CONSOLIDATING FINANCIAL STATEMENTS

As of December 31, 2015, we had outstanding: (i) \$400 million 5.875% Senior Notes due 2024, (ii) \$400 million 4.95% Senior Notes due 2024, (iii) \$400 million 4.5% Senior Notes due 2025, (iv) \$600 million 5.25% Senior Notes due 2026 and (v) \$700 million 4.5% Senior Notes due 2027 (collectively, the “Senior Notes”). The Senior Notes are fully and unconditionally guaranteed, jointly and severally, by each of our 100% owned subsidiaries that are guarantors of Omega or any of the subsidiary guarantors. All of our subsidiaries that guarantee the Senior Notes also guarantee amounts outstanding under the 2014 Credit Facility.

Following summarized condensed consolidating financial information segregates the financial information of the non-guarantor subsidiaries and the financial information of Omega Healthcare Investors, Inc. and the subsidiary guarantors under the Senior Notes. Our non-guarantor subsidiaries include subsidiaries securing secured debt that is currently outstanding and our U.K. subsidiaries. The results and financial position of acquired entities are presented from the dates of their respective acquisitions.

The 2014 financial statements presented below have been adjusted to reflect our current guarantor and non-guarantor relationships as of December 31, 2014.

OMEGA HEALTHCARE INVESTOR

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - C

OMEGA HEALTHCARE INVESTOR

CONSOLIDATING BALANCE

(in thousands, except per share a

	December 31, 2015			
	Issuer & Subsidiary Guarantors	Non – Guarantor Subsidiaries	Elimination	Consolidated
ASSETS				
Real estate properties				
Land and buildings	\$6,152,779	\$ 591,179	\$—	\$ 6,743,958
Less accumulated depreciation	(984,947)	(34,203)	—	(1,019,150)
Real estate properties – net	5,167,832	556,976	—	5,724,808
Investment in direct financing leases	587,701	—	—	587,701
Mortgage notes receivable – net	679,795	—	—	679,795
	6,435,328	556,976	—	6,992,304
Other investments – net	89,299	—	—	89,299
	6,524,627	556,976	—	7,081,603
Assets held for sale – net	6,599	—	—	6,599
Total investments	6,531,226	556,976	—	7,088,202
Cash and cash equivalents	1,592	3,832	—	5,424
Restricted cash	7,068	7,539	—	14,607
Accounts receivable – net	196,107	7,755	—	203,862
Goodwill	630,404	15,279	—	645,683
Investment in affiliates	340,850	—	(340,850)	—
Other assets	54,055	7,176	—	61,231
Total assets	\$7,761,302	\$ 598,557	\$(340,850)	\$ 8,018,959
LIABILITIES AND EQUITY				
Revolving line of credit	\$230,000	\$—	\$—	\$230,000
Term loan	750,000	—	—	750,000
Secured borrowings	—	361,460	(125,256)	236,204
Unsecured borrowings – net	2,352,882	—	—	2,352,882
Accrued expenses and other liabilities	326,815	6,891	—	333,706

Edgar Filing: ROYAL CARIBBEAN CRUISES LTD - Form 10-K

Deferred income taxes	—	15,352	—	15,352
Intercompany payable	740	36,299	(37,039)	—
Total liabilities	3,660,437	420,002	(162,295)	3,918,144
Stockholders' equity:				
Common stock	18,740	—	—	18,740
Equity investment in affiliates	—	156,507	(156,507)	—
Common stock – additional paid-in capital	4,609,474	—	—	4,609,474
Cumulative net earnings	1,372,522	21,971	(21,971)	1,372,522
Cumulative dividends paid	(2,254,038)	—	—	(2,254,038)
Accumulated other comprehensive income (loss)	(8,712)	77	(77)	(8,712)
Total stockholders' equity	3,737,986	178,555	(178,555)	3,737,986
Noncontrolling interest	362,879	—	—	362,879
Total equity	4,100,865	178,555	(178,555)	4,100,865
Total liabilities and equity	\$7,761,302	\$ 598,557	\$ (340,850)	\$8,018,999

OMEGA HEALTHCARE INVESTOR

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - C

OMEGA HEALTHCARE INVESTOR

CONSOLIDATING BALANCE

(in thousands, except per share a

	December 31, 2014			
	Issuer & Subsidiary Guarantors	Non – Guarantor Subsidiaries	Elimination	Consolidated
ASSETS				
Real estate properties				
Land and buildings	\$3,108,597	\$ 115,188	\$ —	\$3,223,785
Less accumulated depreciation	(805,679)	(16,033)	—	(821,712)
Real estate properties – net	2,302,918	99,155	—	2,402,073
Investments in direct financing leases	539,232	—	—	539,232
Mortgage notes receivable	648,079	—	—	648,079
	3,490,229	99,155	—	3,589,384
Other investments	48,952	—	—	48,952
	3,539,181	99,155	—	3,638,336
Assets held for sale – net	12,792	—	—	12,792
Total investments	3,551,973	99,155	—	3,651,128
Cash and cash equivalents	4,489	—	—	4,489
Restricted cash	21,943	7,133	—	29,076
Accounts receivable – net	163,610	4,566	—	168,176
Investment in affiliates	28,687	—	(28,687)	—
Other assets	60,820	7,956	—	68,776
Total assets	\$3,831,522	\$ 118,810	\$ (28,687)	\$3,921,645
LIABILITIES AND EQUITY				
Revolving line of credit	\$85,000	\$ —	\$ —	\$85,000
Term loan	200,000	—	—	200,000
Secured borrowings – net	167,379	84,075	—	251,454
Unsecured borrowings – net	1,842,049	—	—	1,842,049
Accrued expenses and other liabilities	135,767	6,048	—	141,815
Intercompany payable	—	17,096	(17,096)	—

Total liabilities	2,430,195	107,219	(17,096)	2,520,318
Equity:				
Common stock	12,761	—	—	12,761
Common stock – additional paid-in capital	2,136,234	—	—	2,136,234
Cumulative net earnings	1,147,998	11,591	(11,591)	1,147,998
Cumulative dividends paid	(1,895,666)	—	—	(1,895,666)
Total stockholders' equity	1,401,327	11,591	(11,591)	1,401,327
Total liabilities and equity	\$3,831,522	\$ 118,810	\$ (28,687)	\$3,921,645

OMEGA HEALTHCARE INVESTOR

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - C

OMEGA HEALTHCARE INVESTOR

CONSOLIDATING STATEMENT OF OPERATIONS AND COMPREHENSIVE I

(in thousands, except per share a

	Year Ended December 31, 2015			
	Issuer & Subsidiary Guarantors	Non – Guarantor Subsidiaries	Elimination	Consolidated
Revenue				
Rental income	\$560,211	\$ 45,780	\$ -	\$ 605,991
Income from direct financing leases	59,936	-	-	59,936
Mortgage interest income	68,910	-	-	68,910
Other investment income – net	8,780	-	-	8,780
Total operating revenues	697,837	45,780	-	743,617
Expenses				
Depreciation and amortization	192,375	18,328	-	210,703
General and administrative	38,140	428	-	38,568
Acquisition costs	55,012	2,513	-	57,525
Impairment loss on real estate properties	17,681	-	-	17,681
Provisions for uncollectible mortgages, notes and accounts receivable	5,966	1,905	-	7,871
Total operating expenses	309,174	23,174	-	332,348
Income before other income and expense	388,663	22,606	-	411,269
Other income (expense):				
Interest income	269	16	-	285
Interest expense	(134,478)	(12,903)	-	(147,381)
Interest – amortization of deferred financing costs	(6,969)	(21)	-	(7,000)
Interest – refinancing costs	(29,714)	877	-	(28,837)
Realized loss on foreign exchange	(173)	-	-	(173)
Equity in earnings	10,380	-	(10,380)	-
Total other expense	(160,685)	(12,031)	(10,380)	(183,096)
Income before gain on assets sold	227,978	10,575	(10,380)	228,173
Gain on assets sold - net	6,353	-	-	6,353
Income from continuing operations before income taxes	234,331	10,575	(10,380)	234,526

Edgar Filing: ROYAL CARIBBEAN CRUISES LTD - Form 10-K

Income taxes	(1,016)	(195)	-	(1,211)
Net income	233,315	10,380	(10,380)	233,315
Net income attributable to noncontrolling interest	(8,791)	-	-	(8,791)
Net income available to common stockholders	\$224,524	\$ 10,380	\$ (10,380)	\$ 224,524
Net income	\$233,315	\$ 10,380	\$ (10,380)	\$ 233,315
Other comprehensive loss – foreign currency translation	(8,413)	-	-	(8,413)
Other comprehensive loss – cash flow hedges	(718)	-	-	(718)
Total comprehensive income	224,184	10,380	(10,380)	224,184
Add: comprehensive income attributable to noncontrolling interest	419	-	-	419
Comprehensive income attributable to common stockholders	\$224,603	\$ 10,380	\$ (10,380)	\$ 224,603

OMEGA HEALTHCARE INVESTOR

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - C

OMEGA HEALTHCARE INVESTOR

CONSOLIDATING STATEMENT OF OPER

(in thousands, except per share a

	Year Ended December 31, 2014			
	Issuer & Subsidiary Guarantors	Non – Guarantor Subsidiaries	Elimination	Consolidated
Revenue				
Rental income	\$375,279	\$ 13,164	\$ -	\$ 388,443
Income from direct financing leases	56,719	-	-	56,719
Mortgage interest income	53,007	-	-	53,007
Other investment income – net	6,618	-	-	6,618
Total operating revenues	491,623	13,164	-	504,787
Expenses				
Depreciation and amortization	117,976	5,281	-	123,257
General and administrative	25,759	129	-	25,888
Acquisition costs	3,948	-	-	3,948
Impairment loss on real estate properties	3,660	-	-	3,660
Provisions for uncollectible mortgages, notes and accounts receivable	2,723	-	-	2,723
Total operating expenses	154,066	5,410	-	159,476
Income before other income and expense	337,557	7,754	-	345,311
Other income (expense):				
Interest income	29	15	-	44
Interest expense	(116,075)	(3,294)	-	(119,369)
Interest – amortization of deferred financing costs	(4,437)	(22)	-	(4,459)
Interest – refinancing costs	(3,041)	-	-	(3,041)
Equity in earnings	4,453	-	(4,453)	-
Total other expense	(119,071)	(3,301)	(4,453)	(126,825)
Income before gain on assets sold	218,486	4,453	(4,453)	218,486
Gain on assets sold - net	2,863	-	-	2,863
Net income available to common stockholders	\$221,349	\$ 4,453	\$ (4,453)	\$ 221,349

OMEGA HEALTHCARE INVESTOR

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - C

OMEGA HEALTHCARE INVESTOR

CONSOLIDATING STATEMENT OF OPER

(in thousands, except per share a

	Year Ended December 31, 2013			
	Issuer & Subsidiary Guarantors	Non – Guarantor Subsidiaries	Elimination	Consolidated
Revenue				
Rental income	\$ 362,033	\$ 13,102	\$ -	\$ 375,135
Income from direct financing leases	5,203	-	-	5,203
Mortgage interest income	29,351	-	-	29,351
Other investment income – net	9,025	-	-	9,025
Total operating revenues	405,612	13,102	-	418,714
Expenses				
Depreciation and amortization	123,443	5,203	-	128,646
General and administrative	21,466	122	-	21,588
Acquisition costs	245	-	-	245
Impairment loss on real estate properties	415	-	-	415
Provisions for uncollectible mortgages, notes and accounts receivable	2,141	-	-	2,141
Total operating expenses	147,710	5,325	-	153,035
Income before other income and expense	257,902	7,777	-	265,679
Other income (expense):				
Interest income	26	15	-	41
Interest expense	(96,673)	(3,708)	-	(100,381)
Interest – amortization of deferred financing costs	(2,763)	(16)	-	(2,779)
Interest – refinancing gain	11,112	-	-	11,112
Equity in earnings	4,068	-	(4,068)	-
Total other expense	(84,230)	(3,709)	(4,068)	(92,007)
Income before gain (loss) on assets sold	173,672	4,068	(4,068)	173,672
Loss on assets sold - net	(1,151)	-	-	(1,151)
Net income available to common stockholders	\$ 172,521	\$ 4,068	\$ (4,068)	\$ 172,521

OMEGA HEALTHCARE INVESTOR

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - C

OMEGA HEALTHCARE INVESTOR

CONSOLIDATED STATEMENTS OF CASH

(in th

	Year Ended December 31, 2015			
	Issuer & Subsidiary Guarantors	Non-Guarantor Subsidiaries	Elimination	Consolidated
Cash flows from operating activities				
Net income	\$233,315	\$ 10,380	\$ (10,380)	\$233,315
Adjustment to reconcile net income to net cash provided by operating activities:				
Depreciation and amortization	192,375	18,328	—	210,703
Provision for impairment on real estate properties	17,681	—	—	17,681
Provision for uncollectible mortgages, notes and accounts receivable	5,966	1,905	—	7,871
Amortization of deferred financing and refinancing costs	36,683	(856)	—	35,827
Accretion of direct financing leases	(11,007)	—	—	(11,007)
Stock-based compensation	11,133	—	—	11,133
Gain on assets sold – net	(6,353)	—	—	(6,353)
Amortization of acquired in-place leases - net	(13,846)	—	—	(13,846)
Change in operating assets and liabilities – net of amounts assumed/acquired:				
Accounts receivable, net	248	—	—	248
Straight-line rent receivables	(32,815)	(3,242)	—	(36,057)
Lease inducements	994	—	—	994
Effective yield receivable on mortgage notes	(4,065)	—	—	(4,065)
Other operating assets and liabilities	(9,654)	16,715	10,380	17,441
Net cash provided by operating activities	420,655	43,230	—	463,885
Cash flows from investing activities				
Acquisition of real estate – net of liabilities assumed and escrows acquired	(116,698)	(177,484)	—	(294,182)
Cash acquired in merger	84,858	—	—	84,858
Investment in construction in progress	(164,226)	—	—	(164,226)
Investment in U.K. subsidiary	(165,760)	165,760	—	—
Investment in direct financing leases	(6,793)	—	—	(6,793)
Placement of mortgage loans	(14,042)	—	—	(14,042)
Proceeds from sale of real estate investments	41,543	—	—	41,543
Capital improvements to real estate investments	(24,599)	(1,798)	—	(26,397)
Proceeds from other investments	45,871	—	—	45,871
Investments in other investments	(65,402)	—	—	(65,402)

Edgar Filing: ROYAL CARIBBEAN CRUISES LTD - Form 10-K

Collection of mortgage principal	1,359	—	—	1,359
Net cash used in investing activities	(383,889)	(13,522)	—	(397,411)
Cash flows from financing activities				
Proceeds from credit facility borrowings	1,826,000	—	—	1,826,000
Payments on credit facility borrowings	(1,681,000)	—	—	(1,681,000)
Receipts of other long-term borrowings	1,838,124	—	—	1,838,124
Payments of other long-term borrowings	(2,161,661)	(25,653)	—	(2,187,314)
Payments of financing related costs	(54,721)	—	—	(54,721)
Receipts from dividend reinvestment plan	150,847	—	—	150,847
Payments for exercised options and restricted stock – net	(26,706)	—	—	(26,706)
Net proceeds from issuance of common stock	439,322	—	—	439,322
Dividends paid	(358,232)	—	—	(358,232)
Distributions to OP Unit holders	(11,636)	—	—	(11,636)
Net cash used in financing activities	(39,663)	(25,653)	—	(65,316)
(Decrease) increase in cash and cash equivalents	(2,897)	4,055	—	1,158
Effect of foreign currency translation on cash and cash equivalents	—	(223)	—	(223)
Cash and cash equivalents at beginning of period	4,489	—	—	4,489
Cash and cash equivalents at end of period	\$1,592	\$ 3,832	\$ —	\$5,411

OMEGA HEALTHCARE INVESTOR

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - C

OMEGA HEALTHCARE INVESTOR

CONSOLIDATED STATEMENTS OF CASH

(in th

	Year Ended December 31, 2014			
	Issuer & Subsidiary Guarantors	Non-Guarantor Subsidiaries	Elimination	Consolidated
Cash flows from operating activities				
Net income	\$221,349	\$ 4,453	\$ (4,453)	\$221,349
Adjustment to reconcile net income to net cash provided by operating activities:				
Depreciation and amortization	117,976	5,281	—	123,257
Provision for impairment on real estate properties	3,660	—	—	3,660
Provision for uncollectible mortgages, notes and accounts receivable	2,723	—	—	2,723
Amortization of deferred financing and refinancing costs	7,479	21	—	7,500
Accretion of direct financing leases	(9,787)	—	—	(9,787)
Stock-based compensation	8,592	—	—	8,592
Gain on assets sold – net	(2,863)	—	—	(2,863)
Amortization of acquired in-place leases - net	(4,986)	—	—	(4,986)
Change in operating assets and liabilities – net of amounts assumed/acquired:				
Accounts receivable, net	(2,264)	—	—	(2,264)
Straight-line rent receivables	(19,750)	(1,206)	—	(20,956)
Lease inducements	2,656	—	—	2,656
Effective yield receivable on mortgage notes	(2,878)	—	—	(2,878)
Other operating assets and liabilities	11,432	(4,348)	4,453	11,537
Net cash provided by operating activities	333,339	4,201	—	337,540
Cash flows from investing activities				
Acquisition of real estate – net of liabilities assumed and escrows acquired	(131,689)	—	—	(131,689)
Placement of mortgage loans	(529,548)	—	—	(529,548)
Proceeds from sale of real estate investments	4,077	—	—	4,077
Capital improvements to real estate investments	(15,526)	(2,391)	—	(17,917)
Proceeds from other investments	13,589	—	—	13,589
Investments in other investments	(9,441)	—	—	(9,441)
Collection of mortgage principal	122,984	—	—	122,984
Net cash used in investing activities	(545,554)	(2,391)	—	(547,945)
Cash flows from financing activities				
Proceeds from credit facility borrowings	900,000	—	—	900,000

Edgar Filing: ROYAL CARIBBEAN CRUISES LTD - Form 10-K

Payments on credit facility borrowings	(1,141,000)	—	—	(1,141,000)
Receipts of other long-term borrowings	842,148	—	—	842,148
Payments of other long-term borrowings	(240,734)	(1,810)	—	(242,544)
Payments of financing related costs	(17,716)	—	—	(17,716)
Receipts from dividend reinvestment plan	71,487	—	—	71,487
Payments for exercised options and restricted stock – net	(3,577)	—	—	(3,577)
Net proceeds from issuance of common stock	61,981	—	—	61,981
Dividends paid	(258,501)	—	—	(258,501)
Net cash provided by (used in) financing activities	214,088	(1,810)	—	212,278
Increase in cash and cash equivalents	1,873	—	—	1,873
Cash and cash equivalents at beginning of period	2,616	—	—	2,616
Cash and cash equivalents at end of period	\$4,489	\$ —	\$ —	\$4,489

OMEGA HEALTHCARE INVESTOR

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - C

OMEGA HEALTHCARE INVESTOR

CONSOLIDATED STATEMENTS OF CASH

(in th

	Year Ended December 31, 2013			
	Issuer & Subsidiary Guarantors	Non-Guarantor Subsidiaries	Elimination	Consolidated
Cash flows from operating activities				
Net income	\$ 172,521	\$ 4,068	\$ (4,068)	\$ 172,521
Adjustment to reconcile net income to net cash provided by operating activities:				
Depreciation and amortization	123,443	5,203	—	128,646
Provision for impairment on real estate properties	415	—	—	415
Provision for uncollectible mortgages, notes and accounts receivable	2,141	—	—	2,141
Amortization of deferred financing and refinancing costs	(8,349)	16	—	(8,333)
Accretion of direct financing leases	(770)	—	—	(770)
Stock-based compensation	5,942	—	—	5,942
Loss on assets sold – net	1,151	—	—	1,151
Amortization of acquired in-place leases - net	(5,083)	—	—	(5,083)
Change in operating assets and liabilities – net of amounts assumed/acquired:				
Accounts receivable, net	867	—	—	867
Straight-line rent receivables	(25,402)	(1,497)	—	(26,899)
Lease inducements	3,080	—	—	3,080
Effective yield receivable on mortgage notes	(1,757)	—	—	(1,757)
Other operating assets and liabilities	10,854	(6,894)	4,068	8,028
Net cash provided by operating activities	279,053	896	—	279,949
Cash flows from investing activities				
Acquisition of real estate – net of liabilities assumed and escrows acquired	(32,515)	—	—	(32,515)
Investment in direct financing leases	(528,675)	—	—	(528,675)
Placement of mortgage loans	(3,378)	—	—	(3,378)
Proceeds from sale of real estate investments	2,292	—	—	2,292
Capital improvements to real estate investments	(31,347)	—	—	(31,347)
Proceeds from other investments	30,962	—	—	30,962
Investments in other investments	(36,655)	—	—	(36,655)
Collection of mortgage principal	485	—	—	485
Net cash used in investing activities	(598,831)	—	—	(598,831)
Cash flows from financing activities				

Edgar Filing: ROYAL CARIBBEAN CRUISES LTD - Form 10-K

Proceeds from credit facility borrowings	511,000	—	—	511,000
Payments on credit facility borrowings	(343,000)	—	—	(343,000)
Receipts of other long-term borrowings	159,355	—	—	159,355
Payments of other long-term borrowings	(113,746)	(896))	(114,642)
Payments of financing related costs	(3,234)	—	—	(3,234)
Receipts from dividend reinvestment plan	55,825	—	—	55,825
Payments for exercised options and restricted stock – net	(5,774)	—	—	(5,774)
Net proceeds from issuance of common stock	278,373	—	—	278,373
Dividends paid	(218,116)	—	—	(218,116)
Net cash provided by (used in) financing activities	320,683	(896))	319,787
Increase in cash and cash equivalents	905	—	—	905
Cash and cash equivalents at beginning of period	1,711	—	—	1,711
Cash and cash equivalents at end of period	\$2,616	\$ —	\$ —	\$2,616

OMEGA HEALTHCARE INVESTOR

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - C

NOTE 22- SUBSEQUENT

January 29, 2016, we entered into a Third Amendment to Credit Agreement (the “Third Amendment to Omega Credit Agreement”), which amended the First Amendment to Omega Credit Agreement to provide, among other things, for a \$350 million senior unsecured incremental term loan facility (the “Tranche A-3 Term Loan Facility,” and together with the Tranche A-1 Term Loan Facility and the Tranche A-2 Term Loan Facility, the “Tranche A-1, A-2 and A-3 Term Loan Facilities”), which was borrowed in full at closing. The Tranche A-3 Term Loan Facility matures on January 29, 2021. The proceeds of the Tranche A-3 Term Loan Facility were used to pay down the Revolving Credit Facility and for general corporate purposes. The Tranche A-3 Term Loan Facility bears interest at a rate equal to LIBOR plus an applicable percentage (beginning at 150 basis points, with a range of 100 to 195 basis points) based on our ratings from Standard & Poor’s and/or Fitch Ratings. The Third Amendment to Omega Credit Agreement also permits us, subject to compliance with customary conditions, to increase the amount of the Revolving Credit Facility or to add one or more tranches of incremental term loans, or both, by an aggregate principal amount not to exceed \$250 million.

February 1, 2016, we acquired 10 SNFs from Laurel for approximately \$169.0 million in cash and leased them to an unrelated existing operator. Immediately following our acquisition, the unrelated existing operator acquired all of the outstanding equity interests of Laurel, including the interests previously held by a director of the Company and his family. The director, together with certain members of his immediate family, beneficially owned approximately 34% of the equity of Laurel prior to the transaction. The SNFs, consisting of 985 operating beds are located in Ohio (6), Virginia (2) and West Virginia (1). The new master lease has an initial annual cash yield of 8.5% and annual escalators of 2.0% and is cross defaulted to the operator’s other master lease agreements.

OMEGA HEALTHCARE INVESTOR

SCHEDULE III REAL ESTATE AND ACCUMULATED DEPRECIATION

OMEGA HEALTHCARE INVESTOR

December 31, 2015

Initial Cost to Company Buildings and Land Improvements	Cost Capitalized			(3) Gross Amount at Which Carried at Close of Period Buildings and Land Improvements Total	(4) Accumulated Depreciation	Date of Construction	Date Acquired	Life on Which Depreciation in Latest Income Statement is Computed
	Subsequent to Acquisition	Improvements	Impairment Other					
\$238,354,341	\$1,800,767	\$-	\$-	\$240,155,108	\$4,620,737	1968-2015	2015	40 years
89,889,681	23,799,252	-	-	113,688,933	1,583,999	1988-1994	2015	30 years to
-	116,423,931	-	-	116,423,931	-	-	2015	-
11,863,638	12,115,202	-	-	23,978,840	193,134	1999	2015	40 years
340,107,660	154,139,152	-	-	494,246,812	6,397,870			
341,097,695	5,534,280	-	-	346,631,975	14,909,229	1955-2015	2010-2015	20 years to
16,599,859	-	-	-	16,599,859	591,701	1967-1992	2015	26 years to
357,697,554	5,534,280	-	-	363,231,834	15,500,930			
23,584,956	6,523,220	-	-	30,108,176	16,153,134	1964-1974	1997	33 years
15,618,263	26,652	-	-	15,644,915	8,181,493	1927-1972	1997	33 years
38,341,877	5,444,311	-	-	43,786,188	12,219,868	1963-1975	2006	39 years
19,491,960	974,012	-	-	20,465,972	5,550,009	1920-1987	1997-2015	20 years to

Edgar Filing: ROYAL CARIBBEAN CRUISES LTD - Form 10-K

71,446,102	2,660,093	(8,257,521)	-	65,848,674	21,355,093	1866-1993	1997-2015	20 years to
21,619,503	1,462,797	-	-	23,082,300	7,819,421	1963-1999	1998-2006	33 years to
22,652,488	3,550,986	-	-	26,203,474	16,264,936	1964-1986	1994-1997	30 years to
11,653,451	20,246	-	-	11,673,697	6,217,229	1968-1983	1997	33 years
38,740,812	4,792,882	-	-	43,533,694	14,693,658	1965-1981	2006	25 years to
7,905,139	2,537,508	-	-	10,442,647	6,268,623	1984-1985	1994	30 years
6,322,888	602,296	-	-	6,925,184	2,237,449	1971	2004	39 years
10,000,000	1,798,844	-	-	11,798,844	11,034,888	1965	1995	20 years
44,277,206	6,528,560	-	-	50,805,766	23,068,927	1961-1986	1997-2008	25 years to
331,654,645	36,922,407	(8,257,521)	-	360,319,531	151,064,728			
11,588,534	6,392,567	-	-	17,981,101	12,588,052	1960-1982	1992	31.5 years
133,762,829	5,712,049	(6,603,745)	-	132,871,133	21,508,043	1949-1999	1998-2015	20 years to
201,572,337	13,169,759	(36,350)	-	214,705,746	48,640,738	1960-2009	1992-2015	20 years to
490,902,316	3,492,869	-	-	494,395,185	33,730,723	1938-2013	1997-2015	20 years to
33,527,071	2,346,167	-	-	35,873,238	13,344,365	1958-1973	1998-2011	20 years to
5,324,200	980,393	(5,425,656)	-	878,937	-	1965	1999	N/A
667,833,234	23,362,442	(6,951,897)	(2,784,718)	681,459,061	174,698,077	1925-2009	1992-2015	20 years to
43,096,820	3,950,028	-	-	47,046,848	11,480,058	1964-1998	1998-2015	20 years to years
50,889,041	341,170	-	-	51,230,211	4,238,429	1911-2008	1999-2015	20 years to
118,108,747	510,576	-	-	118,619,323	10,750,250	1926-1990	1996-2015	20 years to
402,853,211	2,332,364	(3,419,264)	(2,296,391)	399,469,920	61,998,182	1923-2008	1992-2015	20 years to
70,549,074	2,084,807	-	-	72,633,881	10,408,588	1961-1998	1997-2015	20 years to
53,836,542	3,453,770	-	-	57,290,312	2,930,226	1957-1985	2010-2015	20 years to
174,052,192	10,314,747	-	-	184,366,939	31,640,307	1917-2002	1994-2015	20 years to
55,046,915	1,748,900	-	-	56,795,815	16,408,775	1957-1983	1997-2006	33 years to
77,361,184	1,787,838	-	-	79,149,022	17,002,780	1921-1985	2010-2011	25 years to
5,804,554	-	-	-	5,804,554	2,015,500	1964	2009	20 years
168,554,079	25,000	-	-	168,579,079	9,134,074	1964-1997	2011-2015	25 years to

Edgar Filing: ROYAL CARIBBEAN CRUISES LTD - Form 10-K

61,256,047	160,912	-	-	61,416,959	1,696,595	1958-1983	2015	25 years to
52,416,905	826,654	-	-	53,243,559	12,492,706	1962-1988	2009-2010	20 years to
130,105,483	518,236	(149,386)	(3,189)	130,471,144	9,968,625	1955-1994	1999-2015	20 years to
12,922,122	-	-	-	12,922,122	365,003	1963-1971	2015	28 years to
24,713,411	-	-	-	24,713,411	833,206	1963-1969	2015	20 years to
56,460,311	6,520,453	-	-	62,980,764	7,138,584	1972-2004	2009-2015	26 years to
77,417,687	130,323	-	-	77,548,010	4,505,927	1960-1989	2008-2015	20 years to
102,450,560	-	-	-	102,450,560	10,067,103	1927-1992	2010-2015	25 years to
714,157,279	39,057,863	-	(540,000)	752,675,142	126,494,171	1920-2008	1994-2015	20 years to
45,178,160	-	-	-	45,178,160	6,495,153	1965-2013	2010-2015	20 years to
50,133,027	-	-	-	50,133,027	1,355,373	1959-2004	2014-2015	20 years to
351,858,552	11,281,116	-	-	363,139,668	60,983,104	1873-2012	1998-2015	20 years to
57,482,493	-	-	-	57,482,493	3,000,884	1959-1990	2014-2015	20 years to
98,233,849	8,046,100	-	-	106,279,949	35,719,553	1958-1983	1992-2015	20 years to
348,007,669	15,500,178	(2,079,893)	(1,820,356)	359,607,598	55,453,711	1952-2014	1997-2015	20 years to
177,484,058	-	-	(7,784,463)	169,699,595	3,639,903	1750-2000	2015	30 years
3,620,000	-	-	-	3,620,000	124,908	1977	2015	24 years
32,642,987	-	-	-	32,642,987	550,145	1995	2015	35 years to
152,778,525	65,607	-	-	152,844,132	6,493,557	1930-2004	1999-2015	20 years to
24,641,423	348,642	-	-	24,990,065	6,690,397	1961-1996	1994-2011	33 years to
60,601,506	2,369,865	-	(1,500)	62,969,871	9,600,375	1930-1994	2009-2015	20 years to
5,399,224,934	166,831,395	(24,666,191)	(15,230,617)	5,526,159,521	846,186,150			
\$6,428,684,793	\$363,427,234	\$(32,923,712)	\$(15,230,617)	\$6,743,957,698	\$1,019,149,678			

Real estate included in this schedule is being used in either the operation of skilled nursing facilities (SNF), assisted living facilities (AL), independent living facilities (ILF), traumatic brain injury (TBI), medical office building (MOB) or specialty hospitals (SH) located in the states in

(2) Certain of the real estate indicated are security for the HUD loan borrowings totaling \$56,204,170 at December 31, 2015.

(3)	Year Ended December 31,		
	2013	2014	2015
Balance at beginning of period	\$3,038,552,898	\$3,099,547,182	\$3,223,711,991
Acquisitions	35,529,419	131,689,483	3,371,911
Impairment	(414,687)	(3,660,381)	(12,911,911)
Improvements	31,346,919	17,916,855	220,271,911
Disposals/other	(5,467,367)	(21,707,844)	(58,411,911)
Balance at close of period	\$3,099,547,182	\$3,223,785,295	\$6,743,711,991

(4)	Year Ended December 31,		
	2013	2014	2015
Balance at beginning of period	\$580,373,211	\$707,409,888	\$821,711,991
Provisions for depreciation	128,523,788	123,141,880	210,551,911
Dispositions/other	(1,487,111)	(8,839,777)	(13,111,911)
Balance at close of period	\$707,409,888	\$821,711,991	\$1,019,151,991

5) The reported amount of our real estate at December 31, 2015 is greater than the tax basis of the real estate by approximately \$1.1 billion.

OMEGA HEALTHCARE INVESTOR

SCHEDULE IV MORTGAGE LOANS ON REAL ESTATE

OMEGA HEALTHCARE INVESTOR

December 31, 2023

Description (1)	Interest Rate	Final Maturity Date	Periodic Payment Terms	Prior Liens	Face Amount of Mortgages	Carrying Amount	Pr
						of Mortgages (2)	
						(3)	to De
							Pr
							or In
Florida (3 SNF facilities)	11.04	% 2030	Interest payable monthly	None	\$ 15,900,000	\$ 15,780,156	
Louisiana (1 AL facility)	8.75	% 2018	Interest payable monthly	None	2,939,312	2,939,312	
Maryland (7 SNF facilities)	11.00	% 2023	Interest payable monthly	None	74,927,751	69,927,759	
Maryland (1 SNF facility)	12.00	% 2046	Interest payable monthly	None	10,000,000	10,000,000	
Maryland (1 SNF facility)	12.00	% 2046	Interest payable monthly	None	9,500,000	9,500,000	
Maryland (1 SNF facility)	12.00	% 2046	Interest payable monthly	None	5,500,000	5,500,000	
Michigan (31 SNF facilities)	9.23	% 2029	Interest plus \$96,000 of principal payable monthly	None	415,000,000	413,399,042	
Michigan (1 SNF facility)	10.51	% 2021	Interest payable monthly	None	3,382,260	3,382,260	
Michigan (1 SNF facility)	10.00	% 2029	Interest payable monthly	None	692,446	692,446	
Michigan (1 SNF facility)	10.00	% 2029	Interest payable monthly	None	439,925	439,925	
Michigan (1 SNF facility)	10.25	% 2021	Interest payable monthly	None	3,521,113	3,521,113	
Michigan (1 SNF facility)	10.00	% 2029	Interest payable monthly	None	175,900	175,900	
Michigan (1 SNF facility)	10.00	% 2029	Interest payable monthly	None	49,008	49,008	
Michigan (1 SNF facility)	10.00	% 2029	Interest payable monthly	None	66,087	66,087	
Michigan (1 SNF facility)	10.00	% 2029	Interest payable monthly	None	674,541	674,541	
Michigan (1 SNF facility)	10.00	% 2029	Interest payable monthly	None	384,343	384,343	
Michigan (1 SNF facility)	12.00	% 2046	Interest payable monthly	None	1,500,000	1,500,000	
Missouri (1 SNF facility)			Interest plus \$8,800 of principal payable monthly	None	6,997,610	6,445,399	
and Tennessee (1 SNF facility)	8.35	% 2015					
Ohio (2 SNF facilities)	9.64	% 2024	Interest payable monthly	None	112,500,000	112,500,000	
and Pennsylvania (5 SNF facilities)							

and 2 AL facilities)

Ohio (1 SNF facility)	12.00	% 2022	Interest plus \$2,400 of principal payable monthly	None	6,112,406	6,023,197
	12.00	% 2022	Interest payable monthly	None	345,011	345,011
	12.00	% 2022	Interest payable monthly	None	796,397	796,397
	12.00	% 2022	Interest payable monthly	None	112,100	112,100
	12.00	% 2022	Interest payable monthly	None	194,806	194,806
Ohio (1 SNF facility)	11.42	% 2018	Interest payable monthly	None	11,874,013	12,508,966
South Carolina (1 AL facility)	8.75	% 2018	Interest payable monthly	None	1,134,935	1,134,935
Virginia (1 AL facility)	8.75	% 2018	Interest payable monthly	None	1,802,533	1,802,533
					\$ 686,522,497	\$ 679,795,236

loans included in this schedule represent first mortgages on facilities used in the delivery of long-term healthcare of which such facilities are located in the states indicated.

(2) The aggregate cost for federal income tax purposes is equal to the carrying amount.

(3)	Year Ended December 31,		
	2013	2014	2015
Balance at beginning of period	\$238,621,161	\$241,514,812	\$648,078,550
Additions during period - Placements	3,378,357	529,547,836	33,200,000
Deductions during period - collection of principal/other	(484,706)	(122,984,098)	(1,500,000)
Balance at close of period	\$241,514,812	\$648,078,550	\$679,795,236

Supplemental Indenture, dated as of November 25, 2014, among Omega Healthcare Investors, Inc., each of the subsidiary guarantors listed therein and U.S. Bank National Association, as trustee, related to the 5.875% Senior Notes due 2024, including the Form of 5.875% Senior Notes and Form of Subsidiary Guarantee related thereto and that certain Tenth Supplemental Indenture, dated as of January 23, 2015, among Omega Healthcare Investors, Inc., each of the subsidiary guarantors listed therein and U.S. Bank National Association, as trustee, related to the 5.875% Senior Notes due 2024, including the Form of 5.875% Senior Notes and Form of Subsidiary Guarantee related thereto (Incorporated by reference to Exhibit 4.1E to the Company's Annual Report on Form 10-K, filed on February 27, 2015).

Eleventh Supplemental Indenture, dated effective as of March 2, 2015, among Omega Healthcare Investors, Inc., each of the subsidiary guarantors listed therein and U.S. Bank National Association, as trustee, related to the 5.875% Senior Notes due 2024, including the Form of 5.875% Senior Notes and Form of Subsidiary Guarantee related thereto (Incorporated by reference to Exhibit 4.2B to the Company's Quarterly Report on Form 10-Q, filed on March 2, 2015).

Twelfth Supplemental Indenture, dated as of April 1, 2015, among Omega Healthcare Investors, Inc., each of the subsidiary guarantors listed therein and U.S. Bank National Association, as trustee, related to the 5.875% Senior Notes due 2024, including the Form of 5.875% Senior Notes and Form of Subsidiary Guarantee related thereto (Incorporated by reference to Exhibit 4.2C to the Company's Quarterly Report on Form 10-Q, filed on March 2, 2015).

Thirteenth Supplemental Indenture, dated as of August 4, 2015, among Omega Healthcare Investors, Inc., each of the subsidiary guarantors listed therein and U.S. Bank National Association, as trustee, related to the 5.875% Senior Notes due 2024, including the Form of 5.875% Senior Notes and Form of Subsidiary Guarantee related thereto (Incorporated by reference to Exhibit 4.2 to the Company's Quarterly Report on Form 10-Q, filed on August 4, 2015).

Fourteenth Supplemental Indenture, dated as of November 9, 2015, among Omega Healthcare Investors, Inc., each of the subsidiary guarantors listed therein and U.S. Bank National Association, as trustee, related to the 5.875% Senior Notes due 2024, including the Form of 5.875% Senior Notes and Form of Subsidiary Guarantee related thereto.*

Fifteenth Supplemental Indenture, dated as of March 11, 2014, by and among Omega, the guarantors named therein, and U.S. Bank National Association, as trustee related to the 4.950% Senior Notes due 2024, including the Form of 4.950% Senior Notes and Form of Subsidiary Guarantee related thereto. (Incorporated by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K, filed on March 11, 2014).

Sixteenth Supplemental Indenture, dated as of June 27, 2014, among Omega Healthcare Investors, Inc., each of the subsidiary guarantors listed therein and U.S. Bank National Association, as trustee, related to the 4.950% Senior Notes due 2024, including the Form of 4.950% Senior Notes and Form of Subsidiary Guarantee related thereto (Incorporated by reference to Exhibit 4.4 to the Company's Quarterly Report on Form 10-Q, filed on August 4, 2015).

Seventeenth Supplemental Indenture, dated as of November 25, 2014, among Omega Healthcare Investors, Inc., each of the subsidiary guarantors listed therein and U.S. Bank National Association, as trustee, related to the 4.950% Senior Notes due 2024, including the Form of 4.950% Senior Notes and Form of Subsidiary Guarantee related thereto and that certain Third Supplemental Indenture, dated as of January 23, 2015, among Omega Healthcare Investors, Inc., each of the subsidiary guarantors listed therein and U.S. Bank National Association, as trustee, related to the 4.950% Senior Notes due 2024, including the Form of 4.950% Senior Notes and Form of Subsidiary Guarantee related thereto (Incorporated by reference to Exhibit 4.4E to the Company's Annual Report on Form 10-K, filed on February 27, 2015).

Eighteenth Supplemental Indenture, dated effective as of March 2, 2015, among Omega Healthcare Investors, Inc., each of the subsidiary guarantors listed therein and U.S. Bank National Association, as trustee, related to the 4.950% Senior Notes due 2024, including the Form of 4.950% Senior Notes and Form of Subsidiary Guarantee related thereto (Incorporated by reference to Exhibit 4.3B to the Company's Quarterly Report on Form 10-Q, filed on March 2, 2015).

Nineteenth Supplemental Indenture, dated as of April 1, 2015, among Omega Healthcare Investors, Inc., each of the subsidiary guarantors listed therein and U.S. Bank National Association, as trustee, related to the 4.950% Senior Notes due 2024, including the Form of 4.950% Senior Notes and Form of Subsidiary Guarantee related thereto (Incorporated by reference to Exhibit 4.3C to the Company's Quarterly Report on Form 10-Q, filed on March 2, 2015).

Twentieth Supplemental Indenture, dated as of August 4, 2015, among Omega Healthcare Investors, Inc., each of the subsidiary guarantors listed therein and U.S. Bank National Association, as trustee, related to the 4.950% Senior Notes due 2024, including the Form of 4.950% Senior Notes and Form of Subsidiary Guarantee related thereto (Incorporated by reference to Exhibit 4.3 to the Company's Quarterly Report on Form 10-Q, filed on November 9, 2015).

Supplemental Indenture, dated as of November 9, 2015, among Omega Healthcare Investors, Inc., each of the subsidiary guarantors listed therein and U.S. Bank National Association, as trustee, related to the 4.950% Senior Notes due 2024, including the Form of 4.950% Senior Notes and Form of Subsidiary Guarantee related thereto.*

Supplemental Indenture, dated as of September 11, 2014, by and among Omega, the subsidiary guarantors named therein, and U.S. Bank National Association, as trustee, related to the 4.50% Senior Notes due 2025, including the Form of 4.50% Senior Notes and Form of Subsidiary Guarantee related thereto (Incorporated by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K, filed on September 11, 2014).

Supplemental Indenture, dated as of November 25, 2014, among Omega Healthcare Investors, Inc., each of the subsidiary guarantors listed therein and U.S. Bank National Association, as trustee, related to the 4.50% Senior Notes due 2024, including the Form of 4.50% Senior Notes and Form of Subsidiary Guarantee related thereto and that certain Second Supplemental Indenture, dated as of January 23, 2015, among Omega Healthcare Investors, Inc., each of the subsidiary guarantors listed therein and U.S. Bank National Association, as trustee, related to the 4.50% Senior Notes due 2024, including the Form of 4.50% Senior Notes and Form of Subsidiary Guarantee related thereto (Incorporated by reference to Exhibit 4.5A to the Company's Annual Report on Form 10-K, filed on February 27, 2015).

Supplemental Indenture, dated effective as of March 2, 2015, among Omega Healthcare Investors, Inc., each of the subsidiary guarantors listed therein and U.S. Bank National Association, as trustee, related to the 4.50% Senior Notes due 2025, including the Form of 4.50% Senior Notes and Form of Subsidiary Guarantee related thereto (Incorporated by reference to Exhibit 4.2B to the Company's Registration Statement on Form S-4, filed on March 6, 2015).

Supplemental Indenture, dated as of April 1, 2015, among Omega Healthcare Investors, Inc., each of the subsidiary guarantors listed therein and U.S. Bank National Association, as trustee, related to the 4.50% Senior Notes due 2025, including the Form of 4.50% Senior Notes and Form of Subsidiary Guarantee related thereto (Incorporated by reference to Exhibit 4.2B to the Company's Registration Statement on Form S-4, filed on April 1, 2015).

Supplemental Indenture, dated as of August 4, 2015, among Omega Healthcare Investors, Inc., each of the subsidiary guarantors listed therein and U.S. Bank National Association, as trustee, related to the 4.50% Senior Notes due 2025, including the Form of 4.50% Senior Notes and Form of Subsidiary Guarantee related thereto (Incorporated by reference to Exhibit 4.4 to the Company's Quarterly Report on Form 10-Q, filed on November 10, 2015).

Supplemental Indenture, dated as of November 9, 2015, among Omega Healthcare Investors, Inc., each of the subsidiary guarantors listed therein and U.S. Bank National Association, as trustee, related to the 4.50% Senior Notes due 2025, including the Form of 4.50% Senior Notes and Form of Subsidiary Guarantee related thereto.*

Supplemental Indenture, dated as of March 18, 2015, by and among Omega Healthcare Investors, Inc., the subsidiary guarantors named therein and U.S. Bank National Association, as trustee, related to the 4.500% Senior Notes due 2027, including the Form of 4.500% Senior Notes and Form of Subsidiary Guarantee related thereto (Incorporated by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K, filed on March 24, 2015).

Supplemental Indenture, dated as of April 1, 2015, among Omega Healthcare Investors, Inc., each of the subsidiary guarantors listed therein and U.S. Bank National Association, as trustee, related to the 4.500% Senior Notes due 2027, including the Form of 4.500% Senior Notes and Form of Subsidiary Guarantee related thereto (Incorporated by reference to Exhibit 4.5A to the Company's Quarterly Report on Form 10-Q, filed on March 10, 2015).

Supplemental Indenture, dated as of August 4, 2015, among Omega Healthcare Investors, Inc., each of the subsidiary guarantors listed therein and U.S. Bank National Association, as trustee, related to the 4.500% Senior Notes due 2027, including the Form of 4.500% Senior Notes and Form of Subsidiary Guarantee related thereto (incorporated by reference to Exhibit 4.2A to Omega's Registration Statement on Form S-4 filed on October 1, 2015).

Supplemental Indenture, dated as of November 9, 2015, among Omega Healthcare Investors, Inc., each of the subsidiary guarantors listed therein and U.S. Bank National Association, as trustee, related to the 4.500% Senior Notes due 2027, including the Form of 4.500% Senior Notes and Form of Subsidiary Guarantee related thereto. (incorporated by reference to Exhibit 4.2B to the Amendment to Omega's Registration Statement on Form 10-K, filed on November 10, 2015).

Supplemental Indenture, dated as of September 23, 2015 by and among Omega, the subsidiary guarantors named therein, and U.S. Bank National Association, as trustee, related to the 4.500% Senior Notes due 2027, including the Form of 4.500% Senior Notes and Form of Subsidiary Guarantee related thereto (incorporated by reference to Exhibit 4.1 to Omega's Current Report on Form 8-K, filed with SEC on September 29, 2015).

Supplemental Indenture, dated as of November 9, 2015, among Omega Healthcare Investors, Inc., each of the subsidiary guarantors listed therein, U.S. Bank National Association, as trustee, related to the 5.250% Senior Notes due 2026, including the Form of 5.250% Senior Notes and the Subsidiary Guarantee related thereto (Incorporated by reference to Exhibit 4.1A to the Company's Registration Statement on Form S-4, filed November 12, 2015).

of Directors and Officers Indemnification Agreement. (Incorporated by reference to Exhibit 10.11 to the Company's Quarterly Report on Form 10-Q, filed on August 14, 2000).

of Officers' Multi-Year Performance Restricted Stock Unit Award for 2011 to 2014 (Incorporated by reference to Exhibit 10.12 of the Company's Annual Report on Form 10-K, filed on February 27, 2012).+

ded and Restated Deferred Stock Plan, dated October 16, 2012, and forms of related agreements (Incorporated by reference to Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q, filed November 7, 2012).

Agreement, dated as of June 27, 2014, among Omega Healthcare Investors, Inc., certain subsidiaries of Omega Healthcare Investors, Inc. identified therein as guarantors, the lenders named therein and Bank of America, N.A., as administrative agent for such lenders. (Incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K, filed July 2, 2014).

Amendment dated April 1, 2015 to the Credit Agreement dated June 27, 2014 by and between Omega Healthcare Investors Inc., the subsidiary guarantors listed therein, a syndicate of financial institutions, as Lenders, and Bank of America, N.A., as Administrative Agent (Incorporated by reference to Exhibit 10.12 to the Company's Current Report on Form 8-K, filed on April 3, 2015).

nd Amendment to Credit Agreement, dated as of August 7, 2015, among Omega Healthcare Investors, Inc., certain subsidiaries of Omega Healthcare Investors, Inc. identified therein as guarantors, the lenders named therein and Bank of America, N.A., as administrative agent for such lenders (Incorporated by reference to Exhibit 10.2 to the Company's Current Report on Form 8-K, filed December 22, 2015).

Amendment to Credit Agreement, dated as of January 29, 2016, among Omega Healthcare Investors, Inc., certain subsidiaries of Omega Healthcare Investors, Inc. identified therein as guarantors, the lenders named therein and Bank of America, N.A., as administrative agent for such lenders (Incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K, filed February 3, 2016).

Agreement, dated as of December 16, 2015, among Omega Healthcare Investors, Inc., certain subsidiaries of Omega Healthcare Investors, Inc. identified therein as guarantors, the lenders named therein and The Bank of Tokyo-Mitsubishi UFJ, Ltd., as administrative agent for such lenders (Incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K, filed December 22, 2015).

nd Amended and Restated Agreement of Limited Partnership by and among Omega Healthcare Investors, Inc., OHI Healthcare Properties Limited Partnership, Inc., and Aviv Healthcare Properties Limited Partnership (Incorporated by reference to Exhibit 10.11 to the Company's Current Report on Form 8-K, filed on April 3, 2015).

Agreement dated as of April 1, 2015, by and between OHI Healthcare Properties Limited Partnership, each of the subsidiary guarantors listed therein, a syndicate of financial institutions as listed therein as Lenders, and Bank of America, N.A., as Administrative Agent (Incorporated by reference to Exhibit 10.13 to the Company's Current Report on Form 8-K, filed on April 3, 2015).

Amendment to Credit Agreement, dated as of August 7, 2015, among Omega Healthcare Properties Limited Partnership, certain subsidiaries of Omega Healthcare Properties Limited Partnership identified therein as guarantors, the lenders named therein and Bank of America, N.A., as administrative agent for such lenders (Incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K, filed January 3, 2016).

of Equity Distribution Agreement dated September 3, 2015, entered into by and between Omega Healthcare Investors, Inc. and each of the following financial institutions: BB&T Securities, LLC, Capital One Securities, Inc., Credit Agricole Securities (USA) Inc., J.P. Morgan Securities LLC, Merrill Lynch, Pierce, Fenner & Smith Incorporated, Mitsubishi UFJ Securities (USA), Inc., Morgan Stanley & Co. LLC, RBC Capital Markets, LLC, Stifel, Nicolaus & Company, Incorporated, SunTrust Robinson Humphrey, Inc. and Wells Fargo Securities, LLC (incorporated by reference to Exhibit 1.1 to Omega's Current Report on Form 8-K filed with the SEC on September 4, 2015).

a Healthcare Investors, Inc. 2013 Stock Incentive Plan (Incorporated by reference to Annex A to the Registrant's Proxy Statement on Form S-1, filed on April 22, 2013). +

ndment to 2013 Stock Incentive Plan (Incorporated by reference to Exhibit 10.10 to the Company's Current Report on Form 8-K, filed on August 5, 2013). +

+
of Officer Deferred Performance Restricted Stock Unit Agreement (Incorporated by reference to Exhibit 10.2 of the Company's Quarterly Report on Form 10-Q, filed on August 5, 2013). +

Employment Agreement, dated November 15, 2013, between Omega Healthcare Investors, Inc. and C. Taylor Pickett (Incorporated by reference to Exhibit 10.1 of the Company's Current Report on Form 8-K, filed on November 19, 2013). +

Employment Agreement, dated November 15, 2013, between Omega Healthcare Investors, Inc. and Daniel Booth (Incorporated by reference to Exhibit 10.2 of the Company's Current Report on Form 8-K, filed on November 19, 2013). +

Employment Agreement, dated April 1, 2015, between Omega Healthcare Investors, Inc. and Steven J. Insoft (incorporated by reference to Exhibit 10.3 of the Company's Current Report on Form 8-K filed with the SEC on April 3, 2015). +

Employment Agreement, dated November 15, 2013, between Omega Healthcare Investors, Inc. and Robert O. Stephenson (Incorporated by reference to Exhibit 10.3 of the Company's Current Report on Form 8-K, filed on November 19, 2013). +

Employment Agreement, dated November 15, 2013, between Omega Healthcare Investors, Inc. and R. Lee Crabill (Incorporated by reference to Exhibit 10.4 of the Company's Current Report on Form 8-K, filed on November 19, 2013). +

Consulting Agreement, effective as of August 1, 2015, among Omega Healthcare Investors, Inc., Omega Asset Management LLC and R. Lee Crabill, Jr. (incorporated by reference to Exhibit 3.1 to Omega's Current Report on Form 8-K filed with the SEC on July 31, 2015). +

Employment Agreement, dated November 15, 2013, between Omega Healthcare Investors, Inc. and Michael Ritz (Incorporated by reference to Exhibit 10.5 of the Company's Current Report on Form 8-K, filed on November 19, 2013). +

Summary of Time-Based Restricted Stock Unit Agreement for Transition Grants (2013) (Incorporated by reference to Exhibit 10.6 of the Company's Current Report on Form 8-K, filed on November 19, 2013). +

Summary of Time-Based Restricted Stock Unit Agreement for 2015 Grants (Incorporated by reference to Exhibit 10.7 to the Company's Current Report on Form 8-K, filed on April 3, 2015). +

Summary of Performance-Based Restricted Stock Unit Agreement for Transition Grants (2013) (Incorporated by reference to Exhibit 10.7 of the Company's Current Report on Form 8-K, filed on November 19, 2013). +

Summary of Performance-Based Restricted Stock Unit Agreement for 2015 Grants (Incorporated by reference to Exhibit 10.8 to the Company's Current Report on Form 8-K, filed on April 3, 2015). +

Summary of Time-Based Restricted Stock Unit Agreement for Annual Grants (commencing 2014) (Incorporated by reference to Exhibit 10.8 of the Company's Current Report on Form 8-K, filed on November 19, 2013). +

Summary of Performance-Based Restricted Stock Unit Agreement for Annual Grants (commencing 2014) (Incorporated by reference to Exhibit 10.9 of the Company's Current Report on Form 8-K, filed on November 19, 2013). +

Partnership Limit Waiver Agreement, dated as of October 30, 2014, by and between Omega Healthcare Investors, Inc. and LG Aviv L.P. (Incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K, filed on November 5, 2014). +

Summary of Performance-Based LTIP Unit Agreement for 2015 Grants (Incorporated by reference to Exhibit 10.9 to the Company's Current Report on Form 8-K, filed on April 3, 2015). +

Aviv REIT, Inc. 2010 Management Incentive Plan (Incorporated by reference to Exhibit 10.3 to the Aviv REIT, Inc.'s Registration Statement on Form S-4, filed on May 2, 2011). +

Amendment to the Aviv REIT, Inc. 2010 Management Incentive Plan (Incorporated by reference to Exhibit 4.5 to Aviv REIT, Inc.'s Registration Statement on Form S-8, filed on March 25, 2013). +

Second Amendment to the Aviv REIT, Inc. 2010 Management Incentive Plan (Incorporated by reference to Exhibit 4.3 to the Company's Registration Statement on Form S-8, filed on April 2, 2015). +

Summary of Time-Based Nonqualified Stock Option Award Agreement under the Aviv REIT, Inc. 2010 Management Incentive Plan (Incorporated by reference to Exhibit 10.4 to Aviv REIT, Inc.'s Registration Statement on Form S-4, filed on May 2, 2011). +

Summary of Nonlimited Performance-Based Nonqualified Stock Option Award Agreement under the Aviv REIT, Inc. 2010 Management Incentive Plan (Incorporated by reference to Exhibit 10.5 to Aviv REIT, Inc.'s Registration Statement on Form S-4, filed on May 2, 2011). +

Aviv REIT, Inc. 2013 Long-Term Incentive Plan (Incorporated by reference to Exhibit 4.3 to Aviv REIT, Inc.'s Registration Statement on Form S-8, filed on March 25, 2013). +

Amendment to the Aviv REIT, Inc. 2013 Long-Term Incentive Plan (Incorporated by reference to Exhibit 4.5 to the Company's Registration Statement on Form S-8, filed on April 2, 2015). +

Term of Restricted Stock Unit Award Agreement for time-based restricted stock units under the Aviv REIT, Inc. 2013 Long-Term Incentive Plan (Incorporated by reference to Exhibit 10.2 to Aviv REIT, Inc.'s Current Report on Form 8-K, filed on July 15, 2013). +
Amended and Restated Phantom Partnership Unit Award Agreement, dated as of September 17, 2010, among Aviv Asset Management, L.P., Steven J. Insoft and Aviv Healthcare Properties Limited Partnership, (Incorporated by reference to Exhibit 10.8 to Aviv REIT, Inc.'s Registration Statement on Form S-4, filed on May 2, 2011). +
Ratio of Earnings to Fixed Charges.*
Ratio of Earnings to Combined Fixed Charges and Preferred Stock Dividends.*
Subsidiaries of the Registrant.*
Consent of Independent Registered Public Accounting Firm.
Certification of the Chief Executive Officer under Section 302 of the Sarbanes-Oxley Act of 2002.*
Certification of the Chief Financial Officer under Section 302 of the Sarbanes-Oxley Act of 2002.*
Certification of the Chief Executive Officer under Section 906 of the Sarbanes-Oxley Act of 2002.*
Certification of the Chief Financial Officer under Section 906 of the Sarbanes-Oxley Act of 2002.*
XBRL Instance Document.
XBRL Taxonomy Extension Schema Document.
XBRL Taxonomy Extension Calculation Linkbase Document.
XBRL Taxonomy Extension Definition Linkbase Document.
XBRL Taxonomy Extension Label Linkbase Document.
XBRL Taxonomy Extension Presentation Linkbase Document.

* Exhibits that are filed

+ Management contract or compensatory plan, contract or arrangement

SIGNA

to the requirements of Sections 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed
 behalf by the undersigned, thereunto duly au

OMEGA HEALTH
 INVESTORS, INC

By: /s/ C. Taylor Pickett
 C. Taylor Pickett
 Chief Executive

Date: February

the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons on behalf of the Registrant
 the capacities on the date in

<u>Signatures</u>	<u>Title</u>	<u>Date</u>
PRINCIPAL EXECUTIVE OFFICER		
/s/ C. Taylor Pickett C. Taylor Pickett	<u>Chief Executive Officer</u>	<u>February 26, 2016</u>
PRINCIPAL FINANCIAL OFFICER		
/s/ Robert O. Stephenson Robert O. Stephenson	Chief Financial Officer	February 26, 2016
/s/ Michael D. Ritz Michael D. Ritz	Chief Accounting Officer	February 26, 2016
DIRECTORS		
/s/ Bernard J. Korman Bernard J. Korman	Chairman of the Board	February 26, 2016
/s/ Craig M. Bernfield Craig M. Bernfield	Director	February 26, 2016

/s/ Norman Bobins Norman Bobins	Director	February 26, 2016
/s/ Craig R. Callen Craig R. Callen	Director	February 26, 2016
/s/ Thomas F. Franke Thomas F. Franke	Director	February 26, 2016
/s/ Barbara B. Hill Barbara B. Hill	Director	February 26, 2016
/s/ Harold J. Kloosterman Harold J. Kloosterman	Director	February 26, 2016
/s/ Edward Lowenthal Edward Lowenthal	Director	February 26, 2016
/s/ C. Taylor Pickett C. Taylor Pickett	Director	February 26, 2016
/s/ Ben W. Perks Ben W. Perks	Director	February 26, 2016
/s/ Stephen D. Plavin Stephen D. Plavin	Director	February 26, 2016